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Abstract 
Obesity is a fast growing medical issue worldwide and is one of the leading causes of 
mortality. There is evidence to suggest that various forms of dietary fibre may be used in 
weight management and for their general health benefits. There is evidence to suggest 
that the addition of alginate to a food or beverage has the potential to alter the digestion 
process and potentially reduce the activity of digestive enzymes. Data from this 
laboratory have demonstrated that alginate possesses the ability to inhibit pancreatic 
lipase in-vitro. Pancreatic lipase is secreted in the small intestine and hydrolyses fat so 
that it can be absorbed in the digestive system. If the activity of pancreatic lipase can be 
reduced then the amount of fat absorbed will be reduced.  
A modified Periodic Acid Schiffs (PAS) assay is an effective, repeatable and simple 
method for quantifying alginate in solution. Furthermore with any potential weight loss 
treatment the release rate must be determined. The model gut system developed in this 
laboratory is able to digest the alginate enriched bread and the modified PAS assay 
system is able to quantify the release rate of the alginate, with between 12-20% released 
in the gastric phase and 80-88% released in the small intestinal phase. The data here also 
confirms that the bread is protecting the alginate during the cooking process, and that the 
alginate retains its inhibition properties despite the cooking and digestion process.  
The model gut is an effective model for digesting fat substrates and foods high in fat such 
as butter and olive oil. Alginate enriched bread has the ability to inhibit fat substrates 
glyceryl trioleate, trioctanoate, tributyrate, and foods butter and olive oil 62, 39 and 32, 
95 and 78% respectively after 180 minutes in the model gut.  
Alginate enriched bread is able to modulate fat digestion in ileostomy subjects following 
ingestion. This was evident by a significant increase in fat content of the effluent fluid. 
There was an increase in fat content of 81g and 112g when subjects consumed alginate 
bread when compared with control bread at 240-270-300 minutes and when total fat was 
combined for all time points respectively. There was also an increase of 292g in wet 
effluent weight for alginate bread when compared with the control bread. In addition a 
significant relationship between the wet effluent weight and fat content of the effluent 
was reported. The alginate enriched bread had no problems with palatability or adverse 
side effects associated with fat digestion and suggest that alginate enriched bread may be 
a suitable method for the delivery of alginate into a normal diet. The data in this thesis 
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suggests that alginate enriched products are able to attenuate the digestion of fat and 
therefore may be used in weight management and in the treatment of obesity, however 
further longitudinal clinical research is required in a healthy population before any health 
claims can be made.  
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Chapter 1: General Introduction 
 
1:1 Obesity  
The World Health Organisation (WHO) defines the term “obese” as “abnormal or 
excessive fat accumulation” which has been strongly linked with ill health and disease. 
To classify whether an individual is obese a simple technique that uses an index of height 
and weight, called body mass index (BMI) is used. A BMI of 25kg/m
2
 is judged to be 
overweight, and over 30kg/m
2
 is defined as obese, with almost all social science 
associated with obesity uses BMI, despite its inability to distinguish between fat and fat 
free mass such as bone and muscle (Burkhauser & Cawley, 2008). Despite the flaws with 
this technique the WHO reported that in 2005 1.6 billion people were overweight and 400 
million were obese, however this is expected to have risen to 2.3 billion and 700 million, 
respectively by 2015. Furthermore obesity can no longer be considered an issue just for 
western countries. Similar obesity trends are being experienced in the so called 
developing 3
rd
 world countries, specifically in urban settings (Tucci, Boyland, & Halford, 
2010).      
The fundamental cause for becoming obese and overweight is an energy imbalance 
between the number of calories consumed, and the number of calories expended. The 
current social environment  provides frequent opportunities for consuming large amounts 
of food that are easily accessible and relatively inexpensive (Hill, Peters, & Wyatt, 2007). 
These easily accessible foods are generally processed and high in fat and sugars, but low 
in fibre, vitamins and mineral (Hill, 2006). This dependency on processed foods that are 
high in fat and sugars has been compounded by the low levels of physical activity. Low 
levels of physical activity are due to the sedentary nature of many jobs, increased 
urbanisation and a greater reliance on transport as opposed to walking.  
Those individuals with a BMI of over 30kg/m
2
 have been linked to an increased risk of 
chronic diseases, such as cardiovascular disease (CVD), which accounts for over 17 
million deaths per year. The WHO indicated the number of people who are obese is 
increasing, as is the number of people with diabetes. Musculoskeletal disorders such as 
osteoarthritis is also on the rise, due to the excess weight placing extra stress on the 
weight bearing joints, such as the knees and hips increasing the risk of cartilage damage. 
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Although not completely understood or the initial cause, certain cancers have been 
associated with obesity. Cancers such as pancreatic, endometrial, breast and colon have 
all been linked to obesity. Due to the excessive cost associated with the high level of 
inactivity and increased risk of disease, a suitable and cost effective treatment for obesity 
is sought after.  
1.1.2 Current obesity treatments 
The NHS’s attempt at prevention as opposed to treatment is to advise people to eat a more 
healthy diet and exercise more, thus increasing energy expenditure and decreasing 
calories consumed. Exercising more is a key factor to weight loss with the NHS advising 
the most effective types of exercise as ‘aerobic’ activities that use large muscle groups in 
an attempt to increase the energy expenditure. Despite the advice of many experts, 
exercise is rarely maintained, with people preferring to lose weight through a variety of 
different diets (Miller, 1999). Anderson, Konz, and Jenkins (2000) addressed the issue 
that the majority of diets are ‘fad’ diets supporting unsafe practices, which have 
detrimental health issues attached. Such diets include “Atkins Diet”, “Protein Power”, 
“Sugar Busters” and “The Zone”. Anderson et al. (2000) echoed the recommendations 
from the WHO and NHS, and stated that diets should include wholegrain or wholemeal, 
such as brown rice, pasta and bread, as these can contain large quantities of fibre. A 
healthy diet or even the fad diets as mentioned previously are rarely maintained, with an 
overall success rate of just 15% (Ayyad & Andersen, 2000) thus the weight they have lost 
generally returns within one or two months of the initial weight loss. Due to individual’s 
inability to maintain diet and exercise other obesity treatments have been developed, 
including pharmaceutical interventions. (Ayyad & Andersen, 2000). 
Of those alternative obesity treatments possibly the most common one is bariatric 
surgery, specifically for those who are morbidly obese. Bariatric surgery includes a wide 
variety of procedures, with one of the most common reducing the size of the stomach 
with a medical apparatus which is inserted into the stomach (gastric banding). Another 
common treatment is the removal of part of the stomach or re-routing the small intestine 
to a small stomach pouch (gastric bypass) (Santry, Gillen, & Lauderdale, 2005). A review 
by Buchwald et al. (2004) identified that between 1997 and 2003 patients who underwent 
gastric banding and gastric bypass had a weight loss of 61.6% and 68.2% respectively. In 
addition to weight loss a considerable number of patients also had improvement in a 
number of obese related conditions including hypertension, obstructive sleep apnea and 
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diabetes. Irrespective of the beneficial effects of bariatric surgery the costs and 
complications associated with it may outweigh the benefits. Encinosa, Bernard, Chen, and 
Steiner (2006) conducted a study of insurance claims in the USA and 21.9% of all 
patients suffered with some form of complication whilst in hospital, and a further 40% in 
the subsequent six months. Complications included gastric dumping syndrome, leaking at 
the surgical site, incisional hernia, infections and pneumonia.  
An additional treatment is drugs that target the mechanisms underlying the regulation of 
appetite and energy. There are a number of pharmacological anti-obesity treatments 
available that target the central nervous system to suppress appetite and therefore 
decrease food intake. Although these treatments do possess the ability to aid in weight 
loss, they also have serious detrimental health effects. Amphetamines, 
Phenylpropanolamine and Rimonabant are all drugs used as appetite suppressant and 
reduce the Kcal an individual may consume (Fujimiya, Okumiya, & Kuwahara, 1997; Pi-
Sunyer, 2006; Rich, Rubin, Walker, Schneeweiss, & Abenhaim, 2000). Although all of 
these drugs have been associated with weight loss, the adverse side effects including 
headaches, irregular heartbeat, vision problems, rash, psychological problems and in 
extreme cases stroke and damage to the valves of the heart has led to the removal of these 
drugs from the market.  
The most frequently used anti-obesity drug is Orlistat, released in 1998 by Roche 
Pharmaceutical Company. Orlistat (tetrahydolipstatin) (Figure 1) as an alternative 
treatment to obesity. Unlike the previously mentioned drugs Orlistat acts peripherally at 
the gastrointestinal tract, with only 1% being absorbed into circulation, therefore reducing 
the risk of physiological and psychological side effects. Orlistat is a semi synthetic 
hydrogenated derivative of natural occurring Streptomyces toxytricini, which has been 
shown to inhibit gastric and pancreatic lipase and colipase (Al-Suwailem, Al-Tamimi, Al-
Omar, & Al-Suhibani, 2006; Sternby, Hartmann, Borgstrom, & Nilsson, 2002). 
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Figure 1.  Chemical structure of tetrahydrolipstatin (Orlistat). 
Orlistat has the ability to bind to the active site of pancreatic lipase, resulting in acylation 
of a hydroxyl group on serine residue at the active site of the enzyme. The acylation of a 
hydroxyl group is an irreversible reaction, and one that results in its redundancy as a 
lipase (Hadvary, Lengsfeld, & Wolfer, 1988). In human studies enzyme inhibition up to 
>90% has been reported, without affecting trypsin, amylase, chymotrypin and 
phospholipases, which is surprising especially as trypsin has a serine at the active size of 
the enzyme (Cudrey, van Tilbeurgh, Gargouri, & Verger, 1993; Sternby et al., 2002).  
Sternby et al. (2002) observed the effects of Orlistat mixed into a liquid meal and in 
capsule form in healthy individuals. The authors reported that adequate mixing of Orlistat 
(60mg three times a day) and the liquid meal in the gastrointestinal tract was sufficient to 
inhibit all the major enzymes involved in lipid digestion, such as gastric lipase, colipase 
dependant lipase and carboxyl ester lipase by up to 90%. Furthermore Cudrey et al. 
(1993) identified that Orlistat has a powerful inhibition specifically towards pancreatic 
lipase which is responsible for the breakdown of dietary triglcerides into absorbable free 
fatty acids and monoglycerides. Therefore by inhibiting pancreatic lipase Orlistat reduces 
triglyceride digestion and thus its absorption by up to 35% (Al-Suwailem et al., 2006).  
In a clinical setting Orlistat has also been used to treat obesity in humans, in an attempt to 
observe if enzyme inhibition can reduce fat digested, and ultimately fat absorbed and 
stored as adipose tissue. Prior to the release of Orlistat in the UK, Lucas (1998) conducted 
a longitudinal study to test the efficacy of the drug as a long term treatment for obesity. 
The study was conducted over 52 weeks to observe the effects on weight loss, low density 
lipoproteins (LDL)-cholesterol and blood pressure in 753 obese and overweight 
individuals with BMI of 28-40 kg/m². The treatment group received 120mg of Orlistat 
and the second group received 120mg of placebo with both groups consuming 600 
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Kcal/day less than the normal recommendation for male and females. In the treatment 
group participants lost 10.25% of their weight, compared to 6% in the placebo group. In 
addition the treatment group had greater reductions in LDL-cholesterol and diastolic 
blood pressure in comparison with the placebo group (5.5% vs. 2.2% and 8.2mmHg vs. 
6.1mmHg, respectively). The conclusion from this study suggest that long term treatment 
of obese and overweight individuals using Orlistat in combination with a hypocaloric diet 
can significantly reduce weight and reduce additional risk factors associated with obesity. 
Unlike amphetamines and phenlypropanolamine only one serious misuse of Orlistat has 
been reported. This individual used Orlistat during binge eating which resulted in 
abnormal bowel movements up to seven times a day, severe fecal urgency, oily rectal 
spotting and severe flatulence after every binge (Malhotra & McElroy, 2002). Despite this 
one incident of misuse there have been limited to no physiological or psychological 
adverse effects. Zhi et al. (1996) provided evidence for the safe use of Orlistat and 
confirmed this by demonstrating that only 1% was recovered in the urine of participants; 
with a further 96% recovered in the stool samples over four days post treatment. In 
addition the authors also analysed plasma samples over 16 days post treatment, reporting 
that Orlistat was undetectable in plasma samples, supporting the indication that Orlistat 
has minimal risk of physiological and psychological adverse effects. Although the 
findings of Zhi et al. (1996) suggest that Orlistat was not present in urine, stool and 
plasma samples four days post treatment there was no evidence regarding cell content in 
the gastrointestinal tract. As previously mentioned Orlistat is lipophilic in nature and 
therefore could be readily incorporated into cellular membranes and may even result in 
cellular death due to a build-up of Orlistat. 
Although there is substantial evidence supporting Orlistat as an obesity treatment, there is 
also research suggesting that Orlistat has adverse effects associated with it (Finer, James, 
Kopelman, Lean, & Williams, 2000). Despite the positive results in terms of weight loss 
of Orlistat participants did suffer with undesirable side effects including over 58% 
suffering with gastrointestinal events. Such events ranged from flatulence, vomiting, 
uncontrolled oily discharge, increased defecation, abdominal pain, faecal urgency and 
loose stools. In addition respiratory problems, headaches and back pain were also 
experienced, albeit a smaller percentage of participants. These findings were also echoed 
in a more recent short-term study by Kaya et al. (2004). This study conducted a 12 week 
randomised study using Orlistat as an anti-obesity treatment on participants with a BMI 
of 36kg/m². Just as with previous studies weight loss was reported, with mean of 9.35kg 
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in the treatment group. Nevertheless similar to previous studies (Finer et al., 2000) 48% 
participants reported adverse side effects such as diarrhoea, flatulence, fatty stools, fecal 
incontinence, headaches and even forgetfulness in some participants throughout the entire 
12 week study. In retrospect the long and short-term benefits of Orlistat as an obesity 
treatment cannot be denied; nonetheless the adverse side effects can make it an 
unpleasant treatment for patients, therefore an obesity treatment which may still offer the 
same benefits as mentioned, without adverse side effects needs to be produced.   
1.2 Dietary Fibre 
The term dietary fibre was believed to be first applied by Hipsley (1953), as a shorthand 
expression for non-digestible constituents that make up the cell walls of plants. It is 
essentially a non-starch polysaccharide, which includes components of plants such as 
arabinoxylans, cellulose, inulin, lignin, pectins and beta-glucans (DeVries, 2003). Dietary 
fibre is not homogeneous in nature and can vary in its composition, which is generally a 
mixture of water soluble (pectin, algal polysaccharides and some hemicelluloses) and 
water insoluble (cellulose, lignin and some hemicelluloses) components (Roehrig, 1988). 
Hipsley (1953) first made the observation that populations consuming a diet high in 
dietary fibre had lower rates of pregnancy toxaemia, leading to other health implications. 
In light of the earlier work numerous studies have been conducted since, suggesting that 
dietary fibre intake was associated with a range of nutritional and health related benefits 
(Burkitt, Walker, & Painter, 1972; Trowell, 1973, 1978). Asp (1987) concluded that 
dietary fibre resisted hydrolysis by human alimentary enzymes and therefore escape 
digestion and absorption in the gastrointestinal tract. The beneficial effects of fibre are 
related to gut health where fibres add bulk to faeces and aid passage through the digestive 
system preventing constipation. Additional advantages of a high fibre diet include 
reducing harmful microflora (Terada, Hara, & Mitsuoka, 1999), prolonging satiety, 
increasing transit time, decreasing gastric emptying (Holt, Heading, Carter, Prescott, & 
Tothill, 1979), reducing break down of carbohydrates thus slowing down absorption of 
glucose, reducing LDL in blood and increasing cholesterol turnover (Sandberg et al., 
1994).  
The WHO and the NHS recommend that a healthy diet should include dietary fibre. 
Howarth, Saltzman, and Roberts (2001) confirmed this in a review and suggested that a 
diet including up to 30g/d of dietary fibre may reduce the growing number of people 
becoming obese. Despite the recommendation from the WHO, NHS and the review from 
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Howarth et al. (2001) regarding the potential health benefits of dietary fibre the 
recommend quantity of dietary fibre that should be consumed varies between countries. 
The daily fibre intake recommended today by the America Heart Association is 14g per 
1000 calories consumed; therefore the average male consuming 2700 calories should be 
consuming 38g of fibre per day. Contrastingly the British Heart Foundation suggests only 
18g of fibre per day, in the average male consuming 2550 Calories. It is apparent that 
there are varying recommendations for the levels of fibre intake each day, however it 
remains an area of debate what the optimal amount of fibre consumed should be. 
Irrespective of this debate, there is substantial research supporting the idea that dietary 
fibre may reduce the risk of morbidity and aid the digestive process, through such 
mechanisms as enzyme inhibition and those previously mentioned. 
1.3 Enzyme Inhibition 
Current evidence suggests that dietary fibres may inhibit digestive enzymes such as 
lipase, trypsin, pepsin and amylase amongst others (Eastwood, 1992). The research into 
the use of dietary fibres as enzyme inhibitors stemmed from earlier work (Burkitt et al., 
1972; Hipsley, 1953; Trowell, 1973, 1978). Schneeman and Gallaher (1980) fed rats for 
10 days on semi-purified diets including either 20% cellulose or no fibre for 10 days. The 
rats were killed 30 minutes post eating, after which the whole intestine was removed and 
washed with cold sodium chloride before being frozen at -60˚. Prior to analysis of the 
intestinal contents were defrosted and then homogenised. They were then assayed for the 
activity of trypsin, chymotrypsin, amylase and lipase. The group of rats who consumed 
cellulose had lower activity of trypsin, chymotrypsin, amylase and lipase. In a slightly 
later study, in which Schneeman was involved, Dunaif and Schneeman (1981) provided 
further evidence for the use of dietary fibres as enzyme inhibitors. They observed the 
effects of dietary fibre on amylase, lipase, trypsin and chymotrypsin in human pancreatic 
juice. A sample of human pancreatic juice was collected from a pancreatic fistula from a 
female participant, before being incubated with one of several dietary fibres ranging from 
alfalfa, pectin, cellulose, hemicelluloses, wheat bran or oat bran. The cellulose and 
hemicelluloses samples resulted in a significant reduction in all enzyme activity. Wheat 
bran and oat bran reduced amylase and chymotrypsin activity and alfalfa reduced the 
activity of trypsin and chymotrypsin. Interestingly pectin increased the activity of 
amylase and chymotrypsin. Although these results do provide an interesting insight into 
in-vitro research there was only one participant, therefore making it difficult to generalise 
the findings. Further supporting evidence was provided by Shah, Mahoney, and Pellett 
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(1986), who demonstrated that feeding growing rats a diet containing 10% pectin, guar 
gum and lignin resulted in reduced pepsin activity of 57%, 44% and 20% respectively.  
 
In contrast to the aforementioned studies there is also evidence that suggests dietary fibre 
has no effect on enzyme activity (Calvert, Schneeman, Satchithanandam, Cassidy, & 
Vahouny, 1985; El Kossori et al., 2000). Calvert et al. (1985) reported that feeding rats on 
strict diet including 10% levels of insoluble fibre (cellulose and alfalfa) and 5% levels of 
viscous fibre derivatives (pectin, guar gum and metamucil) for four weeks had no effect 
on pancreatic amylase and proteolytic enzymes. In more recent work from El Kossori et 
al. (2000) they also provided evidence to suggest that dietary fibres locust bean gum, 
citrus pectin, arabic gum, carrageenan and alginic acid had no inhibitory effect on the 
activity of  pepsin. Despite El Kossori et al. (2000) reporting no decrease in enzyme 
activity, they do report that the level of casein digested was lower in the dietary fibre 
group. However the authors do not discuss how they have distinguished between enzyme 
activity and binding, which makes the findings of this study questionable. Although there 
is evidence to suggest that dietary fibres may be able to attenuate the activity of digestive 
enzymes, some of the methods are questionable. For example the lack of controls used 
make it difficult to compare the dietary fibre group with a control, animal models used 
and small sample sizes making the findings difficult to generalise. 
 
In contrast to the work of El Kossori et al. (2000) work from this laboratory has 
demonstrated that dietary fibre possesses the ability to alter digestion in the 
gastrointestinal tract. Sunderland, Dettmar, and Pearson (2000) demonstrated in-vitro 
pepsin activity could be inhibited by a mean percentage of 52%. This inhibition was 
observed in 58 various alginate concentrations by using an N-terminal assay. Further 
work by this group in 2005 observed the inhibitory effect of a wide variety of alginates 
with various levels of mannuronic (M) and guluronic (G) residues on pepsin activity 
(Strugala, Kennington, Campbell, Skjak-Braek, & Dettmar, 2005). Strugala et al. (2005) 
reported that the greatest mean inhibition of alginate was as high as 89% by alginates at a 
concentration of 5mg/ml. There was a range of 39-89% inhibition of pepsin which was 
dependant on the structure of the alginate. The authors reported that there was a negative 
correlation between pepsin inhibition and G residue but a positive correlation of pepsin 
inhibition and alternating blocks of G and M residues. The authors suggested that the 
increased flexibility that is observed in alternating M and G residues provides an 
available interaction with the active site of the pepsin. In addition Smidsrod and Skjak-
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Braek (1990) reported a positive correlation between alternating sequences of M and G 
residues and flexibility. Consequently alginates that are made up of consecutive G 
residues have poor flexibility and are therefore are more resistant to an interaction with 
the pepsin active site and G residues, which was demonstrated in a significant negative 
correlation (Strugala et al., 2005). (Wilcox, Brownlee, Richardson, Dettmar, & Pearson, 
2014) reported in-vitro that alginate was able to inhibit pancreatic lipase by up to 75%, 
and that this inhibition may be able to aid in weight loss by reducing the amount of fats 
digested, and therefore absorbed.  
Although there is a considerable basis for the use of dietary fibre as an anti-obesity 
treatment, the earlier inconsistencies may be due to the large range of dietary fibres used. 
For example as mentioned here there is conflicting evidence for the use of pectin as an 
enzyme inhibitor, which may be due to the degree of esterification involved (El Kossori 
et al., 2000). Despite these inconsistencies there is a sizeable body of research reporting 
that dietary fibre can affect digestion, and may possess enzyme inhibition properties. This 
evidence along with the beneficial nutritional and health related benefits associated with 
dietary fibre suggests that alginate may be able to be used as a dietary fibre in the 
treatment of obesity and aid in weight loss, without the undesirable side effects associated 
with current pharmacological obesity treatments. Although dietary fibres may not have 
the side effects associated with the obesity treatments previously mentioned there is not 
enough clinical evidence to support the claim that dietary fibres may be used to treat 
obesity. 
1.4 Potential Enzyme Inhibition Mechanisms 
The mechanisms by which dietary fibres affect the digestive process is not completely 
understood, however there are several suggested mechanisms. As previously mentioned 
Shah et al. (1986) reported that guar gum, pectin and lignin inhibited pepsin activity. The 
authors suggested that the greater inhibition reported in the pectin and guar gum group 
compared to lignin may have been due to the viscosity within the stomach. With a greater 
viscosity the mobility of enzymes and substrates will be slower, therefore slowing 
digestion. Both pectin and guar gum are highly viscous when dissolved in solutions above 
pH 2, therefore when consumed these become gels within the gastrointestinal tract 
thereby slowing mixing and digestion. This sluggish mixing process may slow the access 
of the enzymes to substrates and ultimately reduce the amount of protein digested. These 
findings contradict those mentioned earlier by El Kossori et al. (2000), who indicated a 
possible mechanism responsible for reduced protein digestion may be substrate binding. 
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Although both of the mechanisms mentioned above may be involved in the reduction in 
protein digestion neither offer a complete explanation and therefore raise the question as 
to what other mechanisms are involved.   
Schneeman and Gallaher (1980) suggested that dilution of intestinal contents may be an 
additional mechanism that is responsible for a reduction in enzyme activity. The authors 
observed that enzyme activity in the intestinal contents of rats fed cellulose was 
significantly different from the controlled diet rats. In the rats who consumed cellulose 
there was less enzyme activity per milligram of intestinal contents and a reduction in the 
total amount of enzyme activity. The authors reported that the enzymes and substrates 
may be diluted due to the addition of non-digestible material (cellulose). This was further 
supported by the fact that there was less enzyme activity reported in the chyme, resulting 
in slower digestion. This slower rate of digestion was evident due to the elevated level of 
protein in intestine of the cellulose group of rats. The authors also suggested that an 
additional mechanism that may play a role in inhibiting digestive enzymes may be a 
direct effect by reducing the enzyme substrate binding. Strugala et al. (2005) suggested 
that alginates may replace the substrate and potentially interact with the active site of 
pepsin, and therefore pepsin is unable to effectively digest protein. In addition to a 
potential binding of alginate with digestive enzymes, there is evidence to suggest that 
alginates may chelate calcium and thus impact upon pancreatic lipase activity. Although 
the exact role that calcium may play in pancreatic lipase activity remains unknown the 
enzyme is more active when calcium is present. If alginate chelates calcium then this too 
may have a role to play in reducing the activity of pancreatic lipase (Smidsrod, 1974). 
However Wilcox, Brownlee, Richardson, Dettmar, and Pearson (2013) reported that even 
if the alginate did bind to all of the calcium present, then this may only result in 20% 
inactivation of the lipase. Therefore this mechanism cannot account for the high levels of 
inhibition of lipase reported (Wilcox et al., 2013). 
It is apparent that dietary fibres possess the ability to govern the activity of the enzymes 
involved in digestion. By reviewing the current literature it appears that there is no one 
specific mechanism that is responsible, and that there may be several mechanisms that 
contribute towards regulating the digestive process. It is also apparent that further 
research is required as the majority of research thus far investigating the mechanisms 
involved in regulating digestive enzymes are either in animals, consist of a small sample 
or are in-vitro and thus cannot truly be comparable to in-vivo digestion. 
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1.5 Alginate Structure  
Alginates are present in brown algae as a matrix polysaccharide in the cell walls, and are 
by far the most abundant polysaccharide present, making up to 40% of the dry weight. 
Ertesvåg and Vallaa (1998) suggested that the habitats of various species of the brown 
algae vary regarding exposure to periodic drying due to the tide and waves. These varying 
habitats may be responsible for the variability in stiffness, elasticity and water binding 
capacity between alginates. These properties have been suggested to be accountable for 
why various species of algae produce different conformations of M and G residues.  
The structure of alginate was first fully defined in 1972 by Penman and Sanderson (1972) 
using proton magnetic resonance (PMR) spectroscopy, however a further technique called 
C-nuclear magnetic resonance (C-NMR) which allows further definition of the α-L-
guluronic acid (G residue) and β-D-mannuronic acid residues (M residue) in an un-
branched chain (Grasdalen, Larsen, & Smidsrod, 1977) (Figure 2). These residues can 
combine to form G rich (G blocks), M rich (M blocks) or a mixture of M and G as seen in 
Figure 2. It is this make up of MM blocks, GG blocks or MG blocks that account for the 
differences and function of alginates that allows them to be used in nutrition, medicines 
and the textile industry (Brownlee et al., 2005). 
a)                                                                                            b) 
 
 
 
Figure 2.  Diads of MM (a) and GG (b) residues (Remminghorst & Rehm, 2006). 
 
1.6 Gelling of Alginate 
As mentioned previously alginate possesses an innate ability of chelating divalent cations, 
eg. calcium and thus forming a stable gel. This interaction between divalent ions and G 
residues despite conflicting views is commonly referred to as the “egg box model” 
12 
 
(Morris & Rees, 1978). The ability of the inter chain binding sites has been suggested by 
several authors to involve the carboxyl and hydroxyl groups and the ring oxygen atoms 
which are all involved in the binding sites. Rees (1981) indicated that the egg box model 
can be used to describe the chain packing of M and G residues in alginate, that 
accommodate the ions of various sizes. Evidence supporting the “egg box model” was 
provided by Braccini and Perez (2001) who used a molecular modelling program. They 
used a pairing procedure that analysed all the possible associations of the G and M 
residue chains bindings to calcium ions to form dimmers. Further evidence for the “egg 
box model” was provided by Draget, Stokke, Yuguchi, Urakawa, and Kajiwara (2003) 
who demonstrated that the forming of this ionic gel occurs in two stages. Initially 
quasiordered junction zones composed of three to four lateral chains form; although this 
is insufficient lateral growth to support continuous chain formation. Therefore during 
second phase around three to four of the junction zones join together, forming domains of 
around 50Å and a gel is formed.  
The stiffness of alginate gels is generally measured by Youngs modulus, which is a 
measure of the stiffness of an elastic material. Smidsrod (1974) indicated that the 
mechanical property (stiffness) of the individual polymer chains is one the main feature 
which determines the viscosity of the gel. Smidsrod (1974) demonstrated that GG blocks 
had a superior ability of binding to calcium ions in solution, greater hysteresis and signs 
of heterogeneity with regard to binding sites, compared to MM and MG blocks. This 
superior ability of GG blocks to bind calcium ions has been suggested to be responsible 
for higher Youngs modulus and thus a stronger and more rigid gel (Draget, Skjak-Braek, 
& Smidsrod, 1997). Although the G residue content is paramount to the stiffness of the 
gel, length of the G blocks also plays a role. Whereas M blocks link together via end to 
end, GG blocks are linked side to side, thus a greater content of GG blocks shortens the 
length of the interacted chains. The shorter chains in GG blocks increases mechanical 
stiffness, as opposed to alternating M and G resides which increases the flexibility and 
reduces stiffness. Despite the literature supporting the “egg box model” for alginates it 
remains an area of debate as to whether this is the most suitable model for all ionic 
polysaccharides, such as pectins (Braccini & Perez, 2001).  
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1.6.1 Ionic Gels 
In addition to ionic gel formation alginates can also form acid gels in the presence of a 
low pH. Atkins, Parker, and Smolko (1971) indicted that acid gel formation is dependent 
on the acid dissociation constant (pKa) of the individual residues that make up alginate. 
The authors reported that if the pH of the solution containing alginate was reduced below 
the pKa for mannuronic and guluronic residues (3.38 and 3.65 respectively) an acid gel is 
formed. It must be emphasised that when the pH is lowered in a controlled manner an 
acidic gel is formed. In contrast an abrupt reduction in pH below the pKa will result in 
precipitation of the alginate.   
The formation of an acid gel was suggested to be as a result of intermolecular hydrogen
 
bonds that connect the polyuronon chains, however it remains uncertain how the 
molecular weight and composition of the alginates will affect acid gel formation (Atkins 
et al., 1971). Since this earlier work Draget, Skjåk Bræka, and Smidsrøda (1994) 
conducted research using Youngs modulus in an attempt to identify what effect the 
chemical sequence, molecular weight and composition had on acid gel formation. The 
authors determined that gel strength was dependent on the chemical sequence and 
molecular composition. The stronger gels were those rich in G residues and those that 
consisted of multiple GG blocks, as represented by a significantly larger Youngs modulus 
when compared to alginates rich in M residues and consisting of MM and MG blocks. 
Hoad et al. (2004) confirmed these earlier findings when comparing alginates with high 
and low G residues using magnetic resonance images (MRI) in human. They reported that 
alginates with a high G content accounted for large gel formation in the stomach as 
opposed to those alginates with a low G content. In addition the authors indicated that 
along with chemical composition gel strength was dependant on molecular weight, with 
the larger apparent Youngs modulus being recorded for the larger molecular weights. A 
possible explanation for the low gel strength and poor gel formation in MM and MG 
blocks may be due to a less hospitable environment for the formation of stable 
intermolecular  H
+
 bonds (Atkins et al., 1971; Draget et al., 1997; Hoad et al., 2004). 
 
1.6.2 Acidic Gels 
As mentioned previously alginate can form ionic gels at a range of pHs in the presence of 
divalent cations such as Ca²
+
, (Morris & Rees, 1978), and acidic gels when the pH is 
reduced below the pKa value of the uronic acid residues, which as mentioned earlier may 
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be due to intermolecular hydrogen bonds (Atkins et al., 1971). Yang, Chen, and Fang 
(2009) observed the effect of a range of pH’s on the viscosity of alginate in solution. 
They reported that as the pH was reduced from 6.6 to 5.0 that there were minimal changes 
in viscosity, suggesting that there was only a small, if any alteration in electrostatic 
repulsion. However when the pH was reduced further from pH 5.0 to 3.0, the authors 
reported a significant augmentation in viscosity. The increase in viscosity was suggested 
to be the result of inhibition of electrostatic repulsion. With reduction in electrostatic 
repulsion there is the opportunity for an enhancement of intermolecular hydrogen bonds, 
and possibly entanglements between parallel polymer chains forming structures. The 
enhancement of intermolecular hydrogen
 
bonds and entanglement between polymers is a 
result of two interactions.  
The first interaction is a reduction in the charge repulsion between dissociated carboxylic 
groups and the hydrogen bonding formed between carboxylic acid and ionised 
carboxylate groups (Bu, Kjoniksen, & Nystrom, 2005). In conjunction with a reduction in 
pH of the alginate solution, the number of dissociated carboxylic acid groups in the M 
and G residues of the alginate also reduces, thus having a knock on effect on the 
hydrophilicity of the alginate. Cao et al. (2005) demonstrates that as the pH continues to 
decrease the carboxylic acid groups in the alginate will become protonated, and as a 
consequence hydrophobic sections appeared in the alginate chains. In addition the 
reduction in negative charge of the opposing carboxylic acid groups reduces and therefore 
encouraging the development of intermolecular hydrogen
 
bonds, and thus increase the 
viscosity through entanglements of opposing alginate polymer chains (Yang et al., 2009).  
 
1.7 Uses of Alginate 
Hipsley (1953) defined dietary fibre as a shorthand expression for non-digestible 
constituents that make up the cell walls of plants. Haug, Larsen, and Smidsrod (1966) 
established that alginate is a dietary fibre as it is resistant to hydrolysis in mineral acid. 
Through the use as a dietary fibre and its ability to form viscous gels, alginate can be used 
for various applications. These include stabilisers, gel forming, film forming and water 
binding agents. These application allow alginates  to be used in industries ranging from 
pharmaceutical to the textile industry, however the main uses of alginate are in the food 
industry (Brownlee et al., 2005). In the pharmaceutical industry alginates are used for 
dental impressions, control of drug release and have also been used since 1947 as wound 
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dressing. For example Groves and Lawrence (1986) used alginate in an attempt to reduce 
blood loss from skin graft sites. There was significant reduction in the amount of blood 
lost post-surgery when compared to other treatments, with no adverse reactions reported. 
In the textile industry alginates have been used for various applications ranging from 
textile printing and manufacturing of ceramics (Ertesvåg & Vallaa, 1998). Despite the 
various uses of alginates as mentioned there is substantially more income generated from 
the use of seaweed and seaweed products in human nutrition. Alginates can be made up to 
various viscosities by altering the level of calcium (Ca
+
²) and hydrogen (H
+
) which are 
stable at temperatures up to 100˚C and at a low pH, thus providing an excellent gelling 
agent in food. Amongst the many applications of alginates in the food industry it can be 
used in bakery creams (Gibbs, Kermasha, Alli, & Mulligan, 1999) with approximately 
0.1-0.3% of the dry weight of the product being added. When alginate is added to the 
cream of cakes and pastries it increases the stability of the product when freezing and 
thawing and therefore reduces the separation of the solid and liquid components 
(Brownlee et al., 2005). 
 
1.8 Obesity treatment 
Data from previous research suggests that alginate as a dietary fibre may be used as an 
obesity treatment. However the main obstacle appears to be how to introduce alginate into 
the everyday diet. The addition of alginate to food vehicles is not a new concept and has 
been developed since the early 90s. With the addition of alginate to food and drink 
vehicles resulting in a reduction in glycaemic response (Williams et al., 2004), a 
reduction in blood glucose, reduced gastric emptying (Torsdottir, Alpsten, Holm, 
Sandberg, & Tolli, 1991; Wolf et al., 2002), increased fat excretion, decreased bile 
excretion (Sandberg et al., 1994) and a reduction in Kcal intake (Paxman, Richardson, 
Dettmar, & Corfe, 2008). Despite these beneficial effects, alginate enriched products are 
plagued with poor palatability. Ellis, Apling, Leeds, and Bolster (1981) reported that 
foodstuffs that contain viscous fibres usually exhibit slimy, sticky and gummy 
characteristics resulting in poor palatability and therefore poor compliance. This was 
especially evident when alginate is mixed with calcium carbonate, forming a strong rigid 
gel in the mouth resulting in poor palatability (Paxman et al., 2008).  
As previously mentioned there are a number of studies suggesting that diets including 
dietary fibre possess the ability to lower the risk of morbidity and mortality from various 
16 
 
diseases. However for every study suggesting that dietary fibre may reduce the risk of 
morbidity, there are a number of studies to the contrary  (Brownlee, 2009). These 
indescrepencies are generally due to small sample sizes, animals models such as mice and 
dogs being used or the various amounts and types of dietary fibre that have never been 
directly compared with each other. Of these dietary fibres alginate has received 
considerable attention due to its ability to modulate the activity of the enzymes involved 
in digestion (Strugala et al., 2005; Sunderland et al., 2000; Wilcox et al., 2014). The 
unique physical property of alginate separates them from other dietary fibres. This is 
generally because alginate can be taken at low viscosity, which is excellent for 
palatability and allows for larger doses to be consumed. Additionally alginates are able to 
form gels in both acidic and calcium rich environments and can be used to reduce the 
digestion of fats and increase satiety (Brownlee et al., 2005).  
Although there is good evidence supporting the use of alginate, the main hurdle appears 
to be how to introduce alginate into the diet. As mentioned beforehand the overall success 
rate of diets is only 15% (Ayyad & Andersen, 2000) therefore alginate must be included 
in foods/drinks that people consume on a regular basis. In addition to ensuring that the 
alginate is in food/drinks that people regularly consume is the concern of palatability. 
Previous work that has attempted to include dietary fibre into beverages and crispy bars 
has resulted in poor palatability and therefore has never been produced into an everyday 
product. The question remains as to whether the addition of alginate to a food/drink will 
affect the palatability (Ramirez, 1990).  
There have been a number of in-vivo studies attempting to use alginate as a dietary fibre, 
with mixed results. Torsdottir et al. (1991) was one of the first studies that used alginate 
as a dietary fibre. The authors used a beverage which included 5g of sodium alginate, 
containing 60% mannuronic and 40% guluronic acid. The authors reported significantly 
lower postprandial rise in blood glucose and a slower gastric emptying in the treatment 
group as compared to the control group in diabetic patients. A similar study was 
conducted by Sandberg et al. (1994) who attempted to observe the effects of a 500g milk 
shake containing 7.5g of alginate (40% guluronic) per day for two weeks in ileostomy 
patients. The authors reported an increase in fat excretion and decreased bile excretion in 
the ileostomy effluent. Despite the positive effects from both of the aforementioned 
studies, the samples used were small with seven in Torsdottir et al. (1991) and six in 
Sandberg et al. (1994) making it difficult to interpret the findings. Both studies used 
alginate with chemical composition of 60% mannuronic acid, and as mentioned 
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previously G blocks have a greater ability to form stronger more stable viscous gels. 
Furthermore acid gels made up of M blocks or alternating MG residues have a lower 
apparent Youngs modulus compared to G blocks, thus making them less stable than G 
blocks in the stomach (Draget et al., 1994; Hoad et al., 2004). Paxman et al. (2008) 
addressed the molecular make-up of the alginate used in beverages and used an alginate 
made up of 65-75% guluronate. All participants recorded a seven day food diary of all 
food and drink consumed. The treatment and control group were given seven 100ml 
coded plastic bottles with tamper evident caps. The treatment beverage included 1.5g 
sodium alginate, 0.7g calcium carbonate and flavourings, and the control group consumed 
a slim fast drink. Both groups were advised to add water to one drink per day to make 
them up to 100ml and then consume the beverage 30 minutes prior to the breakfast or 
evening meal once a day for seven days. Upon analysing the seven day food diaries the 
authors reported that those in the treatment group consumed on average 134.8 Kcal less 
per day over the seven day treatment compared to the control group. However due to the 
difference in beverages consumed between the groups the questions remains as to 
whether the difference in Kcal consumed would have been greater if the control group 
had consumed a beverage similar to the treatment without alginate. Irrespectively of the 
above there is sufficient evidence to suggest that the use of alginate beverages at reducing 
such variables as energy intake and postprandial blood glucose and increasing satiety. 
Nevertheless the question still remains over the palatability of the drinks in the mouth and 
as it travels down the gastrointestinal tract. When alginate is added to solution it can 
become viscous, even in de-ionised H₂O (DH₂O) at relatively low concentrations and 
exhibit slimy characteristics (Ellis et al., 1981).  
Wolf et al. (2002) attempted to tackle the problem of poor palatability of alginate in 
solution. They indicated that they could produce a liquid that is not viscous at neutral pH, 
but then becomes viscous in the stomach. They combined alginate with water and 
potassium citrate, in an attempt to reduce the level of viscosity within the mouth and 
stomach. The authors suggested that by adding potassium citrate to H₂O it will bind the 
calcium. This would mean that when alginate is added the viscosity of the solution should 
remain low at a neutral pH and therefore not affect palatability. Upon drinking the 
solution and mixing with gastric juice the pH will reduce to around 1-2 and the alginate 
will only then form an acidic gel. Through the formation of an acid gel the authors 
reported attenuation of postprandial glycemic response, nevertheless the question remains 
would they have observed even greater reduction if potassium citrate was not used. 
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Despite the larger sample size used by Wolf et al. (2002) (30 healthy participants) in 
comparison with those mentioned previously (Sandberg et al., 1994; Torsdottir et al., 
1991), the authors did not report what the molecular makeup or concentration of the 
alginate, thus making it difficult to draw any conclusion based on the alginate added to 
the beverage. Hoad et al. (2004) indicated that the major flaw with using alginate in a 
beverage form is that no chewing is required and therefore gastric secretion would 
initially be low resulting in a low initial dilution of the beverage (Hoad et al., 2004).  The 
lack of gastric juice secretion may result in a poor gel formation and therefore the effects 
of alginate beverages previously mentioned may not be as effective as food including 
alginate.    
An alternative delivery of alginate which has been considered is the inclusion of alginate 
into a cereal bar. Williams et al. (2004) added 1.6g of alginate to a crispy bar and 
observed the effect on postprandial glycemic response. The treatment group had a 
significantly attenuated postprandial glycemic response in comparison with the control 
cereal bar, with no adverse gastrointestinal effects. The authors attributed this blunting of 
the postprandial glycemic response to the cereal bar becoming viscous as the bar is 
digested and the alginate is released. Although the authors did not measure additional 
affects such as gastric emptying they suggested that the formation of a gel in the stomach 
would have increased motility through the upper GI tract and therefore also affect nutrient 
digestion and absorption. Contrastingly Mattes (2007) reported no significant difference 
between an alginate cereal bar and the control bar for hunger and dietary intake. Although 
they didn’t specify the molecular composition of the alginate, they did include 4.9g of 
dietary fibre compared to 0.62g in the control bar. Therefore the dietary fibre used may 
not have been alginate. Mattes (2007) may have used another dietary fibre that is not 
soluble and thus there was no gel formation in the stomach and no impact upon hunger. 
The molecular composition of the alginate may have been the reason why there was no 
significant difference between groups. Furthermore the taste, pleasantness, sweetness and 
texture and palatability of the control bar were all significantly higher compared to the 
treatment bar. The most recent study using alginate as a supplement was a study by 
Jensen, Kristensen, and Astrup (2012 (a)) who used alginate as a blackcurrant beverage 
with a calorie restricted diet. The study reported a reduction in weight loss in the 
treatment group of 6.78 compared to 5.04kg in the control group, however these 
differences were non-significant. Furthermore the treatment group also reported poorer 
palatability and other symptoms such as abdominal pain and distension compared to the 
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control group. Issues with both beverages and cereal bars may be due to a lack of 
appropriate mixing in the stomach and specifically in beverages the slimy texture of the 
beverage resulting in poor palatability despite the addition of a calcium source to reduce 
this. The mixing of the alginate with other ingredients and other meal constituents appears 
to be necessary to increase the viscosity inside the stomach which appears to be essential 
in order to experience the physiological benefits of alginate (Torsdottir, Alpsten, 
Andersson, & Einarsson, 1989). 
1.9 Bread Rationale 
Although there is both in-vitro and in-vivo evidence supporting the use of alginate as a 
possible anti-obesity treatment, the vehicle in which to deliver alginate in appears to be a 
major obstacle. The work from this laboratory to date has only been carried out in test-
tubes and has not taken into account the various stages involved in digestion (Strugala et 
al., 2005; Sunderland et al., 2000; Wilcox et al., 2014). Furthermore the in-vivo studies 
that have added alginate to a food or drink have faced issues such as palatability and a 
slimy feeling in the mouth.  
Bread was chosen as a potential delivery method for alginate as it is regularly eaten on a 
day to day basis by most people. Furthermore the UK bread market is worth in excess of 
£3.4 billion per year, which equates to 11 million loaves of bread cooked per day 
(Federation of bakers). In addition to this the ingredients of bread make is a suitable 
vehicle for the delivery of alginate. The main constituent of bread is carbohydrates and as 
the majority of carbohydrates in bread which is generally starch is digested in the small 
intestine. If the alginate is bound to the ingredients within the bread then the anticipated 
result would be that the alginate would be released here as the bread is digested as long as 
alginate does not inhibit α-amylase in the small intestine. Although the release of the 
alginate in the small intestine is not crucial, it may have its benefits as it is in the small 
intestines where between 85-90% of fat is digested (Miled et al., 2000). 
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Chapter 2: Alginate Quantification      
2.1 Introduction 
Alginates are present in brown algae as a matrix polysaccharide in the cell walls, and are 
by far the most abundant polysaccharide present, making up to 40% of their dry weight 
(Ertesvåg & Vallaa, 1998). Alginates are a co-polymer of 1-4 linked D-mannuronic (M) 
and L-guluronic (G) acid residues (Stokke et al., 2000). These M and G residues can 
combine to form MM blocks (mannuronic), GG blocks (guluronic) and MG blocks which 
have a profound effect on the physiochemical properties of the alginate (Brownlee et al., 
2005). The differing physiochemical properties are what makes alginate unique and 
highlights it applicability for use, ranging from shoe polish to medical use (Uludag, De 
Vos, & Tresco, 2000; Yamamoto, Kumagai, Sakiyama, Song, & Yano, 1992). Despite the 
variety of industries alginate is used within, it is there use in the food industry that 
generates the most revenue with over 27,000 tonnes produced yearly (Jensen, 1993). 
Interestingly more and more work is being conducted regarding the use of alginate as an 
obesity treatment (Strugala et al., 2005), and more specifically the addition of alginate to 
a food vehicle as an obesity treatment. Cereal bars and drinks have been used previously, 
with studies reporting increased fat excretion (Williams et al., 2004), increased bile 
excretion (Sandberg et al., 1994) and a reduced Kcal intake (Paxman et al., 2008). Studies 
such as these support the use of alginate as a possible treatment for obesity; however the 
main issue amongst these studies is the poor palatability of the vehicle used for delivery, 
and therefore people think of these as a medicine as oppose to a dietary supplement. 
Furthermore the sample sizes used previously are relatively small making it difficult to 
compare the findings. Previous research into diets has reported an adherence rate of only 
15% (Ayyad & Andersen, 2000), therefore any weight lost during this time period is 
regained quickly afterwards. It therefore seems a reasonable assumption that if alginate 
can be delivered in a vehicle that is not associated with poor palatability, and that people 
are already consuming then this may be a useful tool that may contribute towards tackling 
the obesity epidemic. 
If alginate is to be used as an obesity treatment the release rate of alginate from said 
vehicle needs to be determined. Methods to quantify alginate must be sensitive, accurate, 
repeatable, high throughput and must be robust enough to remove any interference from 
un-digested debris. The most accepted techniques used for the quantification of alginate 
include chromatographically, after acid hydrolysis, colorimetrically subsequent to uronic 
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acid degradation and UV spectrophotometry following detergent complexation (Usov, 
1999). Although these techniques are effective at quantifying alginates, they involve 
extensive sample preparation and are only sensitive over a narrow pH range. Such 
methods may not be suitable for samples taken from in-vivo digestion, as the pH can 
range from anywhere between 1-8. Furthermore there are other factors such as bile and 
pancreatic juice which may also interfere with current techniques for quantifying alginate.   
Several alternative methods for the quantification of alginate have been designed which 
all use varying methods to prepare the alginate, but essentially a colorimetrically 
technique to stain the alginate and then measure absorbance has been used. Blumenkrantz 
and Asboe-Hansen (1973) adapted an earlier technique and quantified alginate by heating 
uronic acids to 100˚C in concentrated sulphuric acid/tetraborate treated with meta-
hydroxydiphenyl. They then measured the absorbance of samples through the appearance 
of chromogen. This heating process may not be suitable if the samples concerned require 
further analysis of digested products, as temperatures in excess of 100˚C will denature the 
enzymes within the samples. Furthermore there is evidence to suggest that alginate is not 
heat stable at temperatures above 80˚C (Leo, McLoughlin, & Malone, 1990). Leo et al. 
(1990) and Serp, Mueller, Von Stockar, and Marison (2002) reported that once the 
alginates were exposed to temperatures in excess of 80˚C the gel bead strength and 
viscosity decreased, however bead diameter increased, suggesting the bonds between the 
alginate molecule are also collapsing. An alternative method for quantifying alginate was 
designed by Halle, Landry, Fournier, Beaudry, and Leblond (1993), who developed a 
sensitive assay with the purpose of quantifying the amount of alginate in a solution and 
microcapsules. This method was based on the metachromatic changes induced when the 
cationic dye 1,9-dimethyl methylene blue (DMMB) binds to alginate. This assay was 
sensitive enough to work over a wide range of concentrations of alginate and a wide 
range of pH ranging from 6.5 to 13. Nonetheless as with the earlier methods this range of 
pH would not be suitable for in-vivo digestion. Richardson, Dettmar, Hampson, and Melia 
(2004) developed and evaluated this method further to observe its reliability, and to 
observe if alginate molecular composition and weight affected the complexation of 
DMMB and alginate. They reported that this method had excellent reproducibility 
(coefficient of variation (CV) <3%), sensitivity (0.3g/L) and excellent linearity (r = 0.99). 
However the alginate in the study was used in combination with an anti-reflux treatment 
and was scraped from the mucosal of the oesophagus, which may explain why these 
results were not repeatable with samples within this laboratory. An alternative assay that 
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may be suitable is the Periodic acid Schiffs (PAS) assay which was developed by Mantle 
and Allen (1979). The PAS assay was developed as a technique for the estimation of 
glycoproteins containing carbohydrates with adjacent hydroxyl groups, which was 
sensitive enough to detect small amounts of glycoproteins (10-100μg/ml). The PAS assay 
is dependent on the number of hydroxyl groups in the molecule and the mechanism of 
how it works can be subdivided into three steps. The initial phase involves preparation of 
the basic fuchsin with metabisulphate, which decolourises the solution forming sulphonic 
acid groups. Secondly periodic acid and acetic acid are mixed and then added to the 
sample, resulting in oxidation. This oxidation splits the rings between adjacent hydroxyl 
groups converting them to aldehydes. Upon addition of the fuchsin the adjacent sulphonic 
acid group combines with the adjacent aldehydes, producing a red colour. As the intensity 
of the red colour is dependent on the number of hydroxyl groups, the larger amounts of 
alginate should produce a darker red and thus a larger OD value (Mantle & Allen, 1979). 
Alginate also possesses adjacent hydroxyl groups at C
2
 and C
3
 suggesting that the PAS 
may be a suitable method for quantifying alginate within a solution. 
In addition to quantify alginate within a solution, any methods must also be able to 
quantify the release rate of alginate from a given vehicle once said vehicle has been 
digested. The use of alginate as a food additive is not new concept, however its use as an 
obesity treatment in a palatable food vehicle consumed during an ordinary day to day diet 
is. Determining the release rate of alginate from the vehicle and understanding how the 
alginate acts within foods and how these foods behave both in-vivo and in-vitro digestion 
requires further understanding.  
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2.2 Aims 
As previously mentioned bread is one of the food types that is consumed on a large basis 
and is easily accessible to the majority of the population. For these reasons bread was 
developed in conjunction with Greggs PLC, which contained a powder mix of alginate 
added to a bread mixture based on 4% by weight, and can be seen in Figure 3. If alginate is 
to be used as a potential obesity treatment the release rate of alginate from the bread 
during digestion in a synthetic model gut must be determined.  
The aims of the current chapter are: 
 Assess the ability of cationic dyes DMMB, Safranin-0 and Toludine Blue to 
quantify alginate in DH₂O and in samples taken from the model gut. 
 To modify and utilise the PAS assay and determine if it can be used to quantify 
alginate in DH₂O and in samples taken from the model gut.  
 To assess whether the model gut is able to replicate in-vivo digestion and digest 
the bread and potentially release the alginate into the model gut. 
 To determine if the cationic dyes or the PAS assay is able to determine the release 
rate of alginate from an alginate enriched bread.  
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2.3 Methods 
2.3.1 Materials 
The alginate bread (AB) was similar to an everyday bread and this can be seen in Figure 3. 
Greggs master baker was given a selection of alginates that inhibited pancreatic lipase 
and selected the alginate that created the most palatable and aesthetically pleasing bread. 
The only major addition to the AB was sodium alginate and an increase in the fat (Table 1 
and Table 2). The alginate used for the bread was MANUCOL DM selected by Greggs 
PLC master baker as this alginate made the best performing bread. The alginate was a gift 
from FMC BioPolymer AS, Drammen, Norway and was stored at 4˚C in tightly-sealed 
containers and all alginate weights were corrected for water content. 
 
Figure 3.  Alginate bread produced by Greggs Plc. 
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Table 1.  Greggs Plc control bread ingredients. 
Regular Bread BF0003-5 
Nutrients per  100g 
   
Energy (kcal)  247 
Energy (kJ)  1046 
Protein (g)  10.2 
Carbohydrates (g)  46.2 
 sugars 1.1 
  starch 45 
Fat (g)   1.7 
  saturates 0.5 
 monosaturates 0.3 
 polyunsaturates 0.6 
 trans 0 
Dietary Fibre (AOAC) (g)  3 
Sodium (g)  0.4 (374mg) 
Water (g)  36.8 
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Table 2.  Greggs Plc alginate enriched bread ingredients. 
Alginate Bread R110063/0 
Nutrients per  100g 
   
Energy (kcal)  335 
Energy (kJ)  1406 
Protein (g)  8.1 
Carbohydrates (g)  43.9 
 sugars 2.6 
  Non milk extrinsic sugars 2.6 
 starch 38.4 
Fat (g)   14.1 
  saturates 6.2 
 monosaturates 6.3 
 polyunsaturates 0.8 
 trans 0.1 
Dietary Fibre (AOAC) (g)  3 
DM Alginate  4 
Sodium (g)  1.5 
Water (g)  31.3 
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Sodium metabisulphate, basic fuchsin, periodic acid at 50%, acetic acid, methanol, 
Safranin-O (S-O) and Methylene Blue Hydrate (DMMB) were purchased from Sigma-
Aldrich Co Ltd, Dorset, UK. Artificial saliva was composed of 62mM sodium hydrogen, 
6mM di-potassium hydrogen, 15mM sodium chloride, 6.4mM potassium chloride and 
3mM calcium chloride. Artificial gastric juice was composed of 49.6mM sodium 
chloride, 9.4mM potassium chloride, 2mM monopatassium phosphate and 5mM urea. 
Artificial pancreatic juice was composed of 110mM sodium bicarbonate, 2.5mM di-
potassium hydrogen, 54.9mM sodium chloride, 1mM calcium chloride and 1.67mM urea, 
all components of artificial solutions were purchased from Sigma-Aldrich Co Ltd, Dorset, 
UK. Enzymes α-amylase from hog pancreas (50 U/mg), Pepsin from gastric mucosa (> 
2500 units/mg protein, P7012-5G) and Pancreatin from porcine pancreas (P7545-500G) 
were purchased from Sigma and gastric like lipase was purchased from Amano enzyme 
(Inc AP12) for use in the model gut.  
2.3.2 Equipment 
All assays were carried out using BioTek 96 well plate reader at 550nm (ELx808 BioTek, 
Bedfordshire, UK). Two Grant GD 100 water baths were used for incubating synthetic 
model gut solutions and samples within the model gut at 37˚C (Fisher Scientific, 
Loughborough, UK). A Sci-Q 401U/D peristaltic pump was used to pump synthetic 
solution into samples in the synthetic model gut (Watson-Marlow, Fisher Scientific, 
Loughborough, UK), three IKA
® 
laboratory egg compact mixers were used for mixing in 
the model gut. A 213 microprocessor pH meter (Hana instruments, Leighton Buzzard, 
UK) was used to assed pH. A Thermo Jouan BR4i Mu Scientific Centrifuge 
(Basingstoke, UK) and an Eppendorf Centrifuge 5415 R (Stevenage, UK) were used for 
samples <4ml and >2ml, respectively. 
2.3.3 Synthetic Model Gut Procedure 
In order to ascertain if alginate is released from the bread vehicle the bread had to be 
digested. Therefore an open model gut system, as seen Figure 4, which replicates 
digestion in the mouth, stomach and small intestines with three experiments running 
simultaneously. Each sample initially started at zero minutes with either i) 5.2g AB, ii) 
5.2g control bread (CB) or iii) model gut (MG) and all with 5µl of 3mg/ml amylase (α-
amylase from hog pancreas, Sigma 10080-25G c.50 U/mg), 5ml DH₂O and 5ml synthetic 
saliva. Samples of bread were taken at random and were homogenous in nature. The 
alginate and control bread were broken up into crumbs ranging between 2-4cm prior to 
adding to the model gut to simulate mastication in the mouth. The three samples were 
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then placed into water bath two and mixed at 75 revolutions (rpm)/min for 30 seconds, 
which represents mastication in the mouth. 50ml synthetic gastric juice was then added, 
which included 0.5mg/ml pepsin (Sigma, P7012-5G) and 0.04mg/ml gastric lipase 
(Amano Enzyme Inc AP12) whilst mixing continued. The remaining synthetic gastric 
juice (also containing pepsin and gastric lipase) was fed to the three experiments via a 
peristaltic pump at 0.5ml/min for 60 minutes whilst continually mixing, which represents 
digestion in the stomach. After 60 minutes 25ml porcine bile, which was homogenised 
and pre warmed to 37˚C (a gift from Thompson abattoir, Bishop Auckland, UK) before 
being added to each of the three experiments. Synthetic pancreatic juice (which included 
pancreatin at 7g/100ml) was then pumped into the three experiments at 0.25ml/min for 
120 minutes. During the model gut process a one ml sample was taken at 0.5 minutes 
(after mastication in the mouth), and then every 15 minutes for a total of 180.5 minutes. 
In addition to confirm the model gut system is replicating the pH of in-vivo digestion the 
pH was monitored after 0.5minutes (mouth), and then every 15 minutes for a total of 
180.5 minutes. All enzymes, unless specifically mentioned are added fresh and both water 
baths were set at 37˚C throughout the whole process. 
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AB = Alginate Bread 
CB = Control Bread 
MG = Model Gut Solution 
 
1. 0-30 seconds  - Samples added to water bath 2 with synthetic saliva  
2. 30 seconds – 60 minutes – 50ml synthetic gastric juice added to each sample. Gastric juice 
then pumped from water bath 2 at 0.5ml/min into each sample. 
3. 61-180.5 minutes – 25ml porcine bile added and synthetic pancreatic juice pumped in from 
water bath 2 at 0.25ml/ml into each sample. 
 
Figure 4.  Model gut set up for in-vitro digestion shown in the gastric phase. 
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2.3.4 DMMB, S-O, T-B and PAS Assay 
DMMB, S-O and T-B were made up at concentrations ranging from 0.1-2.5mM in DH₂O. 
Alginate DM was made up in DH₂O using serial dilutions ranging from 0.1-10mg/ml. 
200µl of each concentration of alginate were then added to a 96 well plate in duplicate 
and 50µl of each dye at varying concentrations was added to each concentration of 
alginate and incubated at room temperature for 30 minutes, and then the absorbance was 
measured at wavelengths between 575 and 595nm on the microplate reader. The PAS 
assay was adapted from Mantle and Allen (1978) to be used on a 96 well plate. 20µl of 
50% periodic acid was added to 10ml of acetic acid at 7% in DH₂O and mixed. 20µl of 
this mixture was then added to 200µl of sample in a 96 well plate in duplicate. Sodium 
metabisulphate was added to schiffs fuchsin-sulphite reagent at 16.7mg/ml and mixed. 
The 96 well plate and schiffs fuchsin-sulphite mixture was then incubated for one hour at 
37˚C. After incubation 20µl of schiffs fuchsin-sulphite was added to each well and the 
plate was then left at room temperature for 30 minutes for colour development, before 
absorbance was measured at 550nm. 
2.3.5 Mucin and Alginate Standard Curves 
Techniques previously described by Mantle and Allen (1978). Isolated porcine gastric 
mucin was made up to a concentration of 1mg/ml in DH₂O. Sodium alginate was 
dissolved in DH₂O or model gut solution (MG) from 180 minutes at a concentration of 
0.49mg/ml and at 2mg/ml respectively. The mucin and alginate in DH₂O were then 
diluted down further in DH₂O to produce a standard curve, and then 200µl of each 
concentration was added to a 96 well plate in duplicate. The alginate in the MG was 
diluted by 50% in methanol and placed in the freezer at -20˚C for 30 minutes, before 
being centrifuged at 4100rpm for 20 minutes at 4˚C. The supernatant was then removed, 
leaving a pellet which was then re-suspended in 4ml DH₂O. Based on the dilutions from 
2mg/ml this left a concentration of 0.25mg/ml which was then diluted in DH₂O to create a 
standard curve. The alginate in DH₂O was used to represent the stomach phase (0.5-60 
minutes) and the alginate in MG was used to represent the small intestinal phase (60.5-
180 minutes). Once mucin and alginate in DH₂O and MG had been added to a 96 well 
plate the PAS assay was run. The absorbance for DH₂O alone was subtracted from the 
mucin and alginate absorbance as a control. The control for the alginate in MG was MG 
alone with the same dilutions used to process the alginate in MG, again to account for any 
interference. 
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2.3.6 Alginate Isolation 
Once the samples have been extracted from the model gut the alginate was isolated. Upon 
extraction samples taken at from 0.5 – 60.5 minutes were titrated to between pH 6-7 using 
1M sodium hydroxide and then centrifuged at 13,500 rpm for 10 minutes to remove any 
insoluble material. Following centrifugation 500µl of the supernatant is added to 500µl 
DH₂O and then vortexed. 200µl of the sample was added to a 96 well plate in duplicate 
for each time point, and for each of the three samples (MG, AB and CB). The samples 
taken between 60.5 minutes (after adding bile) and 180.5 minutes were diluted in 
methanol by 1:1 (vol:vol) and mixed. The samples were then placed in a freezer at -20˚C 
for 30 minutes, before being centrifuged at 4100 rpm for 20 minutes at 4˚C. The 
supernatant from the samples is then removed and 4ml DH₂O is added and the pellet was 
re-suspended. 200µl of the sample was added to a 96 well plate in duplicate for each time 
point for each of the three samples (MG, AB and CB) and the PAS assay was carried out 
as described earlier. As a control the absorbance for the CB was removed from that of the 
AB. 
2.4 Statistical Analysis 
Statistical calculations were undertaken using SPSS Statistics 19 (IBM, Predictive 
Analysis Software, USA). Data presented as mean and standard error of mean (± S.D). A 
Two-way Repeated ANOVA followed by a Post-Hoc Bonferroni were undertaken at a 
significant level (α) of 0.05 to compare the pH of the AB, CB and MG, and to compare 
alginate release from the bread vehicle at 0, 60 and all time points between 60.5 and 180 
minutes. 
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2.5 Results 
2.5.1 Cationic Dyes 
Table 3.  Ability of cationic dyes and basic fuchsin (PAS assay) to estimate alginate concentrations. 
For DMMB * indicates the range covers the absorbance range 1.2-2.1 derived from absorbance at 595 and 
550nm greater than 1. + This range covers absorbance 2.7-3.6 (where absorbance greater than 1 are not 
reliable). n = 6 measurements for each assay system.  
 
DMMB - Table 3 shows the results from the addition of DMMB at 2.5mM to sodium 
alginate at a ratio of 595:550nm, at concentrations ranging from 0-2mg/ml. The Pearsons 
correlation coefficient (r) was 0.86 with an absorbance range of 1.2-2.1 (0.7) for a 0-
2mg/ml. 
 
S-O - DM sodium alginate was added to 2mM S-O at concentrations ranging from 0-
10mg/ml and the absorbance was measured at 595nm. The r was 0.98, and the absorbance 
increased as the alginate concentration increased. However the absorbance range for 0-
10mg/ml was 0.14-0.22 (0.08) (Table 3). 
 
T-B – The r was 0.63 when 2mM T-B was used, with a decrease in absorbance as the 
alginate concentration increased. Although the range of absorbance of 2.7-3.6 (0.9) was 
greater than S-O, the absorbance was beyond the linear scale of 1 (Table 3). 
Dye and Concentration Wavelength Concentration 
Range 
Pearson’s 
coefficient  
(r) 
Absorbance 
Range 
2.5mM DMMB 
 
Ratio 
595/550nm 
0-2 mg/ml 0.86 1.2-2.1  
(0.7)* 
2mM Safranin-0 (S-O) 595nm 0-10 mg/ml 0.98 0.14-0.22 
(0.08) 
2mM Toludine Blue (TB)  595nm 0-0.3 mg/ml 0.63 2.7-3.6 
(0.9)
+
 
PAS Assay on samples from 
gastric phase of model gut  
550nm 0-0.5 mg/ml 0.99 0.02-0.45  
(0.43) 
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2.5.2 Mucin Standard Curve 
The data in Figure 5 illustrates the standard curve for mucin in DH₂O, which was used as a 
positive control and confirms the previous research of Mantle and Allen (Mantle & Allen, 
1978). There is excellent linearity and the range of absorbance and it remains on the 
linear scale between 0-1OD. 
 
Figure 5.  Mean (± S.D) standard curve of mucin in DH₂O using PAS assay (R2 = 0.98) (n=6). 
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2.5.3 Alginate Standard Curve for stomach and small intestinal phase 
The data in Table 3 and Figure 6 illustrate the absorbance range and standard curve for 
sodium alginate in gastric juice (30 seconds-60 minutes) and MG (180.5 minutes) 
respectively. The range of absorbance was 0.02-0.45 and 0.01-0.2 for 0-0.5mg/ml and 0-
0.25mg/ml respectively, with excellent linearity for both phases of the model gut.  
 
 
Figure 6.  Mean (± S.D) standard curve for sodium alginate in model gut solution following alginate 
isolation, using PAS assay (n=6) (representing the intestinal phase) (R2= 0.99). 
 
The data presented here demonstrates that the modified PAS is sensitive, repeatable, high 
throughput and is able to overcome interference from the model gut. When comparing 
dyes DMMB, T-B and S-O at various concentrations with the PAS assay, it is only the 
PAS assay that has good linearity, range of absorbance, and an increase in absorbance 
with an increase in concentration for relatively low concentrations of alginate.  
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2.5.4 pH of model gut system 
The model gut replicates the pH that would be expected for in-vivo digestion (Figure 7). 
The pH at 0 minutes in the mouth was 7.1 (+ 0.1), 7.4 (+ 0.2) and 7.5 (+ 0.3) for MG, CB 
and AB respectively. Following the addition of gastric juice the pH was reduced to 2.0 (+ 
0.1), 2.2 (+ 0.2) and 2.1 (+ 0.1) for MG, CB and AB respectively. After 60 minutes in the 
gastric phase the pH had reduced further to 1.9 (+ 0.1) for MG, but rose for CB and AB to 
2.8 (+ 0.4) and 3.2 (+ 0.3) respectively. At 180.5 minutes the pH had risen for all three 
samples to 7.0 (+ 0.4), 7.3 (+ 0.3) and 6.8 (+ 0.3) for MG, CB and AB respectively. There 
were no significant differences between MG, AB and CB at any time points (p>.05). 
 
 
Figure 7.  Mean (± S.D) pH of the model gut throughout digestion of model gut solution alone, 
alginate and control bread (n=14). 
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2.5.5 Alginate release from bread. 
The standard curve of the modified PAS assay was used to determine if any alginate had 
been released from the model gut during digestion. It is evident from Figure 8 that the 
majority of alginate is released from the bread in the small intestinal phase of the model 
gut. Based on 4% by weight and the amount of bread added to the model gut there could 
be a total of 208mg, ((5.2 / 100) x 4 = 208, depicted on Figure 8) of alginate released if 
complete digestion occurs in the model gut. There was a significant effect of time on the 
release of alginate (p<.05). Based on the total amount of alginate that is present in the 
bread there was 5.1 (7.0), 9.8 (1.0) and 86.1 (15.6) percent of the total alginate released at 
0.5, 60 and 180.5 minutes respectively. The Post-Hoc Bonferroni reported no significant 
difference between 0.5 and 60 minutes (p>.05). In contrast there was a significant 
difference in alginate release from the bread vehicle for all time points from 90-180.5 
minutes when compared to 0.5 and 60 minutes (p<.05) (Figure 8). 
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Figure 8.  Mean (± S.D) milligrams of alginate released from digested bread in the stomach and 
small intestinal phase (corrected for interference from control bread) (n = 13) (* indicates significant 
difference in alginate release between 0 and 180 minutes and 60 and 180 minutes at p<.05). The line at 
208mg to indicate total alginate content within the alginate bread. 
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2.6 Discussion 
The purpose of this chapter was to assess if cationic dyes were able to bind with alginate, 
and provide a suitable method to quantify alginate in a solution. Furthermore to assess if 
this method is suitable for determining if alginate is released from a bread vehicle at 
multiple time points. The data presented here indicates that the PAS assay is a simple and 
reproducible method for quantifying alginate in a solution. In addition the data here also 
indicates that this method may be robust enough to withstand the interference from the 
model gut system and still quantify the release of alginate from a bread vehicle at various 
time points.  
Measurement of alginate is confounded within this system as the model gut has additional 
factors that may interfere with any techniques. Throughout the model gut there may be 
undigested bread which would need to be removed in order to ascertain the alginate 
released from the bread matrix during digestion. In addition the two major phases of the 
model gut also bring with them interference. The pH in the mouth can range between 5-7, 
and between 1.5-3.5 in the stomach (Allen, Flemstrom, Garner, & Kivilaakso, 1993) 
which is confirmed in Figure 7. This may pose a problem because once the pH of a 
solution passes below the acid dissociation constant (pKa) of the alginate gel formation is 
likely to occur (Atkins et al., 1971), making any binding with a dye difficult. Furthermore 
with the addition of porcine bile and pancreatic juice the colour of solution goes from 
transparent to a dark green/brown solution, therefore affecting any colorimetric 
measurement techniques. 
Previous research has suggested several cationic dyes which may bind with alginate such 
as DMMB, T-B and S-O (Day & Marceau-Day, 1990; Richardson et al., 2004). An 
alternative method for quantifying alginate was designed by Halle et al. (1993), who 
developed a sensitive assay with the purpose of quantifying the amount of alginate in a 
solution and microcapsules. This method was based on the metachromatic changes 
induced in the cationic dye 1,9-dimethyl methylene blue (DMMB) as it binds to alginate. 
This assay was sensitive enough to work over a wide range of concentrations of alginate 
and a wide range of pH ranging from 6.5 to 13. Nonetheless as with the earlier methods 
this range of pH would not be suitable for in-vivo digestion. Richardson et al. (2004) 
developed and evaluated this method further to observe its reliability, and to detect if 
alginate molecular composition and weight affected the complexation of DMMB and 
alginate. Richardson et al. (2004) used alginate to bind with an anti-reflux treatment that 
was sprayed onto oesophageal mucosa and then scraped off. These scrapings were then 
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processed and DMMB was added and the absorbance was measured. They reported that 
this method had excellent reproducibility (coefficient of variation (CV) <3%), sensitivity 
(0.3g/L) and excellent linearity (r = 0.99). However the alginate in the study was used in 
combination with an anti-reflux treatment and was scraped from the oesophageal mucosa, 
which may explain why these results were not repeatable with samples within this 
laboratory. The data presented in Table 3 illustrates the most repeatable data replicating 
the methods of Richardson et al. (2004) produced in this laboratory. The R² values of 0.86 
and 0.63 for DMMB and T-B, respectively indicate a poor relationship between alginate 
concentration and absorbance. An alternative dye used here was S-O, which like DMMB 
and T-B is a cationic dye, and thus may complex with alginate through electrostatic 
forces. Although the data in Table 3 elucidate an excellent R² of 0.98, the range of 
absorbance is less than 0.1. This is despite the large concentrations of alginate that would 
suggest a larger absorbance if the dye is binding to the alginate. The anticipated result 
would be that if there is a larger concentration of alginate then this would be represented 
by a substantial increase in absorbance. Pal and Mandal (1990) suggest that cationic dyes 
may possess the ability to bind via electrostatic forces to the uronic acid carboxyl groups 
within alginate. Based on the work of Pal and Mandal (1990) the assumption would be 
that DMMB, S-O and T-B should posse the ability to bind with alginate; however the data 
presented here does not support these suggestions. One possible explanation of why these 
may not bind are that the research of Richardson et al. (2004) and Day and Marceau-Day 
(1990) used DMMB and gentian violet respectively, in conjunction with other 
compounds. For example Richardson et al. (2004) used alginate in combination with an 
anti-reflux treatment. This was sprayed onto oesophageal mucosa and then scraped off. 
This may suggest that it may be something within the anti-reflux treatment, mucin or 
something else from the oesophagus that is binding with the alginate, and in turn binding 
with the DMMB. Furthermore all three dyes are hydrophillic, with minimum positive 
charge, whereas alginate molecules are hydrophilic in nature (Smidsrod, 1974). For 
example DMMB (Taylor & Jeffree, 1969) has one potential binding site, although T-B 
(Bergeron & Singer, 1958) and S-O (Bandoni, 1979) contain more than one potential 
binding sites which may explain the results presented here. Furthermore based on the pKa 
of the dyes there is potential for charge:charge interactions as well as hydrogen bonding 
which would mean additional binding sites for the alginate with two, three and four 
potential binding sites for DMMB, T-B and S-O respectively (Figure 9). There is no 
research reporting a simple high throughput method for the easy and rapid quantification 
of alginate alone in a solution.  
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Figure 9.  Structure of cationic dyes, A –1,9-dimethyl methylene blue (Taylor & Jeffree, 1969), B – 
Toludine Blue (T-B) (Bergeron & Singer, 1958) and C - Safranin-O (S-O) (Bandoni, 1979).  
 
As an alternative option Mantle and Allen (1978) developed a technique, known as the 
PAS assay which was designed to quantify glycoproteins. The PAS is dependent on the 
number of adjacent hydroxyl groups within a molecule, so in essence the larger the 
number of hydroxyl groups, the larger the absorbance value. As the intensity of the red 
colour is dependent on the number of adjacent hydroxyl groups, the larger amounts of 
glycoproteins should produce larger absorbance values. Alginates have similar structures 
to the carbohydrate side chains of glycoproteins and possess adjacent hydroxyl groups at 
C
2
 and C
3 
(Smidsrod, 1974), suggesting the PAS assay may be suitable technique for 
quantifying alginate in solution. To be able to quantify alginate within the model gut a 
standard curve must be created, however as previously mentioned there is interference 
within the model gut which did affect the PAS assay. Sodium alginate was dissolved in 
DH₂O and model gut solution that had been run through the entire model gut up to 180.5 
minutes, at a concentration of 0.49 and 2mg/ml respectively. The background colour from 
the model gut solution added to colour of the PAS assay and therefore this needed to be 
reduced. Using a precipitation and dilution step, as described in the methods, the colour 
of the samples was reduced. A further correction was used to subtract the absorbance for 
the model gut solution alone. It is clear that the standard curve for alginate in both DH₂O 
and model gut solution has a good range of absorbance and linearity as demonstrated in 
Table 3 and Figure 6, and the mucin standard curve confirmed the PAS assays 
effectiveness. A further point of interest is that the absorbance per unit weight was larger 
for alginate in gastric juice than alginate in the small intestine. At any given alginate 
concentration the absorbance was larger in the stomach phase when compared with the 
small intestinal phase. A potential explanation for this may have been that the alginate 
may be interacting with something within the model gut, such as bile acids (Wang, 
A 
B C 
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Onnagawa, Yoshie, & Suzuki, 2001). If this is the case then this may reduce the ability of 
the alginate to interact with the PAS assay and account for the lower absorbance.  
As previously mentioned the PAS appears to be an effective method for quantifying 
alginate under the conditions mentioned here. In order for the bread to be digested the 
model gut must be operating at the optimal pH conditions for digestion (Allen et al., 
1993). Previous research has reported the pH in the stomach to range between 1.8-2.5 
(Lindahl, Ungell, Knutson, & Lennernas, 1997) however this pH can be buffered with the 
addition of a food or drink. The pH of the small intestines can begin as low as 2.5 in the 
duodenum and then raises up to around pH 8 with the addition of bile and pancreatic juice 
as the digesta pass through the small intestines (Brownlee, Forster, et al., 2010). These 
changes in pH during in-vivo digestion are optimal for digestion of protein, fat and 
carbohydrates and therefore it is essential that the model gut follows a similar pattern to 
ensure that digestion of the bread occurs, and that alginate is released from the bread. The 
data presented here supports the use of the model to replicate in-vivo digestion, and has 
optimal pH conditions for the digestion of bread to occur.  
If alginate is to be used as an obesity treatment the release rate of the alginate from the 
bread during digestion must be achieved. It is apparent from the data presented here that 
there is only a small amount of alginate released in the gastric phase, however the alginate 
is predominantly being released from the bread matrix in the small intestine. The main 
constituents of bread are carbohydrates, specifically starch and it has been well 
documented that salivary and pancreatic amylase liberates α-1-4glucose linkages in 
starch, with the majority occurring in the small intestines (Crapo, Reaven, & Olefsky, 
1977; Jenkins et al., 1978; Jenkins et al., 1980). This liberation releases maltose 
maltotriose, α-limit dextrins and small portion of glucose. Once liberated the molecules 
that are released are then hydrolysed at the brush border before being absorbed into the 
blood stream (Jenkins et al., 1980). If the alginate is thoroughly mixed into the bread 
matrix then the expectation would be that as the starch is digested the alginate will be 
released from the bread matrix and this is what the results here show. These data also 
confirm that the PAS assay is a suitable method for determining the release of alginate 
from a bread vehicle in an in-vitro model gut.  
The time point of 180.5 minutes is generally the end of the in-vitro model gut, which does 
replicate in-vivo digestion in the small intestines; however in-vivo digestion may take 
longer depending on the contents of the digested meal. 85-90% of fat in the human diet is 
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digested in the small intestines and absorbed into the blood stream (Miled et al., 2000). 
Previously reported data from this laboratory has demonstrated that alginates can 
attenuate the activity of digestive enzymes (Richardson, Dettmar, Wilcox, Brownlee, & 
Pearson, 2011; Strugala et al., 2005; Sunderland et al., 2000). The reduction in the 
activity of digestive enzymes is dependent on the composition of the alginate, with some 
alginates reducing activity by up to 85% (Richardson et al., 2011). These data and the 
data presented here suggests that if the alginate is released in the small intestinal phase 
this may have an inhibitory effect on the activity of pancreatic lipase. If the lipase does 
not digest the di and triglycerides then they are too large to pass through the cell walls of 
the small intestines and will therefore pass through the upper gastrointestinal (GI) tract 
undigested. These data and the data presented here suggests that if the alginate is released 
in the small intestinal phase this may have an inhibitory effect on the activity of 
pancreatic lipase. Further work is required to assess if the alginate bread is able to inhibit 
fat digestion in the model gut system in the development of potential therapeutics 
treatments against obesity. 
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Chapter 3: Biological Activity of Alginate  
3.1 Introduction 
If dietary fibre, but specifically alginate is to be used in the treatment for obesity an 
appropriate delivery method must be designed. There is evidence that has investigated the 
use of alginate as an obesity treatment, and particularly using beverages and cereal bars as 
a delivery vehicle. Despite the numerous physiological benefits reported when adding 
alginate to a beverage or cereal bar, subjects generally experience poor palatability or 
other symptoms such as abdominal pain or distension compared to the controls (Jensen et 
al., 2012 (a); Sandberg et al., 1994; Torsdottir et al., 1991; Williams et al., 2004). The 
bread vehicle selected in the present study was used to observe an acute effect on 
triglyceride digestion and acceptability in ileostomy patients (both made by Greggs Plc) 
(data presented in Chapter 5). There were no significant differences between the two 
breads suggesting that acceptability of the bread in a clinical trial would not be an issue. 
In addition to the acceptability study the data presented suggests that as the alginate bread 
is digested within the model gut the alginate is released from the bread. This being the 
case then bread may be a suitable delivery method for alginate. Although the digestion of 
the bread, and release rate of alginate have been determined, further work must be 
conducted to assess the ability of the AB is able to reduce fat digestion both in-vitro and 
in-vivo. 
As previously mentioned the ability of alginate to form both ionic and acidic gels has 
received considerable interest, partially as this may be a possible mechanism for a 
reduction in the activity of digestive enzyme activity and increased satiety. Rees (1981) 
provided early evidence to suggest that the carboxyl and hydroxyl groups of the alginate 
were responsible for the binding sites of alginate and the formation of the “egg box 
model”, as depicted in Figure 10. This was later confirmed by the work of Braccini and 
Perez (2001) who developed a molecular modelling program which involved a pairing 
technique that assessed all the possible associations of the polymer chains with calcium 
ions to form dimers. Although Braccini and Perez (2001) generally discussed calcium, 
they indicated that the “egg box model” was able to accommodate ions of various sizes. 
The formation of ionic gels which is likely to occur in beverages that alginate is added to 
may account for the slimy mouth feel and poor palatability (Jensen et al., 2012 (a); Wolf 
et al., 2002). 
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Figure 10.  Egg-box model (Braccini & Perez, 2001). The dark circles depict oxygen atoms required 
for the organisation of the calcium ions.   
 
Furthermore, upon consuming the beverage it will pass from the mouth and into the 
stomach, where the pH can be as low as 1.8. At a pH below the pKa of the guluroinic and 
mannuronic acid (3.65 and 3.38, respectively) within alginate, an acidic gel is formed 
(Atkins et al., 1971). If the alginate forms an acidic gel Draget, Skjåk Bræka, and Stokke 
(2005) suggested that the “egg box model” would not be able to be maintained due to 
increased intermolecular hydrogen bonds. This formation of an acidic gel was confirmed 
when alginate was added to a milk based meal replacement beverage in a study by Hoad 
et al. (2004). This research used MRI scans to observe the characteristics of the beverage 
within the stomach. They reported that the milk based meal replacement that contained 
alginate formed large lumps within the stomach and increased satiety, however there was 
no difference between gastric emptying between the treatment and control groups. The 
formation of large lumps was said to be due to the formation of an acidic gel within the 
stomach and Hoad et al. (2004) suggested that this may be enough to cause poor mixing 
within the stomach between foods and digestive enzymes such as pepsin and gastric 
lipase. Although the development of an acidic gel may be enough to disrupt the digestion 
within the stomach it remains to be seen as to whether this acidic gel can within stand the 
muscular contractions within the stomach and the small intestines. If the gel cannot 
withstand the muscular contractions within the stomach then the gel will cease to exist at 
the high pH of the small intestine. Draget et al. (2005) demonstrated that acidic gels were 
considerably more turbid and had brittle textures compared to ionic gels. Furthermore 
compression analysis showed that acidic gels failed at a tenth of the load required to 
disrupt an ionic gel. These data demonstrate that alginates do form acidic gels within the 
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stomach, nonetheless it remains to be seen as to whether or not this formation is enough 
to have any impact upon digestive enzymes within the upper GI tract. Work by Seal and 
Mathers (2001) indicated that the formation of a gel may be responsible for reducing 
cholesterol and fat digestion in rats fed dry alginate in their food. Within the small 
intestine, the authors suggested that the alginate may reduce the interaction of bile salts 
and cholesterol, and thus affect cholesterol and its metabolites (Seal & Mathers, 2001). 
The data produced by Seal and Mathers (2001) may be due to a re-formation of an ionic 
gel as the pH will increase within the small intestines, indicating a more robust gel that 
may withstand the muscular contractions within the small intestines. However the authors 
failed to confirm this. 
The viscous/gel solution that alginates are able to form once combining with gastric juice 
are also believed to increase satiety and reduce calorie intake (Kristensen & Jensen, 
2011). It is by the same mechanism that Shah et al. (1986) suggested that the viscous 
solutions formed by water soluble dietary fibres was responsible for a reduction in pepsin 
activity. The authors indicated that the viscous solutions created a sluggish mixing 
process within the stomach, resulting in poor substrate-enzyme binding and thus causing 
a reduction in pepsin digestion. The in-vivo and in-vitro data here implies that viscosity 
may have a role to play in satiety and reducing digestive enzyme activity. Nevertheless, 
the question remains as to whether the alginate that is being released during digestion in 
the model gut increases the viscosity of the solution, as the previous data proposes. 
A further point of interest is whether the alginate contained within the bread is affected 
during the mixing and cooking processes involved in bread baking. Although we know 
that alginates are able to form ionic and acidic gels at 37˚C (Draget et al., 1994; Hoad et 
al., 2004), there is not a substantial amount of data on the properties of the alginate once it 
has been heated. McDowell (1977) suggested that when polymers are heated at 
temperatures above 100˚C the alginates structure may depolymerise. McDowell (1977) 
also indicated that at extreme temperatures in excess of 200˚C complete breakdown of the 
alginate and a rapid evolution of one molecule of CO₂ for every uronic acid group would 
occur. This would hinder the ability of alginates forming ionic and acidic gels. These 
temperatures as mentioned above can easily be reached during the cooking process of 
bread (Hasatani et al., 1991), and therefore raises the questions as to whether the alginate 
released from the bread during digestion as illustrated in Figure 8 retains its ability to form 
a viscous solution in the upper GI tract.  
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3.2 Aims 
The data depicted in Figure 8 implies that the release rate of the alginate can be 
determined. However the attributes of the alginate released from the vehicle requires 
further analysis. Specifically how the release of alginate from the bread affects the 
attributes of the solution during digestion. Hoad et al. (2004) and Seal and Mathers (2001) 
indicate that alginate enriched products can form an acidic or an ionic gel in the stomach 
and small intestine, respectively. Although the suggestion is that this gel formation may 
be a possible mechanism in reducing enzyme activity, or the interaction between substrate 
and enzyme this remains to be seen. The aims of this chapter are to: 
 Utilise a model gut that will digest the bread and allow samples to be taken at 
multiple time points throughout, including the stomach and small intestinal phase 
of digestion. This will determine whether the alginate released, as suggested in 
Figure 8, chapter 2 will affect the properties of the solution within the model gut. If 
the alginate is in-fact being released then the expectation would be for the 
viscosity in the small intestines to increase as this is where between 80-90% of the 
alginate is released, and confirm the suggestions of Seal and Mathers (2001). This 
may provide further evidence as to whether viscosity is a potential mechanism 
responsible for reducing digestive enzyme activity. 
 
 To determine whether alginate is able to withstand temperatures up to 180˚C, and 
retain its ability to form a viscous solution within the model gut. McDowell 
(1977) has reported that when polymers are exposed to temperatures in excess of 
100˚C they can undergo depolymerisation. This may ultimately affect the ability 
of the alginate to form a gel within the upper GI tract. 
 
 To assess the physiochemical properties of the solution within the model gut 
following digestion of alginate bread. In addition to the cooking process of the 
bread, this chapter will assess whether alginate can be isolated from the model gut 
and determine whether the alginate retain its inhibition properties despite being 
cooked into the bread, digested in the model gut and isolated. These data will 
ultimately provide an insight into how robust alginate is and whether viscosity is a 
mechanism that contributes to attenuation in the activity of digestive enzymes.   
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 3.3 Methods 
3.3.1 Materials  
Sepharose 2B (60-200µm diameter), methyl orange (MO), dextran blue (DB), sodium 
chloride, sodium azide, Tris, methanol, acetone, colipase, lipase, orlistat 
(tetrahydrolipstatin) were purchased from Sigma-Aldrich (Poole, UK). Aluminium oxide 
were purchased from Fisher Scientific (Loughborough, UK), and olive oil was purchased 
from Co-operatives Foods (Manchester, UK). Bile acids (deoxycholic acid sodium salt 
and taurodeoxycholic acid sodium salt) were purchased from Fluka (Buchs, Switzerland). 
The alginate was a gift from FMC BioPolymer AS, Drammen, Norway and was stored at 
4˚C in tightly-sealed containers and all alginate weights were corrected for water content. 
Alginate and control bread and materials for PAS assay were those used in chapter 2.   
3.3.2 Equipment  
All assays were carried out using BioTek 96 well plate reader at 550nm (ELx808 BioTek, 
Bedfordshire, UK). Two Grant GD 100 water baths were used for incubating synthetic 
model gut solutions and samples within the model gut at 37˚C (Fisher Scientific, 
Loughborough, UK). A Sci-Q 401U/D peristaltic pump was used to pump synthetic 
solution into samples in the model gut (Watson-Marlow, Fisher Scientific, 
Loughborough, UK), three IKA
® 
laboratory egg compact mixers. A Thermo Jouan BR4i 
Mu Scientific Centrifuge (Basingstoke, UK) and an Eppendorf Centrifuge 5415 R 
(Stevenage, UK) were used for samples <4ml and >2ml, respectively. A Fraction 
Collector FRAC-100 and a Peristaltic Pump P-1 were purchased from Pharmacia Fine 
Chemicals (Stockholm, Sweden) to calculate the elution volume from gel filtration. 
Viscosity measurements were assessed using a Low-Shear-30 viscometer from Contraves 
(Malacca, Malaysia), Gallenkamp Hot Box Bench Top Laboratory Economy Incubator - 
with Fan SIZE 2 (Germany). Ultra-Turrax T18 IKA Homogeniser with dispersing tools S 
18 N – 10G and 19G from Fischer Scientific (Loughborough, UK) was used to emulsify 
olive oil substrate and lipase buffer. An Edwards Modulyo EF4-174 Freeze Dryer 
(London, UK) was used to isolate alginate.  
3.3.3 Model Gut Procedure  
The model gut was run as per chapter 2 with model gut solution alone run as a control, 
with the following experiments carried out:  
i) 5.2g Alginate bread (AB) alone  
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ii) 5.2g Control bread (CB) alone  
iii) 208mg of DM alginate alone 
iv) 5.2g CB and 208mg DM alginate 
v) Model gut solution from 180 minutes spiked with 208mg DM alginate   
vi) 5.2g CB from 180 minutes spiked with 208mg DM alginate   
 
In the experiments above 50ml of solution was taken from 180 minutes and incubated at 
37˚C. Model gut solution alone from 180 minutes was used as a control for all samples. In 
experiments v and vi the solutions were spiked with 208mg DM alginate to replicate the 
concentration that would be present if the alginate was released from 5.2g of AB. The 
concentration of alginate in the model gut solution at the end of the model gut can be 
calculated using Equation 1.  
 
5.2g AB = 4% by weight of DM alginate powder 
(5.2/100) x 4 = 208mg at 180 minutes and 30 seconds 
 208mg/132ml (total solution at end of model gut) = 1.57mg/ml 
Equation 1.  Calculation of amount of alginate in 5.2g AB. 
 
3.3.4 Viscosity Measurements  
The six samples of model gut solutions taken from the end of the model gut were, 
compared against model gut solution alone. The heated alginates were measured at 
2mg/ml in DH₂O, compared to DH₂O alone. A 2ml sample from each experiment was 
added to the measuring cup of the viscometer. The viscometer was set to a range 4 or 5 to 
ensure that the sample being measured gave less than 100% deflection. The measuring 
bob was then lowered into the measuring cup and the viscometer records percentage over 
a range of shear rates. This can be used to calculate specific viscosity (ηsp) using Equation 
2 and Equation 3. 
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Equation 2.  Relative Viscosity (ηrel). 
 
 
            
 
Equation 3.  Specific Viscosity (ηsp). 
 
3.3.5 Alginate Isolation 
Upon completion of the model gut procedure the solutions from 5.2g AB, 5.2g CB and 
5.2g CB with 208mg DM alginate (i, ii and iv) were put through an isolation process. 4ml 
and 8ml samples of 5.2g AB and 5.2g CB runs were prepared and a 4ml sample of the 
5.2g CB with 208mg DM alginate. All five samples were diluted by 50% with methanol 
and then mixed and placed into a freezer at -20˚C for 30 minutes. The samples were then 
centrifuged at 4100 rpm for 20 minutes. The supernatant was removed and 4ml methanol 
was added and the pellet re-suspended, before being placed in the freezer at -20˚C for 30 
minutes and then centrifuged at 4100 rpm for 20 minutes. After centrifugation the 
supernatant was removed and the process was repeated using the pellet. All four samples 
were then placed in the freeze dryer until the DH₂O had completely sublimated leaving a 
dry pellet. The pellets for each sample were then weighed. The predicted weights of the 
samples can be calculated using Equation 4. 
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Alginate Bread is 4% alginate by weight = (5.2g/100) x 4% = 208mg 
Predicted Weight:  5.2g AB 4ml = (208/132ml) = 1.57mg/ml x 4ml = 6.3mg 
   5.2gAB 8ml = (208/132) = 1.57mg/ml x 8ml = 12.6mg 
   5.2g CB and 208mg DM = (208/132) = 1.57mg/ml x 4 = 6.3mg 
 
Equation 4.  Predicted weight of samples containing alginate from the end of the model gut. 
 
3.3.6 Heating of Alginate 
5g of three sodium alginates (LFR 5/60, DM and SF200) with a molecular weight with a 
range of 40-380 kDa and a mannuronate/guluronate ratio of 0.44-1.38 were added to glass 
pyrex tubes and then heated at 37, 100 and 200˚C. DM was also heated at further 
temperatures of 50 and 150˚C. Each alginate was heated at the temperatures above for 30 
minutes before being cooled to room temperature. 
3.3.7 Gel Filtration 
Sepharose 2B was added to approximately 500ml of gel filtration elution buffer 
consisting of sodium chloride (0.2M), sodium azide (0.003M) and then made up to 1L in 
DH₂O and then left over night to ensure complete hydration. The sepharose 2B was then 
packed into a column measuring 30 cm in length and 1.46 cm in diameter. Once tightly 
packed the ends of the column were sealed and a tube from the top of the column was 
placed into the buffer reservoir, and a tube from the bottom of the column was placed into 
the peristaltic pump. An additional tube ran from the peristaltic pump into the fraction 
collector, which was set to collect elution volume in 2ml volumes. 
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3.3.7.1 Calibration 
Void volume (Vo) and Total volume (Vt) were determined using dextran blue (DB) and 
methyl orange (MO) respectively, as seen in Figure 11. 
 
 
Figure 11.  Calibration for gel filtration using MO and DB. Vo = 16ml and Vt = 64ml (n=6). 
 
3.3.7.2 Gel Filtration Samples 
Sodium alginates alginate LFR 5/60, DM and SF200, post heating at 37, 100 and 200˚C 
were re-suspended in elution buffer at a concentration of 1.43mg/ml. The freeze dried 
samples from 5.2g AB, 5.2g CB and 5.2g CB with 208mg DM were also re-suspended in 
the elution buffer at a concentration of 1.43mg/ml, based on the freeze dried weight. After 
each of the samples had passed through the column 200µl of each fraction were added to 
a 96-well in duplicate plate and the PAS assay was run as per chapter 2.  
3.3.8 Lipase Inhibition Properties of Heated Samples and Isolated Alginate 
Standard olive oil (ηsp of 72.5 (+ 10) was filtered by passing it through aluminium oxide 
(8cm deep in a glass chromatography column) to remove free fatty acids. 10g of the 
filtered olive oil was made up to 100ml using acetone, giving a 10% solution. This was 
then diluted down with acetone to a 1% stock solution and stored in the fridge at 4˚C 
ready for use. The 1% solution was then used as the olive oil stock solution for all 
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experiments. The substrate solution was 0.05M Tris buffer at pH 8 and was stored in the 
fridge at 4˚C. 100ml of the substrate solution was heated up to 70˚C and sodium 
deoxycholate was then added at 0.35%. 4ml of the 1% olive oil stock solution was then 
added and homogenised for 10 minutes whilst maintaining at 70˚C. The solution was then 
cooled to room temperature and could then be used for the assay for up to 6 hours. The 
enzymes used were 1.29mg/ml lipase and 18µg/ml colipase in DH₂O. Orlistat was made 
up to 0.025mg/ml in DH₂O at the same concentration as a reagent blank. Heated DM 
alginate at 37, 100 and 200˚C and freeze dried 5.2g AB were added to the substrate 
solution that contained the olive oil at 3, 2, 1mg/ml.  
240µl of either substrate solution alone (as a control) or the substrate containing heated or 
freeze dried alginate were added to a 96-well plate in duplicate. On a second 96 well plate 
10µl of enzyme solution or DH₂O was added to the wells. Orlistat was included with one 
row of enzyme solution and one row of DH₂O. Both plates were incubated at 37˚C for 15 
minutes. After incubation 200µl of the substrate solution plate were added to the 
corresponding wells on the 96-well containing the enzymes or DH₂O. The plate was then 
placed on the plate reader at 37˚C and read every 5 minutes at 405 nm for 35 minutes. In 
order to calculate the level of lipase inhibition the blanks were subtracted from their 
corresponding controls, an example can be seen in Equation 5.            
 
                               
                                 
                                 
       
 
Equation 5.  Equation to calculate the percentage of lipase inhibition.  
 
3.4 Statistical Analysis 
Statistical calculations were undertaken using SPSS Statistics 19 (IBM, Predictive 
Analysis Software, USA). Data presented as mean and standard error of mean (S.E.M). A 
Two-way Repeated ANOVA followed by a Post-Hoc Bonferroni were undertaken at a 
significant level (α) of 0.05 to compare the level of pancreatic lipase inhibition of DM 
alginate heated at 37, 100, 150 and 200˚C.  
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3.5 Results 
3.5.1 Viscosity 
3.5.1.1 Model Gut Samples 
The viscosities of the samples from the end of the model gut are shown in Figure 12. The 
viscosity for 5.2g AB and CB were relatively low with 0.42 (+0.01) and 0.11 (+ 0.01) 
respectively. DM alginate alone and 5.2g CB and DM alginate that passed through the 
model gut had a larger specific viscosity of 0.91 (+0.41) and 0.46 (+ 0.11) respectively. 
These data indicate that when bread is present there is a reduction in the ability of alginate 
to form a viscous solution. The viscosity of the gut model solution and 5.2g CB that were 
spiked with DM alginate after the model gut had a substantially larger viscosity of 2.96 (+ 
0.71) and 2.88 (+ 0.57) respectively than the 5.2g AB sample. The data in Figure 12 
demonstrate that alginate passing through the model, either in a bread vehicle or dry had a 
lower specific viscosity than when it is added to solution from the model gut once it has 
finished. A combination of the bread and the model gut appear to be attenuating the 
ability of the alginate to form a viscous solution.   
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Figure 12.  Mean (+ S.E.M) viscosity of samples taken from the end of the model gut (n=6). Alginate 
Bread (5.2g), Control Bread (5.2g), DM alginate (208mg) and 5.2g CB with DM alginate (208mg) were 
added at beginning of model gut. DM alginate (208mg) was added to model gut solution and 5.2g CB 
solution from the end of the mode gut. All viscosity measurements were made at the end of the model gut.  
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3.5.1.2 Alginate Thermal Treatment 
The data presented in Table 4 is for alginates LFR 5/60, DM and SF200 at 37˚C and post 
heating at 200˚C. The specific viscosity relates to the molecular weight with SF200 
having a specific viscosity of 14, DM alginate 12 and LFR 5/60 2.2. Post heating at 
200˚C there was a substantial decrease in ηsp for all three alginates down to 0.1, 0.2 and 
0.2 for DM, LFR 5/60 and SF200 respectively. These data indicate extensive 
fragmentation of the alginate chains following heating at 200˚C. 
 
Table 4.  Mean ηsp of alginates at 2mg/ml  in DH₂O at 37˚C and post heating at 200˚C for 30 
minutes (n=6).  
Alginate 
Molecular 
Weight Pre Heating 
Post Heating @ 
200˚C 
% ∆ in 
ηsp 
DM 250,000-320,000 12.0 0.1 99.6 
LFR 
5/60 40,000 2.2 0.2 90.1 
SF200 380,000 14.0 0.2 98.9 
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The ηsp for DM alginate heated at temperatures between 37-200˚C is illustrated in Figure 
13. The ηsp remained relatively stable between 37, 50 and 100C˚, with only a reduction of 
16 and 21% for 50 and 100˚C when compared with 37˚C. Beyond 100˚C there is an large 
drop in ηsp compared to 37˚C. The ηsp for 150 and 200˚C has 2.2 and 0.2 respectively, 
equating to a reduction of 78 and 99%. The data in Figure 13 indicate that alginates may 
not be able to withstand temperatures in excess of 100˚C, and that these high 
temperatures alter the ability of alginate to form viscous solutions.   
 
 
Figure 13.  Mean (+ S.E.M) ɳsp of DM alginate after being heated at 37, 50, 100, 150 and 200˚C for 
30 minutes. Each sample was then allowed to return to room temperature and then re-suspended in DH₂O at 
1.43mg/ml (n=6). 
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3.5.2 Gel Filtration 
3.5.2.1 Heated Alginates 
Following incubation at 37˚C the initial elution volumes correspond well with the Mr. The 
elution volumes were 25, 33 and 37ml for SF200, DM and LFR 5/60 respectively. 
Heating to 100˚C resulted in a small increase in elution volume for LFR 5/60 up to 38ml 
and 30ml for SF200. However there was no change in elution volume for DM following 
heating at 100˚C. Post heating at 200˚C all three alginates had an increase in elution 
volumes, rising to 44, 41 and 42ml respectively for SF200, DM and LFR 5/60, indicating 
a temperature effect on the alginate Figure 14. These data indicate that the increase in 
elution volume is likely to be as a result of a reduction in Mr. 
 
 
Figure 14.  Mean (+S.E.M) elution volumes for DM, SF200 and LFR 5/60 alginates following 30 
minutes heating at 37, 100 and 200˚C. All three alginates were then re-suspended in DH₂O at 1.43mg/ml 
(n=6). 
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3.5.2.2 Freeze dried samples isolated from the end of the model gut. 
The elution profile for freeze dried samples from the end of the model gut following 
isolation and freeze drying is depicted in Figure 15. 5.2g AB is depicted below with a peak 
elution volume of 18ml which was consistent with the mean elution volume of DB. 5.2g 
CB and 208mg DM alginate had a mean peak elution volume of 18ml, which was the 
same as 5.2g AB. In contrast the 5.2g CB alone had a mean elution volume of 42ml, 
which was 58% larger than both the 5.2g AB and 5.2g CB with 200mg DM alginate. 
These data indicate that samples that contain alginate elicit a smaller elution volume than 
those without, and that the alginates Mr is not being reduced despite the cooking process 
of the bread, digestion in the model gut or the isolation process. These data indicate that 
the CB does not contain high molecular weight material. The PAS assay was a suitable 
method for quantifying samples that contained alginate with absorbance values ranging 
from 0.48 for AB and 0.12 for CB with DM alginate.  
 
 
Figure 15.  Mean (+ S.E.M) ▄ = elution profile from freeze dried 5.2g AB, ▲ = 5.2g CB and ● = 
5.2g CB and 208mg DM alginate from the end of model gut and isolation process. Freeze dried samples 
were then re-suspended in DH₂O at 1.43mg/ml based on the freeze dried weight and processed through the 
gel filtration. PAS assay was used to quantify alginate in fractions collected from gel filtration. Vertical axis 
1 is for AB and vertical axis 2 is for CB alone and CB with DM alginate (n=6). 
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3.5.3 Alginate Recovery at End Point of the Model Gut 
The predicted weight for the freeze dried samples can be calculated using  
Equation 6. 
 
                                                     (    )              
 
Equation 6.  Calculation for predicted weight of freeze dried samples.    
 
The predicted, measured and difference between the weights of the freeze dried samples 
are illustrated in Table 5. Although the measured weight was larger than the predicted 
weight, 4g, 1.8g and 7.7g larger respectively for 4ml CB and 208mg DM alginate, 4ml 
and 8ml AB, these samples still weighed more than the 4ml and 8ml 5.2g CB samples 
alone, suggesting that alginate was isolated from the samples. 
Table 5.  Mean weight of freeze dried samples from the end point of the model gut after isolation 
(n=6). 4ml and 8ml samples were taken for 5.2g AB and CB, and a 4ml sample of 5.2g CB with 208mg DM 
alginate. 
Sample Predicted wt (mg) 
Measured wt 
(mg) 
Difference in wt 
(mg) 
4ml CB and 
208mg DM 
alginate 6.3 15.9 4 
AB 4ml 6.3 13.7 1.8 
AB 8ml 12.6 31.8 7.7 
CB 4ml - 5.6 - 
CB 8ml - 11.5 - 
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Predicted weight was calculated using Equation 4. 
Measured weight was the mean weight of samples following isolation and freeze drying procedure.  
Difference in weight is the predicted weight + control weight  
- 4ml CB with 208mg DM 6.3mg + 4ml CB 5.6mg = 11.9g → 15.9 – 11.9 = 4mg 
- 4ml AB 6.3mg + 5.6g 4ml CB = 11.9mg   13.7-11.9 = 1.8mg 
- 8ml AB 12.6mg + 8ml CB 11.5g = 24.1mg   31.8 – 24.1 = 7.7mg 
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3.5.4 Lipase Inhibition by Isolated and Heated Alginate 
3.5.4.1 Freeze dried AB and CB extracts 
The alginate extract from the end of the model gut was weighed and re-suspended in 
substrate solution to ascertain whether the alginate is able to retain its inhibition 
properties post cooking into the bread, digestion and isolation. The freeze dried extracts 
from 5.2g AB inhibited pancreatic lipase by 39 (+ 0.42), 36 (+ 0.43) and 7% (+ 0.32) at 3, 
2 and 1mg/ml respectively. (Figure 16). These data indicate that although the alginate has 
been cooked into the bread, digested in the model gut and isolated it retains its inhibition 
properties.   
 
 
Figure 16.  Mean (+ S.E.M) pancreatic lipase inhibition with isolated alginate from end of the model 
gut and following freeze drying. Freeze dried AB were re-suspended in lipase buffer at 3, 2 and 1mg/ml and 
the olive oil turbidity assay was run (n=9).  
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3.5.4.2 Heated alginate samples  
Heated DM alginate at 3, 2 and 1mg/ml inhibit pancreatic lipase. These data indicate that 
there is a significant effect for concentration and temperature (p<0.05). There was a dose 
response for 3, 2 and 1mg/ml at temperatures 37, 100 and 150˚C which was significantly 
different (p<0.05). The level of inhibition for 37˚C was 33% (+ 0.58), 18% (+ 0.57) and 
0.6% (+ 0.81), 100˚C was 35 (+ 0.64), 21% (+ 1.46) and 0.6% (+ 0.69) and 150˚C was 
35% (+ 0.32), 18% (+ 0.55) and 3% (+ 0.84) for 3, 2 and 1mg/ml respectively. There 
appears also to be a dose response relationship for DM heated at 200˚C, however this was 
not significant (p>.05). The level of pancreatic lipase activity reduced from 4 (+ 0.48), 0.9 
(+ 0.26) and 0.2 (+ 0.12) for 3, 2 and 1mg/ml respectively when heated at 200˚C. There 
was no significant difference between temperatures 37, 100 and 150˚C for matched 
concentrations at 3, 2 and 1mg/ml (p>0.05). The DM alginate heated at 200˚C was 
significantly different from temperatures 37, 100 and 150˚C at concentration 3 and 
2mg/ml (p<.05) but not at 1mg/ml (p>0.05). The data in Figure 17 indicate that DM 
alginate is able to inhibit pancreatic lipase despite being heated at 150˚C, and 
demonstrates its robustness.    
 
 
Figure 17.  Mean (+ S.E.M) pancreatic lipase inhibition using DM alginate after it has been heated at 
37, 50, 150 and 200˚C for 30 minutes. After being left at room temperature the DM alginate was then re-
suspended in lipase substrate solution at 3,2 and 1mg/ml and the turbidity assay was performed (n=9).  
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3.6 Discussion 
The data in the current chapter demonstrates that alginates are heat stable up to 
temperatures of 100˚C. However beyond 100˚C there is a gradual decrease in viscosity as 
the temperature increases. By contrast the ability of the alginate to inhibit pancreatic 
lipase appears to be unaffected up to temperatures of 150˚C, despite the reduction in 
viscosity and by implication size. Furthermore, despite being used as an additive to a 
bread vehicle, cooked, digested in a model gut and isolated the alginate retains its 
inhibition properties and does not appear to break up.  
The ability of alginate to form acidic and ionic gels is well documented (Braccini & 
Perez, 2001; Draget et al., 2005), which is one of the principal reasons that make alginate 
unique and lends them to various uses including pharmaceutical and the textile industry, 
but predominantly the food industry (Brownlee et al., 2005). It is this unique ability of 
alginate to form gels in both acidic and ionic conditions that has been suggested to be 
responsible for reduced kcal intake (Paxman et al., 2008) and increased satiety and 
reduced hunger (Jensen, Kristensen, Belza, Knudsen, & Astrup, 2012 (b)). In addition to 
human studies Seal and Mathers (2001) reported that rats fed food containing alginate had 
reduced fat and cholesterol digestion. The precise mechanism responsible for the effects 
reported above remain unknown, although amongst those suggested viscosity has come 
under scrutiny. Smidsrod (1974) and Jensen et al. (2012 (b)) indicated that the ability of 
alginates to form both acidic and ionic gels may be responsible for poor mixing within the 
stomach and small intestines, and ultimately this will interfere with the ability of digestive 
enzymes to interact with substrates and attenuate nutrient digestion. Paxman et al. (2008) 
and Hoad et al. (2004) also added to this and stated that if the alginate forms a viscous 
solution/gel in the stomach this may cause distension within the stomach and increase 
satiety, and could therefore reduce the amount of energy absorbed from consumed 
calories. 
Although viscosity may be a mechanism by which digestion is reduced it may also be a 
problem for alginate. The addition of alginate to a beverage or the coating of a cereal bar 
in previous studies has resulted in poor palatability when compared with a control 
beverage or cereal bar (Jensen et al., 2012 (b); Sandberg et al., 1994). If a food or drink 
vehicle is not pleasant in texture and taste then an individual will be less inclined to 
consume said food or drink on a regular basis (Ellis et al., 1981), as would be required if 
alginate is to be used to treat obesity. Amongst others this is one of the reasons why bread 
was selected as the delivery vehicle for alginate. If the alginate can be mixed in with the 
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bread during the baking process then this may reduce the ability of the alginate to form a 
viscous solution in the mouth, yet still possess the potential to increase the viscosity 
within the stomach and small intestines, and ultimately attenuate digestion.  
The data presented in this thesis demonstrates that the majority of the alginate would be 
released in the small intestine based on the model gut data. Therefore it seems reasonable 
to assume that if the alginate is in fact being released, then the viscosity of the solution at 
the end of the model gut should increase. The data in Figure 12 suggests that there is not a 
substantial increase in viscosity from the digested AB when comparing it to CB. The 
ηsp’s of AB and CB from the end of the model gut were 0.42 (+ .01) and 0.11 (+ .01) 
respectively, which is a difference of 74%. Nonetheless this is much lower than the 
viscosity that would be expected for a similar concentration of alginate. For this reason 
alginate was added at the start of the model gut alone and at the end to see if the model 
gut had any effect on the ability of alginate to increase the viscosity. The data presented 
here demonstrates that alginate added to the end of the mode gut had a substantially larger 
ηsp than when alginate was added to the start of the model gut. These data suggest that 
the alginate may be digested or be binding to something within the model gut. If the 
alginate binds with something in model gut such as bile acids (Wang et al., 2001) this 
may impact upon the ability of the alginate to increase viscosity. Additionally it may be 
that the alginate is being digested within the model gut and therefore the alginate is 
broken down and unable to increase the viscosity, although this would contradict 
numerous studies including the work of Trowell (1972) and Asp (1987) who 
demonstrated that dietary fibres evade digestion in the upper GI tract. This may in part 
explain the lack of viscosity, although an alternative explanation may be that the bread 
processing and baking may be affecting the ability of the alginate to form a viscous 
solution. During the cooking process the alginate structure may be altered when the bread 
is exposed to temperatures up to 200˚C. McDowell (1977) reported that if alginates are 
heated beyond 100˚C intra-molecular depolymerisation may occur, which would 
ultimately affect the ability of the alginate to form a viscous solution. The question 
therefore raised is whether the material being released from the bread is in fact alginate, 
and whether this alginate has been affected during the cooking and digestion process. 
The isolated weights of the material can be observed in Table 5. It is immediately apparent 
that the samples containing alginate had a larger weight than those that contained no 
alginate. The weights were marginally larger than the predicted weights, which may be 
due to binding with the contents of the model gut such as bile acids (Adiotomre, 
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Eastwood, Edwards, & Brydon, 1990; Wang et al., 2001). Adiotomre et al. (1990) 
confirmed that a range of dietary fibres were able to bind with bile salts. They used a 
dialysis sacks in an attempt to quantify whether a range of dietary fibres including gellan, 
pectin and carboxymethylcellulose were able to retain bile acids. The dialysis sacks 
simulated bile acid absorption in the small intestines, and anything left in the sacks at the 
completion of the experiment would be retained through binding with the various forms 
of dietary fibre. There was an increase in bile acids retention from 33, 14 and 89%, for 
gellan, pectin and carboxymethylcellulose, respectively. More specifically Wang et al. 
(2001) looked at soluble and insoluble dietary fibres of seaweeds. The authors reported 
that both the soluble and insoluble forms of dietary fibre from seaweeds were able to bind 
with bile acids, although soluble dietary fibres were significantly better at binding them. 
Although both of the afore mentioned studies indicate the ability of dietary fibres to bind 
bile salts these were both in-vitro and require further research to confirm if this is the case 
in-vivo. For the purpose of the in-vitro data presented here suggests that this binding of 
bile salts may account for a portion of the weight discrepancy here. Although Adiotomre 
et al. (1990) and Wang et al. (2001) do not suggest how dietary fibres bind bile acid; there 
are a number of potential mechanisms of how this may occur. The carboxyl group of the 
alginate may be able to bind with the hydroxyl group of the bile acids. In addition the 
hydrophilic aspect of the bile acids may also bind with hydrophilic alginate; however 
neither of these mechanisms have been confirmed, and require further research. Although 
slightly larger than the predictions the essential theme here is that the samples containing 
alginate had a larger weight than the control samples, which supports the previously 
presented data that alginate was being released from the bread. Although this still does 
not answer the question as to why the AB did not cause an increase in viscosity when the 
alginate was released in the model gut.  
A potential mechanism for the lack of viscosity was suggested by McDowell (1977), that 
if the alginate is heated beyond 100˚C then depolymerisation can occur which would 
impede gel formation. During the cooking process the bread may be subject to 
temperatures up to 200˚C for 30 minutes. Although the exact temperature of the entire 
loaf of bread here cannot be determined, Hasatani et al. (1991) observed the effects of 
various bread recipes and measured the temperature of different parts of the bread. 
Although this could not be done during the cooking process this gives a good insight into 
the various temperatures during baking of bread. Hasatani et al. (1991) indicated that the 
centre of the bread may only reach 70-80˚C, however the crust may be exposed to 
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between 180-200˚C. It was for these reasons three alginates SF200, DM and LFR 5/60 
were heated at 37˚C and 200˚C to observe if ηsp is affected post heating at 200˚C. It was 
immediately apparent that there is a substantial loss in viscosity ranging between 92-98%. 
These data indicate that when alginate is exposed to 200˚C the alginate is unable to form 
a viscous solution. As DM alginate was chosen for the bread this alginate was heated at 
37, 50, 100, 150 and 200˚C in an attempt to ascertain at what point if any 
depolymerisation may occur. The ηsp of DM alginate at 37, 50 and 100˚C was not 
significantly different. There was however a significant reduction in ηsp once the 
temperature exceeded 100˚C. These data correspond with the work of McDowell (1977) 
who demonstrated that as alginates in solution are exposed to temperatures above 100˚C a 
gradual depolymerisation occurs until complete breakdown of the polymer. If 
depolymerisation occurs, not only will the bonds between adjacent GG, MG and MM 
blocks be broken, but the size of the alginate molecule will also be reduced which is 
essential for the formation of ionic or acid gels. This breaking down of the polymer may 
account for the reduction or complete lack of viscosity as reported here. McDowell 
(1977) also suggested that exposing alginate to temperatures in excess of 180˚C the 
alginate may completely breakdown causing a rapid evolution of one molecule of CO₂ for 
every uronic acid group. This would mean that the –COOH would then become H, and 
thus almost entirely render the alginate incapable of forming an ionic gel.  
Leo et al. (1990) indicated that if the glycosidic links that holding polymers together are 
affected by heat then this may not only affect viscosity but the size of the polymer as 
well. If alginate is being broken down during the cooking process of the bread then the 
size of the alginate may also be affected. Larger alginates have a larger Youngs modulus 
(Smidsrod, 1974), meaning they can form more viscous gels. Consequently if the size of 
the alginate is being reduced during the cooking process then this also may have an 
impact upon the alginate’s ability for form a gel. Gel filtration can be used to separate 
molecules based on hydrodynamic size. Consequently if alginate is undergoing some 
degree of depolymerisation then the alginate should elute later from the column. The 
alginates DM, LFR 5/60 and SF200 from the viscosity experiments when heated at 37˚C 
and eluted based on the Mr. The elution volume increased for all the alginates post 
heating at 200˚C when compared to 37˚C. These data suggest that at higher temperatures 
the alginate may undergo some degree of depolymerisation and therefore reduce Mr as 
indicated with an increase in elution volume, and reduce the ability of the alginate to form 
a gel. Leo et al. (1990) observed the effects of heat on viscosity of a 3% alginate solution 
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and calcium alginate beads. They exposed the solution and beads to temperatures ranging 
from 20˚C up to 130˚C for 20 minutes. The authors reported that both were unaffected up 
to 100˚C, however beyond this time point there were significant alterations. As the 
temperature increased beyond 80˚C viscosity and gel strength decreased, whilst the bead 
diameter increased. These studies support the earlier work of McDowell (1977) that as 
alginates are heated they undergo some form of intra depolymerisation. Although the 
work of Leo et al. (1990) do lend some support to the work presented here however they 
report a reduction in viscosity of 53% between 37˚C and 110˚C, however here there was 
only a reduction of 13%. This may have been due to the different heating procedures 
used. Leo et al. (1990) heated the alginate once it was in solution, however here we 
heated dry alginate, and thus the alginate in the solution may have been exposed to more 
heat as the alginate would have been mixed throughout. An additional point of interest 
may have been the different alginates used. Although Leo et al. (1990) do state the G:M 
ratio they do not state the Mr of the alginate used. If they used an alginate with a larger 
Mr than the present study then this would be broken down more easily, as demonstrated 
by a more substantial reduction in viscosity. This was also confirmed by the larger 
reduction in Mr as demonstrated by SF200 when compared with LFR 5/60 using gel 
filtration. An additional point of interest may be the molecular composition of the alginate 
used. There is currently no research comparing the heat stability of a range of alginates 
varying in GG, MM and MG blocks. It is well known that the properties of GG blocks are 
different from GM and MM blocks in gel formation. This therefore raises the question as 
to whether alginates with a larger GG content are more or less heat stable than a 
combination of MG and MM blocks. This would not only be beneficial for adding 
alginates to food that requiring cooking but also in drug delivery where alginate gel beads 
are required to undergo some form of heat sterilisation. Further work is required to 
confirm these suggestions, although it is clear that alginates undergo some form of intra 
depolymerisation and suggest that alginate cooked into the bread may not be able to 
withstand the temperatures involved within the cooking process.  
If the alginate is affected by the heating during the cooking process then the isolated 
alginate from the digested alginate bread would have an elution volume, comparable with 
DM alginate after being heated at 200˚C. The gel filtration data shows that the alginate 
released from the bread has not been altered in size by the cooking process of the bread. 
A possible explanation for this may be that the alginate is completely mixed throughout 
the bread and may only be exposed to temperatures ranging from 70-100˚C, however 
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there may be some alginate that is exposed to higher temperatures. Although it appears 
that the bread matrix is actually protecting the alginate from the high temperatures. 
Furthermore the lack of a change in elution volume demonstrates that AB and dry DM 
alginate had not been digested within the model gut. This demonstrates that alginates are 
resistant to digestion in the upper GI tract supporting previous reports in the literature 
(Asp, 1987; FAO/WHO, 2003; Trowell, 1972, 1976). Although these data suggest that 
the alginate is not being digested in the model gut, the question remains as to exactly 
what is the cause for the lack of viscosity at the end of the model gut after the alginate 
bread has been digested. It may be a combination of the alginate binding with something 
in the bread such as sodium, which would replace calcium in the egg box model and 
hinder any development in viscosity. The viscosity data from the end of the model gut 
also suggests that there may be something in the model gut that alginate is binding to, 
such as bile acids which may reduce the ability of alginate to form viscous solution. 
Although still unclear it may be a combination of these suggestions that is causing the 
lack of viscosity, although if the alginate extracts are still able to inhibit pancreatic lipase 
activity then the lack of viscosity may hold no bearing on fat digestion.  
If the alginate cooked into the bread is able to withstand cooking and digestion then it 
would appear that the bread may indeed be a suitable vehicle to add alginate to an 
individual’s diet. Despite being robust to withstand these processes the question remains 
as to whether the alginate retains its inhibition properties once cooked into the bread, 
despite the reported lack of viscosity. Previous in-vitro work from this laboratory by 
Sunderland et al. (2000) and Strugala et al. (2005) have reported the effects alginate have 
on attenuating the activity of pepsin. More specifically Wilcox et al. (2014) and 
Richardson et al. (2011) have reported that certain alginates are able to reduce the activity 
of pancreatic lipase by up to 75%, which is dependent on the structure of the alginate. The 
data from the present study reveals that DM alginate retains its inhibition properties after 
being cooked, digested, isolated or heated at 150˚C. These data not only support the work 
of Asp (1987) but also demonstrates the robustness of alginate after being processed in 
the various methods described here. The data also highlights the ability of alginates to 
withstand high temperatures, even when not being protected by the bread matrix. There 
was no significant difference at temperatures 37, 100 and 150˚C at matched 
concentrations for lipase inhibition despite the reduction in viscosity at these 
temperatures. Upon exposing the alginate to 200˚C the alginate appeared to lose 88% of 
its inhibition properties when matching it for concentration with DM alginate at 37˚C. 
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The ability of alginate to inhibit pancreatic lipase after being exposed to temperatures 37-
100˚C corresponds well with the ηsp data, which again lends support to earlier work (Leo 
et al., 1990; McDowell, 1977; Serp et al., 2002). The data presented here in accordance 
with previous work indicates that alginates undergo depolymerisation when exposed to 
temperatures above 100˚C, which has a profound detrimental impact upon gel formation. 
Interestingly, when exposed to 150˚C the DM alginate lost 78% of its ηsp when compared 
with 37˚C, however there was no such reduction when observing the effect of heat on 
alginates ability to inhibit pancreatic lipase activity. Conversely there was a reduction of 
98 and 88% for ηsp and pancreatic lipase inhibition respectively, when exposed to 200˚C. 
These data suggest that there is substantial alteration in polymer structure at temperatures 
beyond 150˚C which is essential for gel formation (Braccini & Perez, 2001; Draget et al., 
2003), and inhibition properties (Richardson et al., 2011; Strugala et al., 2005; Wilcox et 
al., 2014). 
There is evidence to suggest that viscosity may play a crucial role in the reduction of 
enzyme activity (Seal & Mathers, 2001; Shah et al., 1986), however the data here 
suggests that this is not the case. The data presented shows alginate with a low ηsp, is still 
able to inhibit pancreatic lipase activity by up to 38%. Although this data is positive the 
question remains as to whether the AB will be able to inhibit pancreatic lipase within an 
in-vitro model gut. The turbidity assay used here was adapted from Vogel and Zieve 
(1961) and works on the basis that as the fat is digested the substrate solution becomes 
more transparent. Although this is an effective method for determining pancreatic lipase 
activity, this does not however take into account other factors within the model gut such 
as bile, undigested bread and the plethora of other enzymes involved in digestion within 
the model gut. Further work is required to ascertain whether the lack of viscosity reported 
here has any impact upon the ability of AB to inhibit, if at all fat digestion in a model gut 
and in-vivo. 
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Chapter 4: Fat Digestion     
4.1 Introduction 
Lipids are crucial for all living organisms and serve a fundamental role in a number of 
key functions such as thermal regulators, membrane constituents, protein modification, 
energy storage and the most apparent energy supply (Tucci et al., 2010). The inclusion of 
triglycerides into the diet is the main source of lipids due to their efficacy as a highly 
concentrated energy source. Each gram of triglycerides provides 9 Kcal (37kJ) compared 
with 4 Kcal (17kJ) for one gram of carbohydrates and proteins (Horowitz & Klein, 2000). 
The digestion of triglycerides can be difficult due to their non-polar structure, however 
the digestive system of the human is extremely efficient and is able to digest up to 95% of 
fat ingested (Carey, Small, & Bliss, 1983). The mechanical breakdown of digestion 
begins in the oral cavity (mouth) which functions as a receptacle for food. The process of 
mastication begins when food is mixed with saliva and the teeth break up larger pieces 
into small manageable pieces, which is important further along the digestion process. It is 
within saliva that lingual lipase begins the digestion of triglycerides, albeit a very small 
percentage of total digestion. However lingual lipase then continues to aid with digestion 
within the stomach (Pedersen, Bardow, Jensen, & Nauntofte, 2002).  
It is within the stomach that further digestion of triglycerides is understood to occur, 
through the peristaltic contractions of the stomach and gastric lipase, which has been 
suggested to be responsible for between 15-20% of fat digestion (Birari & Bhutani, 
2007). Armand et al. (1994) indicated that in the stomach one free fatty acid (FFA) is 
cleaved off the glycerol backbone, leaving a diglyceride and one FFA. It is the presence 
of this FFA in the small intestine that has been suggested to be responsible for the release 
of cholecystokinin and pancreatic lipase (Hamosh, 1990). Hamosh (1990) suggested that 
cholecystokinin may play a role in slowing down gastric emptying and thus manage the 
food that enters the small intestines to ensure efficient digestion. Once in the small 
intestines the motility of the food is controlled by a combination of peristaltic and 
segmental contractions, which are also responsible for the emulsification of triglycerides 
with bile salts (Carriere, Barrowman, Verger, & Laugier, 1993). Pancreatic lipase is 
responsible for between 80-90% of fat digestion (Carey et al., 1983). Although pancreatic 
lipase can function alone it activity increases when bound to colipase. The tri and 
diglcerides are digested further producing two FFA and a monoglyceride. The FFA and 
monoglyceride are then able to diffuse across the cell membrane of the intestinal cells 
(Tucci et al., 2010). Once across the cell membrane the FFA’s and monoglycerides are re-
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formed within the chylomicrons into triglycerides, and can then be transported around the 
body via the lymphatic system (Mu & Hoy, 2004). It is the digestive system’s efficiency 
that is one of the main factors that has contributed to the obesity epidemic. As Carey et al. 
(1983) previously stated the human digestive system is able digest around 95% of the fat 
from a consumed meal. This would suggest that if individuals consume larger amounts of 
fat then this additional fat within the food and drinks consumed will also be digested and 
stored.  
Despite the need for lipids an excess, generally of triglycerides has been associated with 
an increased energy intake and increased levels of obesity (Hashim & Tantibhedyangkul, 
1987). There are however divergent opinions about whether diets high in fat or diets high 
in carbohydrate is the major contributing factor towards the obesity epidemic (Bray & 
Popkin, 1998). Although the case of high fat intake has strong correlations with the 
increased incidence of obesity (Kirk et al., 2013). Kirk et al. (2013) conducted a 
longitudinal study over 36 months, which involved 1781 diabetes patients filling in a 
questionnaire for set time points and receiving dietary guidelines. The authors reported 
that a lower serum triglycerides level after 12 months, but more so a reduced risk of 
cardiovascular disease was associated with a reduced fat intake at 12 and 36 months. Bray 
and Popkin (1998) simply stated that when animals and humans do not consume diets 
high in fat they do not experience the obesity issues that are currently prevalent 
worldwide. There is a consensus that some triglycerides may be more predisposed to 
increase an individual’s weight gain more than others (Aoyama, Nosaka, & Kasai, 2007; 
Kirk et al., 2013; St-Onge, Bourque, Jones, Ross, & Parsons, 2003). There is evidence 
that suggests triglycerides that have a medium chain length of between 6-12 carbon atoms 
(Papamandjaris, MacDougall, & Jones, 1998) may be more beneficial due to the rate at 
which they are absorbed, and also their lower calorific content when compared with long 
chain triglycerides.  
Although the majority of triglycerides are absorbed in the manner described above, there 
are a number of factors that can affect the digestion rates. Bach and Babayan (1982) 
suggested that short and medium chain triglycerides may be digested at an accelerated 
rate compared to long chain triglycerides. Medium chain triglycerides are triglycerides 
with chain length of six to twelve carbons, whereas long chain triglycerides have a chain 
length in excess of 12 carbons (Papamandjaris et al., 1998). Aoyama et al. (2007) 
suggested that medium chain triglycerides are hydrolysed in the upper GI tract and are 
absorbed via the hepatic portal vein and directly to the liver where they undergo beta 
72 
 
oxidation to produce ketones, and a rapid source of energy (Aoyama et al., 2007; Lee, 
Tang, & Lai, 2012). Bernard and Carlier (1991) confirmed this in rats by comparing the 
digestion of capric acid (10 carbons) with long chain triglycerides ranging in chain length 
between 16 and 22 carbons long. The authors infused the different fats intraduodenally 
into the rats and then assessed the blood lipid profile. The authors reported that capric 
acid was absorbed significantly quicker and appeared in the blood earlier than long chain 
fatty acids. The authors suggested the absorption of medium and short chain triglycerides 
is due to their lower molecular weight and their solubility in water. The importance of the 
rate of digestibility of triglycerides may play a key role in the battle against obesity. Once 
digested the long chain triglycerides are packed into chylomicrons and then enter the 
lymphatic system. There is evidence to suggest that once reformed into chylomicrons, 
these triglycerides favour distribution to peripheral tissues such as muscle and adipose 
tissue (Figueiredo-Silva et al., 2012; Johnson, Young, Cotter, Lin, & Rowe, 1990). 
Papamandjaris et al. (1998) also reported that medium chain triglycerides are poorly 
esterified into cellular triacylglycerols in adipose tissue and do not induce adipocyte 
differentiation, when compared with long chain triglycerides. In addition Friedman, 
Ramirez, Bowden, and Tordoff (1990) reported that the triglycerides with longer chain 
FA had a slower uptake at the mitochondrial level, and therefore reduce the ability of 
cells to use the fats as an energy source. If the fats are not used as an energy source, or the 
functions previously mentioned then the majority will be reformed into triglycerides and 
stored as adipose tissue. 
There is evidence to suggest that those consuming foods high in long chain triglycerides 
gained more weight than those consuming medium chain triglycerides, which may be due 
to the high calorific content of long chain triglycerides (Hashim & Tantibhedyangkul, 
1987). Hashim and Tantibhedyangkul (1987) fed rats one of two diets that were identical 
except for the fat content. One group of rats was fed a diet including long chain 
triglycerides and the other included medium chain triglycerides for 20 days. The authors 
reported a significant increase in weight, adipose tissue and adipocytes of the rats 
consuming a diet high in long chain triglycerides, when compared to the diet high in 
medium chain triglycerides. The authors also reported here that the medium chain 
triglycerides were oxidised at twice the rate of the longer chain triglycerides, meaning 
that it would take longer to liberate the energy from the longer chain triglycerides. There 
is also evidence in humans that high consumption of medium chain triglycerides increases 
energy expenditures and reduces adiposity compared with long chain triglycerides (St-
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Onge et al., 2003; St-Onge, Ross, Parsons, & Jones, 2003 (b)). St-Onge et al. (2003); St-
Onge et al. (2003 (b)) fed overweight and obese men and women a diet high in medium 
chain triglycerides compared with olive oil (high in long chain triglycerides) for 27 days. 
The diets were identical except for the fat content. There was a significant decrease in 
upper body adipose tissue, an increase in energy expenditure and fat oxidation when 
consuming the diet high in medium chain triglycerides, although the latter two variables 
were not significantly different between the two groups. An additional study was 
conducted by Kasai et al. (2003) who compared the effects of medium and long chain 
triglycerides on the accumulation of body fat in 82 healthy subjects for 12 weeks. The 
authors reported a significant decrease in overall body weight in both groups, Although 
the authors offer no explanation for the decrease in overall body weight in the control 
group consuming the long chain triglycerides, a potential explanation may be that the 
diets that both groups were on was less calorificly dense than the subjects normal diet. 
Although both groups had a reduction in overall body weight those consuming medium 
chain triglycerides exhibited a significantly greater weight loss. This reduction in body fat 
was associated with a reduction in subcutaneous and visceral fat. Furthermore, the authors 
reported a significant reduction in serum total cholesterol. However there were no other 
significant differences in blood chemistry between the two groups. The data from these 
studies suggests that medium chain triglycerides may result in a reduction in body weight, 
accumulation of adipose tissue and plasma determinants associated with obesity and 
disease. Although the work of Kasai et al. (2003) was conducted over 12 weeks, further 
longitudinal work is required to assess various food types high in medium chain 
triglycerides in everyday life to ascertain the efficacy of consuming diets high in medium, 
as opposed to long chain triglycerides.  
If the body is inundated with large amounts of fat that outweigh the energy requirements 
the body will re-form this into triglycerides through lipogenesis, where it will be 
distributed throughout the body as adipose tissue (Mu & Hoy, 2004). In addition to the 
increased amounts of fat people are consuming per meal, it is the ease of access to 
palatable foods, fast foods and mechanised manufacturing of foods with increased fat 
content that is also contributing to the increased levels of obesity (Nestle & Jacobson, 
2000). The problem therefore not only appears to be related to the large amounts of food 
that people are consuming, but also the larger amounts of fat that are within these foods. 
There is evidence to suggest that medium chain triglycerides may be a healthier option for 
a number of reasons, although the incorporation of these medium chain triglycerides into 
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food production may not be possible. Long chain triglycerides are generally used to 
improve the consistency, appearance, taste and shelf life of products (FAO/WHO, 2003). 
It is unlikely that those manufacturing these foods will reduce the use of the longer chain 
triglycerides from foods in the foreseeable future. It is for these reasons that any weight 
loss treatments must target the foods that people are consuming or target food digestion 
once it has been consumed. Any reduction in fat digestion will be beneficial, although a 
treatment that may inhibit the digestion of long chain triglycerides over medium chain 
triglycerides may have the potential to reduce the accumulation of adipose tissue, and 
reduce body weight in obese and overweight individuals.  
Although current obesity treatments do not target long chain triglycerides specifically, 
they are targeting a reduction of calories consumed and absorbed. The most common 
forms of treatment include pharmaceutical interventions and surgery (Santry et al., 2005) 
(Pacher, Batkai, & Kunos, 2006). Despite the encouraging weight loss reported in these 
studies, there are numerous physiological and psychological side effects. An additional 
drug, and potentially the most common pharmaceutical intervention is Orlistat, also 
known as Alli. This drug does not act upon the central nervous system, but rather by 
covalently binding to the active site of pancreatic lipase in the upper GI tract (Al-
Suwailem et al., 2006). This binding renders the pancreatic lipase inactive and therefore 
ineffective at digesting fat within the small intestines, and therefore the fat is unable to 
pass across the cellular membrane within the small intestines and will pass through the 
upper GI tract undigested and out in faeces (Al-Suwailem et al., 2006; Sternby et al., 
2002). Lucas (1998) and Zhi et al. (1996) have both reported weight loss in a clinical 
setting, and demonstrated the efficacy of the drug. Although this drug has been attributed 
to aiding in weight loss there are a number of side-affects caused by this drug, such as 
abdominal pain, diarrhoea, flatulence, fatty stools and faecal incontinence amongst others 
(Finer et al., 2000). Although Orlistat is effective at inhibiting pancreatic lipase there is 
no evidence to suggest that Orlistat is able to distinguishing between long, medium or 
short chain triglycerides, Therefore if all fat digestion is reduced then this may also 
decrease the absorption of medium and short chain triglycerides, which have been linked 
with health benefits (Kasai et al., 2003; St-Onge et al., 2003 (b)).  
Despite the afore mentioned adverse side effects of Orlistat, this drug remains the most 
effective pharmaceutical treatment for obesity. If an obesity treatment can be produced 
that can act in a similar way to Orlistat and reduce fat digestion without the side effects, 
then this may have the potential to reduce the number of obese individuals worldwide.  
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There is in-vitro evidence from Richardson et al. (2011); Strugala et al. (2005); 
Sunderland et al. (2000) and Wilcox et al. (2013) that have all provided evidence 
demonstrating the ability of alginate to inhibit digestive enzymes pepsin and pancreatic 
lipase. The work of Richardson et al. (2011) and Wilcox et al. (2013) have reported that 
specific alginates are able to inhibit pancreatic lipase by up to 85%. Even though these 
data do suggest alginate has the potential to be used as an obesity treatment, these 
experiments were performed using a simplistic model for assessing pancreatic lipase 
activity (Vogel & Zieve, 1961). Although the adapted method from Vogel and Zieve 
(1961) does indicate the activity of pancreatic and co-lipase activity, it does not take into 
account other components within digestion, such as bile, pancreatic juice, a large range of 
pH’s and undigested constituents that may be present during in-vivo digestion. 
Furthermore, these experiments have been conducted using dry alginate, and as 
previously mentioned the main issue with using alginate as an obesity treatment in a 
clinical setting is the delivery vehicle (Ellis et al., 1981). Although there is evidence to 
suggest that the addition of alginate to a beverage or food vehicle can result in a number 
of physiological benefits, the foremost problem with alginate in a beverage is poor 
palatability and thus low compliance, which is generally the main issue with any weight 
loss or maintenance programs (Jensen et al., 2012 (a); Paxman et al., 2008; Torsdottir et 
al., 1989).  
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4.2 Aims 
There is in-vivo and in-vitro evidence to suggest that alginates possess the ability to 
attenuate the activity of digestive enzymes, and therefore reduce the available energy 
from calories consumed. The main issue with adding alginate to a vehicle is the 
palatability of the delivery vehicle. The data previously presented in this thesis indicates 
that there is no substantial increase in viscosity at the end of the model gut and that the 
alginate within the bread maintains its inhibition properties despite the cooking and 
digestion process. Therefore the purpose of this chapter is to: 
 Utilise a model gut system that replicates digestion in the mouth, stomach and 
small intestine. This model allows samples to be taken at multiple times points. 
This will assess whether fat substrates and foods high in fat such as butter and 
olive oil are digested within a model gut system, and to determine if the rate of 
digestion is similar to what would be expected in-vivo. 
 
 To determine if the fat substrates and foods containing fat are digested at a similar 
rate. Various publications have suggested that the rate at which fats are digested is 
dependent on the chain length of the fatty acids (Bach & Babayan, 1982; Bernard 
& Carlier, 1991). If this is the case then the model gut will help identify which fats 
are digested quickest and if there is a link between the digestion rate and the fatty 
acid chain length.  
 
 The data presented earlier in this thesis indicates that alginate is released from the 
bread as it is digested in the model gut. Between 80-90% of the alginate is 
released in the small intestine, which is generally where fat is digested in-vivo. If 
the alginate is released from the bread as indicated here then fat digestion may be 
attenuated. Therefore the final aim of this chapter is to determine if the alginate 
enriched bread is able to reduce the digestion of fat substrate and foods containing 
fat within the model gut system.  
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4.3 Methods  
4.3.1  Materials 
Alginate and control bread were those used in chapter three. Fat substrates glyceryl 
tributyrate, glyceryl trioctanoate and glyceryl trioleate were purchased from Sigma, with 
their properties depicted in Table 6. Anchor butter and olive oil were purchased from Co-
operatives Foods (Manchester, UK). Glycerol reagent A 40ml was purchased from 
Amsbio (Abingdon, UK). All materials used for the model gut were those used in chapter 
three.  
Table 6.  Attributes of fat substrates digested in the model gut.  
Triglyceride Fatty Acid Fatty Acid Chain Length  Fatty Acid pKa 
Glyceryl Tributyrate Butyric Acid 4 4.84 
Glyceryl Trioctanoate  Octanoic Acid (Caprylic Acid) 8 4.9 
Glyceryl Trioleoate Oleic Acid 18 9.95 
 
4.3.2 Equipment 
All assays were carried out using BioTek 96 well plate reader at 550nm (ELx808 BioTek, 
Bedfordshire, UK). Two Grant GD 100 water baths were used for incubating synthetic 
model gut solutions and samples gut at 37˚C (Fisher Scientific, Loughborough, UK). A 
Sci-Q 401U/D peristaltic pump was used to pump synthetic solution into samples in the 
synthetic model gut (Watson-Marlow, Fisher Scientific, Loughborough, UK), three IKA
® 
laboratory egg compact mixers were used to mix digesta. A Thermo Jouan BR4i Mu 
Scientific Centrifuge (Basingstoke, UK) and an Eppendorf Centrifuge 5415 R (Stevenage, 
UK) were used for samples <4ml and >2ml, respectively. 
4.3.3 Model Gut Procedure  
The model gut was run as per chapter three, with the following experiments undertaken: 
i) Model gut solution alone 
ii) Model gut solution with 500µl glyceryl tributyrate, glyceryl trioctanoate or 
glyceryl trioleate. 
iii) 5.2g AB or CB alone. 
iv) 5.2g AB or CB with 500µl glyceryl tributyrate, glyceryl trioctanoate or 
glyceryl trioleate. 
v) Model gut solution with 1g of butter alone 
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vi) 5.2g AB or CB with 1g of butter 
vii) Model gut solution with 500µl of olive oil 
viii) 5.2g AB or CB with 500µl of olive oil 
During the model gut process a one ml sample was taken at 30 seconds (after mastication 
in the mouth), and then every 15 minutes for a total of 180.5 minutes. 
4.3.4 Glycerol Quantification 
4.3.4.1 Glycerol Standard Curve 
To ascertain glycerol content in samples taken from the model gut a standard curve was 
produced for glycerol in DH2O using a 96 well plasma glycerol kit (SGA-1, Amsbio, 
Abingdon, UK) was used. Working reagent A was prepared at room temperature by 
adding glycerol reagent with DH₂O in a 4:1 ratio, respectively. Glycerol control was 
serial diluted down from 2.5 mM in DH2O. 5µl of each concentration of glycerol was 
then added to a 96 well plate in duplicate, before 100µl of the glycerol working reagent 
was added to the appropriate wells and mixed, before being left at room temperature for 
15 minutes. The plate was then read at 540nm on the plate reader, which provided free 
glycerol measurement. 
4.3.4.2 Pre Model gut  
In order to ascertain the amount of the substrate digestion that occurs within the model 
gut, the substrates were digested in a manner that replicated model gut digestion. Three 
samples were prepared replicating the solution that would be present at the end of the 
gastric phase of the model gut. 500µl of glyceryl tributyrate, glyceryl trioctanoate or 
glyceryl trioleate was added and then mixed for 60 minutes at 37˚C. The fat substrates 
were exposed to these conditions rather than gradually adding gastric juice as minimal 
glycerol would be present in the gastric phase of digestion, and this experiment was to 
assess if digestion of the substrate was taking place, which would generally only occur in 
the presence of bile and pancreatic lipase. After 60 minutes bile and pancreatic juice were 
added, in the same volumes that would be present at the end of the model gut (180.5 
minutes). The samples were then continually mixed whilst being maintained at 37˚C. 1ml 
samples were collected after 60 minutes and then in 30 minutes intervals until glycerol 
had plateaued with no additional solution added. A plateau in the glycerol indicated 
complete digestion of the substrate. The solution from this time point is then used to 
create a standard curve for each individual substrate. Glycerol alone was added to model 
gut solution alone from 180.5 minutes and homogenised. This was then diluted to 2.5mM 
using DH₂O to create a standard curve. This standard curve was used to quantify glycerol 
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present in samples AB, CB, butter and olive oil. Once collected all samples were heated 
at 80˚C for 30 minutes to denature the enzymes and then allowed to cool to room 
temperature. Samples were then centrifuged at 10,000rpm for 10 minutes at 10˚C. As the 
amount of substrate added at the start and the total solution at the end are known the 
concentration at each time point can be calculated. As a control model gut solution alone 
was used to subtract any interference from the substrate samples. The supernatant from 
samples were then diluted using DH₂O to 2.5mM for each time point with equal dilutions 
for the control. 5µl of each time point was then added to a 96 well plate in duplicate, 
followed by 100µl of glycerol working reagent (4:1, glycerol reagent:DH₂O). The plate 
was then read on the plate reader at 540nm every 30 seconds for 3 minutes and 30 
seconds, during which time the plate was shaken prior to each measurement. The 
absorbance from 3 minutes was used for analysis, as the absorbance plateaued at this time 
point.  
4.3.4.3 During Model Gut  
1ml samples were extracted from the model gut at 0.5, 30, 60, 60.5 and then 30 minute 
intervals for a total time of 180.5 minutes. The samples were heated at 80˚C for 30 
minutes to denature the enzymes and then allowed to cool to room temperature. The 
samples were then centrifuged at 10,000rpm for 10 minutes at 10˚C, before the 
supernatant was diluted 1:5 (v:v) in DH₂O. 5μl of each sample at each time point was 
added to a 96 well in duplicate, and 100μl of glycerol working reagent A was added to 
each well. The plate was then read on the plate reader at 540nm every 30 seconds for 3 
minutes and 30 seconds, during which time the plate was shaken prior to each 
measurement. The absorbance from 3 minutes was used for analysis, as the absorbance 
plateaued at this time point. 
4.4 Statistical Analysis 
Statistical calculations were undertaken using SPSS Statistics 19 (IBM, Predictive 
Analysis Software, USA). Data is presented as mean and standard error of mean (S.E.M). 
A Two-way Repeated ANOVA followed by a Post-Hoc Bonferroni were undertaken at a 
significant level (α) of 0.05 to compare differences between normal fat substrate and food 
digestion compared with fat substrate and food digestion with 5.2g CB or AB. 
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4.5 Results 
4.5.1 Standard Curve for glycerol in DH2O 
Figure 18 illustrates the standard curve for glycerol in DH₂O, demonstrating that the 
glycerol working reagent A is an effective method for determining free glycerol. The data 
in Figure 18 demonstrates that the assay sensitivity, linearity (r = 0.99) and a range of 
absorbance (0-0.24 OD) for 0.3-2.5mM glycerol concentrations.  
 
 
Figure 18.  Mean standard curve (+ S.E.M) for glycerol in DH₂O (r = 0.99) using glycerol working 
reagent A (n=6). 
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4.5.2 Substrate Digestion 
The digestion of the three substrates glyceryl tributyrate, glyceryl trioctanoate and 
glyceryl trioleate is depicted in Figure 19, Figure 20 and Figure 21. The plateau in 
absorbance demonstrates that substrate digestion has finished after 240, 210 and 360 
minutes for glyceryl tributyrate, glyceryl trioctanoate and glyceryl trioleate, respectively. 
The data here indicates that the fatty acid chain length appears to affect the digestibility of 
fat substrate. Glyceryl trioctanoate is digested first, followed by glyceryl tributyrate and 
glyceryl trioleate. 
 
 
Figure 19.  Mean (+ S.E.M) absorbance from glycerol released during digestion of 500µl of glyceryl 
tributyrate. A plateau in absorbance at 240 minutes identifies end point substrate digestion, highlighted by a 
white marker (n=6). No additional solutions were added beyond 180 minutes.   
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Figure 20.  Mean (+ S.E.M) absorbance from glycerol released during complete digestion of 500µl of 
glyceryl trioctanoate. A plateau in absorbance at 210 minutes identifies end point substrate digestion, 
highlighted by a white marker (n=6). No additional solutions were added beyond 180 minutes.   
 
 
 
Figure 21.  Mean (+ S.E.M) absorbance from glycerol released during complete digestion of 500µl of 
glyceryl trioleate. A plateau in absorbance at 360 minutes identifies end point substrate digestion, 
highlighted by a white marker (n=6). No additional solutions were added beyond 180 minutes.   
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4.5.3 Glycerol Standard Curve for Substrates 
4.5.3.1 Glyceryl Tributyrate 
The data in Figure 22 is the standard curve from the sample taken at 240 minutes, as this 
is the time point the glycerol plateaued. The data here demonstrates sensitivity (0.3mM), 
linearity (r
 = 0.99) and an acceptable range of absorbance (0-0.24 OD).  
 
Figure 22.  Mean standard curve (+ S.E.M) for glyceryl tributyrate from solution taken at 240 
minutes of complete substrate digestion (r = 0.99) using glycerol working reagent A (n=6). 2.5mM 
concentration was calculated by the addition of 500µl neat glyceryl tributyrate being added to 145ml model 
gut solution and then being multiplied by the molarity of the substrate. Therefore (0.5/145) x 3.41 = 
11.7mM which was then diluted down to 2.5mM and a standard curve was produced.    
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4.5.3.2 Glyceryl Trioctanoate 
The data in Figure 23 is the standard curve from the sample taken at 210 minutes, as this 
is the time point the glycerol plateaued. The data here demonstrates sensitivity (0.3mM), 
linearity (r
 
= 0.99) and a acceptable range of absorbance (0-0.26 OD). 
 
Figure 23.  Mean standard curve (+ S.E.M) for glyceryl trioctanoate from solution taken at 210 
minutes of complete substrate digestion (r = 0.99) using glycerol working reagent A (n=6). 2.5mM 
concentration was calculated by the addition of 500µl neat glyceryl trioctanoate being added to 145ml 
model gut solution and then being multiplied by the molarity of the substrate. Therefore (0.5/145) x 2.03 = 
7mM which was then diluted down to 2.5mM and a standard curve was produced.    
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4.5.3.3 Glyceryl Trioleate 
The data illustrated in Figure 24 is the standard curve from the sample taken at 360 
minutes. The data here demonstrates sensitivity (0.3mM), linearity (r = 0.99) and a 
acceptable range of absorbance (0-0.18 OD). 
 
Figure 24.  Mean (+ S.E.M) standard curve for glyceryl trioleate from solution taken at 360 minutes 
of complete substrate digestion (r = 0.99) using glycerol working reagent A (n=6). 2.5mM concentration 
was calculated by the addition of 500µl neat glyceryl trioleate being added to 145ml model gut solution and 
then being multiplied by the molarity of the substrate. Therefore (0.5/145) x 1.03 = 3.5mM which was then 
diluted down to 2.5mM and a standard curve was produced.    
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4.6 Substrate Digestion in Model Gut 
4.6.1 Glyceryl Tributyrate 
Figure 25 shows the digestion of normal digestion of glyceryl tributyrate alone, and with 
either CB or AB. In the gastric phase (0-60 minutes) there appears to be minimal 
digestion of the substrate, however in the small intestinal phase there is an exponential 
increase in free glycerol. There was a significant effect of treatment, demonstrating that 
there was a difference in the amount of free glycerol when AB and CB were present when 
compared with normal substrate digestion alone (p<.05). There was a significant 
difference in the total mean glycerol released during the model gut between AB and 
substrate (2259.6 + 186.5 µMol/L) and substrate (3271.3 + 93.2 µMol/L) digestion alone 
(p<.05). Although there was no significant difference between CB (3303.9 + 322.3 
µMol/L) and normal substrate digestion (p>.05). The glycerol released was lower at all-
time points in the small intestine phase when AB was present compared to the substrate 
alone, although this was only significantly different at 120 and 180.5 minutes (p<.05), 
with 7811.2 µMol/L (± 1228.4) and 11356.5 µMol/L (± 2496.2) glycerol released for AB 
and substrate and substrate alone respectively. However there were no significant 
differences at any other times points between normal substrates digestion when compared 
with AB and CB (p>.05). 
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Figure 25.  Mean (+ S.E.M) glycerol released during normal glyceryl tributyrate (500µl) digestion 
alone and with either 5.2g CB or AB in the model gut system. * denotes a significant difference (n=6). To 
calculate potential glycerol present in 500µl of substrate alone = Density 1.032g/ml, Mr 302.36, therefore 
glycerol in 500µl substrate 1032g in 1L so in 500µl there is 0.516g. Therefore glycerol (0.516 x 92)/302.36 
= 0.157g and therefore moles of glycerol is 0.157/92 = 0.0017 moles. In moles/L = (0.0017 x 1000)/145 = 
0.011 moles/L or 11,770 µmoles/L. 
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4.6.2 Glyceryl Trioctanoate 
The data in Figure 26 illustrates normal glyceryl trioctanoate digestion alone, and with 
CB or AB. The data suggests that there is only a small amount of free glycerol in the 
gastric phase of digestion (0-60 minutes). There was a significant effect of treatment on 
the levels of free glycerol (p<.05). There was no significant difference between CB and 
normal substrate digestion (p>.05), however there was a significant difference between 
both CB and normal substrate alone digestion when compared to AB (p<.05), with a 
mean total glycerol release of 5102.6 µMol/L (+ 350.4), 4266.5 µMol/L (+ 351.5) and 
2174.2 µMol/L (+ 227.1) respectively. ). The glycerol released was lower at all-time 
points in the small intestine phase when AB was present compared to the substrate alone, 
although this was significantly different at 120 and 180.5 minutes (p<.05). There was 
4746.3 µMol/L (± 1167.3) and 7746.3 µMol/L (± 1563.1) glycerol released for AB and 
substrate and substrate alone respectively. However there were no significant differences 
at any other times points between normal substrates digestion when compared with AB 
and CB (p>.05). 
 
 
Figure 26.  Mean (+ S.E.M) glycerol released during normal glyceryl trioctanoate (500µl) digestion 
alone and with either 5.2g CB or AB in the model gut system. * denotes a significant difference (n=6). To 
calculate potential glycerol present in 500µl of substrate = Density 0.956g/ml, Mr 470.68, therefore 
glycerol in 500µl substrate 956g in 1L so in 500µl there is 0.478g. Therefore glycerol (0.478 x 92)/470.68 = 
0.0934g and therefore moles of glycerol is 0.0934/92 = 0.001 moles. In moles/L = (0.001 x 1000)/145 = 
0.007 moles/L or 7000 µmoles/L. 
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4.6.3 Glyceryl Trioleate 
Figure 27 shows normal glyceryl trioleate digestion alone, and with CB or AB. There is 
small amount of free glycerol digested within the gastric phase (0-60 minutes), however 
this increases as the digesta enter the small intestinal phase (60.5-180.5 minutes) of 
digestion. There was a significant effect of treatment, which was demonstrated by a larger 
mean total glycerol release in the substrate digestion alone and with CB compared with 
AB (p<.05). Mean total release for substrate digestion alone was 719.8 µMol/L (+ 43.5) 
compared with 665.1 µMol/L (+ 156.5) and 540.4 µMol/L (+ 34.2) for CB and AB 
respectively. There was a significant difference at in glycerol release for normal digestion 
compared with substrate digestion and AB at 180.5 minutes (p<.05) (2222.4 ± 295.1 and 
859.3 ± 92.6 µMol/L, respectively). There was no significant difference between normal 
substrate digestion, AB and CB at any other time point during digestion (p>.05). 
 
Figure 27.  Mean (+ S.E.M) glycerol released during normal glyceryl trioleate (500µl) digestion 
alone and with either 5.2g CB or AB in the model gut system. * denotes a significant difference (n=6). To 
calculate potential glycerol present in 500µl of substrate = Density 0.91g/ml, Mr 885.43, therefore glycerol 
in 500µl substrate 910g in 1L so in 500µl there is 0.445g. Therefore glycerol (0.445 x 92)/885.43 = 0.0462g 
and therefore moles of glycerol is 0.0462/92 = 0.000513 moles. In moles/L = (0.000513 x 1000)/145 = 
0.00354 moles/L or 3538 µmoles/L. 
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4.6.4 Olive Oil 
The data in Figure 28 shows normal olive oil digestion alone, and in combination with 
either CB or AB. There is around 100 µmol/L of glycerol released at the end of the 
gastric phase of digestion in all three samples. This then increases for the olive oil alone 
and olive oil with CB. There was a significant effect of treatment, which is evident in the 
mean glycerol released during normal olive oil digestion compared with CB and or AB 
(p<.05). The mean glycerol released from olive oil digestion alone was 119.5 µMol/L (+ 
48.1) compared with 110.8 µMol/L (+ 25.4) and 36.1 µMol/L (+ 25.4) for CB and AB 
respectively. There was a significant difference between normal olive oil digestion and 
AB at 180.5 minutes (p<.05) with 531.8 µMol/L (± 84.4) and 31.8 µMol/L (±118.9) 
glycerol released respectively. Although there were no other significant differences 
between normal substrate digestion and CB or AB (p>.05). For all three samples there 
was a lag of glycerol release until 120 minutes, thereafter glycerol increased for both 
olive oil alone and olive oil with CB but not with olive oil and AB. 
 
Figure 28.  Mean (+ S.E.M) glycerol released during normal olive oil (500µl) digestion alone and 
with either 5.2g CB or AB in the model gut system. * denotes a significant difference (n=6). To calculate 
potential glycerol present in 500µl of substrate = Density 1g/ml, Mr 941 (based on the assumption that the 
majority of triglycerides in olive oil have C18 fatty acids), therefore glycerol in 500µl substrate 1000g in 1L 
so in 500µl there is 0.500g. Therefore glycerol (0.500 x 92)/941 = 0.0488g and therefore moles of glycerol 
is 0.0488/92 = 0.00053 moles. In moles/L = (0.00053 x 1000)/145 = 0.0365 moles/L or 3650 µmoles/L. 
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4.6.5 Butter 
Figure 29 illustrates the digestion of butter in the model gut, and in combination with CB 
or AB. There is minimal digestion during the gastric phase of digestion (0.5-60 minutes). 
However glycerol release then begins to increase as the small intestinal phase of 
digestions begins (60.5-180.5 minutes). There was a significant effect of treatment, which 
was evident in the mean total glycerol released during the model gut (p<.05). The mean 
glycerol released for normal butter digestion was 160.6 µMol/L (+ 32.8) compared with 
123.7 µMol/L (+ 15.8) 44.3 µMol/L (+ 8.1) for 5.2g CB and AB respectively. There was 
a significant difference in the free glycerol between butter digestion and butter with AB at 
180.5 minutes (p<.05). There was, however, no significant differences between butter 
digestion and butter with CB or AB at any other time points (p>.05). 
 
 
Figure 29.  Mean (+ S.E.M) glycerol released during normal butter (1g) digestion alone and with 
either 5.2g CB or AB in the model gut system. * denotes a significant difference (n=6). No calculation for 
butter as there is no data on the complete analysis of butter.  
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4.7 Discussion  
The data in the present chapter demonstrates that fat substrates are digestible within the 
model gut and that the fat substrates, glyceryl tributyrate, glyceryl trioctanoate and 
glyceryl trioleate digest at varying rates. Furthermore, the data presented here indicate 
that the alginate enriched bread is able to attenuate fat digestion and potentially inhibit 
triglycerides at different rates/levels based on their chain length, whether it is as a fat 
substrate or fat contained within food. 
Although the non-polar structure of fat implies it may be a difficult to digest, the human 
upper GI tract is able to digest and absorb up to 95% of fat consumed (Carey et al., 1983). 
The majority of fat consumed is made up of triglycerides, which can either be saturated or 
unsaturated, which may include up to six double bonds. In addition, the length of the 
FA’s that are attached to the glycerol backbone can vary greatly, ranging from two up to 
24 carbons (Mu & Hoy, 2004). Irrespective of the chain length of the FA it is generally 
only the FA located at sn1 and sn3 that are hydrolysed, as the pancreatic lipase has 
specificity towards these (Lowe, 2002). This would commonly be sufficient for 
absorption, as this would liberate two FA, leaving a monoglyceride and two FFA which 
are both able to pass across the epithelial walls of the small intestines (Embleton & 
Pouton, 1997). Regardless of pancreatic lipase’s lack of affinity, Embleton and Pouton 
(1997) and Mu and Hoy (2004) suggested that the FA located at sn2 may undergo re-
arrangement to the sn1 or sn3 position, although this re-arrangement is thought to occur 
with no enzymatic action. Constantin, Pasero, and Desnuelle (1960) conducted early 
research on whether complete hydrolysis of triglycerides can occur. The authors used 
synthetic pancreatic juice which included the myriad of enzymes within the small 
intestine. They demonstrated that complete hydrolysis of triglycerides occurred, which 
was evident by a significant increase in glycerol and FFA until hydrolysis plateaued. The 
authors attributed the alkaline environment of the small intestines for re-arrangement of 
the FA present at sn-2, which exposes the final FA for hydrolysis resulting in three FFA 
and a glycerol molecule. The model gut used within this laboratory has no absorption 
capacity, and therefore once the FA at sn1 and sn3 have been hydrolysed this would 
generally leave the FA at the sn2 position. However the data presented here from the 
digestion experiments suggests that hydrolysis of all three FA is occurring as 
demonstrated by a plateau in absorbance and significant release of free glycerol, which 
corresponds well with previous research (Constantin et al., 1960; Embleton & Pouton, 
1997; Mu & Hoy, 2004). Although some free glycerol may be present in the pancreatin or 
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bile this would not account for the substantial increase in absorbance reported here. 
Furthermore the glycerol that may be present within the model gut was accounted for, 
further strengthening the evidence that complete hydrolysis of all three FA is occurring. 
These data provided further evidence that the pH of the small intestines may be 
responsible for the re-arrangement of the third FA located at sn2, and thus allow this to be 
hydrolysed. An additional point to consider is the rate at which this re-arrangement may 
occur at. For example the re-arrangement may take longer when the FA chain length is 
longer compared with short or medium FA length, although to confirm this further 
research is required.  
The data presented here suggests that the rate at which digestion occurs varies between 
different triglycerides. Luddy, Barford, Herb, Magidman, and Riemenschneider (1964) 
and Doreau and Chilliard (1997)indicated that the chain length and the FA that is present 
at the sn2 position has significant implications on the digestion rates of triglycerides. 
Leyton, Drury, and Crawford (1987) reported that the longer the FFA chain length, the 
longer the triglyceride took to digest. Leyton et al. (1987) fed rats triglycerides that 
contained radioactive labelled FA, and then measured expired CO2 over 24 hours. As 
time increased so too did the amount of radioactive CO2 expired, with the smaller length 
FA plateauing before the longer chain FA. The evidence presented by Leyton et al. (1987) 
demonstrates a time dependant digestion and utilisation of triglycerides as an energy 
source based on their FA chain length, with shorter FA being digested quicker than long 
chain FA. The data presented shows that longer chain triglyceride glyceryl trioleate take 
longer to digest than small and medium chain triglycerides. The absorbance for glyceryl 
tributyrate digestion plateaued after 240 minutes; however trioleate took an additional 80 
minutes, representing an increase of 44%. The digestion of triglycerides of various 
lengths has long been established, in as much as the chain length of the FA determines the 
digestion and thus the absorption rate (Bernard & Carlier, 1991; Blomstrand, 1955). 
Bernard and Carlier (1991) observed the digestibility and absorption of capric acid, which 
has a carbon tail of 10 and long chain triglycerides in rats. Either radioactive capric acid 
or long chain triglycerides were infused intraduodenally into the rats and blood samples 
were taken from the portal blood at 5 minute intervals for 1 hour. They reported that 
capric acid was absorbed significantly quicker than the long chain triglycerides and were 
therefore taken up directly via the hepatic portal vein and into the liver, and not re-
constituted into chylomicrons. Although the model gut here does not have an absorption 
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capacity, which makes direct comparison difficult, the earlier plateau of glyceryl 
tributyrate suggests that digestion of this fat substrate occurs prior to glyceryl trioleate.  
Although the long chain triglycerides may take longer to be re-synthesised into 
chylomicrons and therefore take longer to appear in the blood, an additional mechanism 
may be the solubility of the fats. Smits, Wilding, and Cooke (1968) indicated that 
although bile salts are still required for short and medium chain triglycerides, they are not 
as important for micelle formation as when long chain triglycerides are present. They 
indicated that this was due to the water solubility of short and medium chain triglycerides. 
The increased digestibility of capric acid containing triglycerides and glyceryl tributyrate 
used in the present study may also be due to the water solubility of these triglycerides. 
The hydrosolubility of short and medium chain triglycerides may indicate that gastric and 
pancreatic lipase is able to begin hydrolysis of the triglycerides earlier than long chain 
triglycerides. The long chain triglycerides are not water soluble and are only therefore 
totally solubilised at a high pH in the presence of bile salts and calcium (Bracco, 1994). If 
the medium and short chain triglycerides do not require these steps to release long chain 
FA then they can be absorbed quicker and will therefore appear in the blood quicker than 
long chain triglycerides. The ability of the medium and short chain triglycerides to be 
absorbed directly into the blood stream through the portal vein, rather than being re-
constituted into chylomicrons and into the lymphatic system, and again delaying the 
appearance of long chain triglycerides in the blood. An additional explanation may be that 
pancreatic lipase has a higher affinity for the medium and short chain triglycerides when 
compared with the long chain triglycerides. There is no study to date that has observed 
the michaelis constant (Km) for a triglycerides with a range of fatty acid lengths. If the 
medium and short chain triglycerides have a lower Km than the long chain triglycerides 
then this would mean that pancreatic lipase would digest the medium and short chain 
triglycerides at an accelerated rate when compared with the long chain triglycerides. 
Although this may be a justifiable explanation for the varying digestion rates this was not 
confirmed in the current study and requires further research.  
Interestingly the medium chain triglyceride, glyceryl trioctanoate, digested quicker than 
both the glyceryl trioleate and tributyrate as seen by the earlier appearance of glycerol. 
Yang, Kuksis, and Myher (1990) demonstrated that FA chain length played a significant 
role in the digestion rate of triglycerides. They incubated medium and long chain 
triglycerides for various timed periods in synthetic pancreatic juice including porcine 
pancreatic lipase in the presence of bile. They reported that medium chain triglycerides 
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were digested significantly quicker than long chain triglycerides as evident by the 
increased rate of fatty acid production recovered after each time point. Jandacek, 
Whiteside, Holcombe, Volpenhein, and Taulbee (1987) substantiated this further by 
extracting pancreatic juice using a common bile duct cannula from rats and adding 
various fats to the solution and then measured the release of fatty acids per minute for 
each of the fats. In addition the authors also fed rats the various fats before anesthetising 
them and extracting the small intestines at various time points to observe the digestion 
rates of the fat. In both the in-vitro and in-vivo experiments the authors demonstrated that 
the rate of digestion was dependent on the FA chain length, with medium chain lengths 
having the fastest digestion rates, above both short and long chain triglycerides. Although 
the data presented here indicates that glyceryl tributyrate does digest at a slightly slower 
rate than that of glyceryl trioctanoate, which is consistent with Jandacek et al. (1987), this 
does not agree with earlier suggestions that medium and short chain triglycerides digest at 
similar rates (Bernard & Carlier, 1991; Smits et al., 1968). The methods used in this 
thesis are not consistent with either of the previously mentioned studies who used a rat 
model and humans with steatorrhoea respectively, and may explain the differences 
reported here. The data presented here, the physiochemical structure of short chain 
triglycerides and the water solubility suggests they will be digested in a similar manner to 
that of medium triglycerides. A potential explanation of the increased digestion rate of 
medium chain triglycerides over short chain triglycerides may be that the length of the FA 
chain of the short chains FA is too small to fit completely into the open loop of the 
pancreatic lipase active site resulting in weaker binding. Although the data here have not 
confirmed this, further work is required to ascertain if this is the case. Furthermore the 
majority of work conducted on short and medium FA triglycerides has been conducted in 
animals, ill patients in-vivo and in-vitro and therefore it is unknown whether there would 
be any significant difference in digestion rates in normal in-vivo conditions (Yang et al., 
1990). To confirm whether a difference exists between the digestion rates of short and 
medium triglycerides further work must be conducted comparing triglycerides of varying 
FA lengths. 
Initial digestion of triglycerides begins in the stomach where fatty acids from the sn1 and 
sn3 may be hydrolysed leaving a di-glyceride and a FFA (Tucci et al., 2010). Although 
digestion begins in the stomach, between 80-90% of triglycerides are digested within the 
small intestines (Carey et al., 1983). The data presented for the fat substrates glyceryl 
tributyrate, trioctanoate and trioleate digestion indicates that the model gut is digesting 
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them in a similar fashion as would be expected in-vivo digestion. Of the total amount of 
glycerol released during substrate digestion, 9, 12 and 2% of the total glycerol was 
released between 0-60 minutes for glyceryl tributyrate, triocatanoate and trioleate 
respectively. The data from the stomach phase of digestions lend support to the 
suggestion that short and medium chain triglycerides are more soluble rather than they are 
more easily digested than long chain triglycerides as depicted by the larger levels of 
glyceryl released in the gastric phase. In a similar manner the glycerol released between 
0-60 minutes from the olive oil and butter digestion which contains both long and 
medium chain FA was 2 and 5% respectively of the total glycerol released. Beyond 60 
minutes the free glycerol increased substantially in all three substrates and both the olive 
oil and butter, which corresponds well with what, would be expected in-vivo digestion 
(Armand et al., 1994; Armand et al., 1996). The data presented here and earlier in this 
thesis shows the model gut as a suitable model to replicate digestion within the mouth, 
stomach and small intestines for pure triglycerides, confirming earlier studies that 
minimal fat digestion takes place in the stomach (Carey et al., 1983; Tucci et al., 2010). 
However the model gut does not appear to digest olive oil and butter to the same extent 
and therefore suggests that the model gut may not be effective at digesting foods high in 
fat. A potential explanation for this is that the end products of the olive oil and butter 
digestion may actually be inhibiting the release of glycerol. The rate of end product 
production is controlled by the level of accumulated end product (Gerhart & Pardee, 
1962), and therefore if there is too much end product then this will reduce the rate of 
production of more products. As the model gut does not have an absorption capacity there 
may have been a build-up of end products and therefore a reduction in the rate of further 
production. However, when these products are absorbed which would occur in-vivo the 
rate of product production will not be affected. In addition within the model gut there is 
cholesterol, bile and FFA and all of these may be competing with the triglycerides to bind 
with the active site of the pancreatic lipase. Furthermore the butter and olive oil will 
contain a range of triglycerides ranging in medium to long chain FA and a combination of 
saturated and unsaturated triglycerides which may also impact upon the digestion rates 
when compared with pure triglycerides. Although any of these may be a viable 
explanation as to why olive oil and butter were not digested to the same extent as the pure 
triglycerides, the most important finding here was that when alginate bread was present 
the glycerol released was lower in both the olive oil and butter digestion. 
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As previously mentioned, the digestion of fat in the human digestive system is extremely 
efficient, digesting up to 95% of the fat consumed (Carey et al., 1983). Therein lies the 
problem because the amount of fat that people are consuming is increasing. Hill and 
Peters (1998) identified two key factors which may be exacerbating the obesity problem 
further, as portion size and high fat foods. Portion sizes are growing and the opportunity 
to consume these large portion sizes is becoming easier in fast food restaurants, with the 
‘super sizing’ menus on offer. An additional factor is the high levels of fat that are now 
within foods and low costs of these high fat products. Hill and Peters (1998) suggested 
that these two factors are what makes designing an obesity treatment extremely difficult. 
It is for these reasons that an effective obesity treatment that targets food once an 
individual has consumed them may be the most beneficial approach to treat obesity. This 
is the manner by which Orlistat is able to reduce the amount of fat that an individual 
absorbs. Although there may be a high fat content within some foods Orlistat does not 
allow for complete digestion of that fat. This reduction in fat is facilitated by attenuating 
the activity of lipase. As an obesity treatment Orlistat is effective, but the attributed side 
effects are unwanted. Therefore, if alginate is able to attenuate the activity of digestive 
enzymes in a similar manner to Orlistat without these side effects would make alginate a 
potential obesity treatment. 
There is a large body of evidence demonstrating that adding alginate to various delivery 
vehicles, such as cereal bars and drinks, may attenuate postprandial blood glucose 
response, reduce Kcal intake, increase satiety and increase fat excretion (Jensen, 
Kristensen, & Astrup, 2011; Paxman et al., 2008; Sandberg et al., 1994; Torsdottir et al., 
1991). These studies all reported that alginate enriched products possess the ability to 
impact upon dietary intake and thus may be used to treat obesity. However, the poor 
palatability reported in these studies suggests that people will not consume them on a 
regular basis and therefore result in low adherence (Ellis et al., 1981). The bread used in 
the current study has undergone an acceptability study which reported no significant 
differences in acceptability with that of the control bread (data presented in chapter 5). In 
addition some anecdotal data taken from the acceptability study reported that subjects 
preferred the alginate bread compared to the control bread. If the alginate enriched bread 
is pleasant enough to eat then people will consume it on a regular basis, as they would 
any other product. Despite the pleasant taste of the alginate enriched bread, if it does not 
attenuate the activity of digestive enzymes then it is merely just bread with a larger 
amount of dietary fibre. The data in chapter 3 indicates that isolated alginate from 
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digested bread is able to inhibit pancreatic lipase activity by up to 38%, despite being 
exposed to the cooking process, digestion within the model gut and an isolation process. 
Although that demonstrates the stability of alginate, the assay used was an adapted 
version of the olive oil turbidity assay (Vogel & Zieve, 1961) and therefore did not take 
into account the myriad of factors that would be present with in-vivo or in-vitro digestion 
(Brownlee, Forster, et al., 2010). 
This is the first study that has compared the digestion and inhibition of triglycerides 
ranging in chain length in a synthetic model gut. It is apparent that there is a reduction in 
the amount of free glycerol present during substrate digestion when AB was added. The 
digestion of glyceryl trioleate was reduced by 62%, which is larger than that recorded 
with both tributyrate and trioctanoate. Whether or not the digestion rate of glyceryl 
trioleate has a part to play in the larger reduction in glycerol, it appears that AB is able to 
attenuate the digestion of the longer chain triglycerides more than the short and medium 
chain triglycerides. There is previous evidence that indicates alginates or any other 
dietary fibres are able to attenuate the digestion of long chain triglycerides more so than 
short and medium chain triglycerides. One potential explanation may be that because 
pancreatic lipase requires longer to hydrolyse all three fatty acids of glyceryl trioleate, the 
alginate potentially has a longer time period in which they interact with the lipase or 
interfere with the digestion of the substrate, and ultimately reduce fat digestion. 
Additionally it may be that glyceryl tributyrate and trioctanoate are digested earlier 
because they do not always need to be formed into micelles for digestion to occur due to 
their solubility, therefore meaning pancreatic lipase is able to gain access to the substrate 
and cleave off the fatty acids. Alginate may have potential to inhibit the digestion of 
longer chain triglycerides, when compared with short and medium chain triglycerides. If 
alginate is binding with bile salts then this may affect the ability of the bile salts to 
solubilise the longer chain triglycerides and ultimately slow their digestion. Although the 
data presented here cannot confirm any of these suggestions, further work is required to 
ascertain if AB is able to attenuate the digestion of a range of triglycerides differing in FA 
chain length and the measure the bile salt/alginate interactions if any.  
Although it is not known exactly how alginate inhibits pancreatic lipase there are a 
number of possibilities in which it may be binding with the enzyme or the substrate. One 
potential site may be the oil/water interface of the emulsification process where 
pancreatic lipase liberates FA, which is the suggested mechanism of how Chitosan is able 
to reduce the fat digestion (Han, Kimura, & Okuda, 1999; Tsujita et al., 2007). An 
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alternative mechanism may be through binding with the enzyme itself. The G blocks of 
the alginate have been shown to interact with glycoproteins eg. mucin, more specifically 
the exposed protein section of the mucin (Taylor, Draget, Pearson, & Smidsrod, 2005; 
Wilcox et al., 2014), and therefore highlights the ability of alginates to bind with proteins. 
This in addition may mean that the alginate is having a direct interaction with the enzyme 
active site and thus rendering the pancreatic lipase inactive, as is the mechanism of 
Orlistat. Cudrey et al. (1993) and Kumar and Chauhan (2010) postulated that the carboxyl 
group of the pectins may be able to protonate serine and histidine at the active site of 
pancreatic lipase. This could reduce or even stop the proton shuttle mechanism necessary 
for pancreatic lipase to become active. The similar structures present in pectins and 
alginates and the positioning of the carboxyl groups could make this mechanism possible. 
Although there is evidence for both substrate and enzyme binding it remains unknown as 
to what the exact mechanism of pancreatic lipase inhibition with alginate is.  
The fat substrates used here ranged from 4-18 carbon long fatty acids, which are 
consistent with the fats that are used within the food industry to improve texture, shelf life 
and palatability (Satchithanandam et al., 2004). In addition the majority of foods contain a 
mixture of saturated and unsaturated fats, but generally tend to include triglycerides 
which consist of longer fatty acid chains. The use of these longer chain triglycerides is 
generally because they are solid at room temperature and have a higher melting point for 
cooking (Connor et al., 1986; Koh et al., 2011). It was for these reasons that butter and 
olive oil were selected for analysis as these include triglycerides, specifically butter which 
contains 85-88% long chain triglycerides with a small percentage of short and medium 
chain triglycerides (Fallon & Enig, 2000). Although the digestion rate of butter and olive 
oil were not digested to the same level as the pure triglycerides, they do follow the same 
pattern of digestion that would be expected in-vivo (Carey et al., 1983). There was 
minimal digestion in the gastric phase and 98 and 96% for olive oil and butter 
respectively occurred in the small intestinal phase. These data show that the model gut 
can be used in digesting real food sources such as bread, butter and olive oil. In addition 
the digestion of both the butter and olive oil were significantly reduced when digested 
with AB. In a similar fashion the mean glycerol released from butter digestion alone and 
with CB was reduced by a third with the addition of AB. Although the digestion of the 
olive oil was not significantly different at various time points, there was a significant 
difference between olive oil and butter alone when compared with olive oil and butter and 
AB at 180 minutes. The data here indicates that alginate enriched bread has the ability to 
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reduce the digestion of fat in olive oil and butter. The large reduction in butter and olive 
oil digestion supports the previous data suggesting AB may be able to attenuate the 
digestion of long chain triglycerides more so than short and medium chain triglycerides. 
This is the first study that has looked at the digestion and inhibition of pure triglycerides 
and foods high in fat content using AB and has clinical implication because if the 
digestion of long chain triglycerides can be reduced then this would reduce the calories 
absorbed from the consumed food and thus potentially have a positive impact upon 
obesity, and diseases associated with obesity. 
As previously mentioned, the three fat substrates, butter, and olive oil consist of a mixture 
of short, medium and long chain triglycerides which are currently used within the food 
industry (Satchithanandam et al., 2004). Glyceryl triocatanoate and tributyrate digestion 
was reduced by 39 and 32%. However glyceryl trioleate, butter and olive oil digestion 
was reduced by 62, 78 and 95% respectively. Glyceryl trioleate, olive oil and butter and 
all contain a large proportion of triglycerides with long chain FA, which are higher in 
calorific content than triglycerides that are made up of medium and short FA. It is for this 
reason that triglycerides containing long chain FA have been associated with larger 
weight gains than diets high in medium and short chain triglycerides (Hashim & 
Tantibhedyangkul, 1987). In addition, in rat and human research there is evidence that has 
demonstrated consuming a diet high in medium chain triglycerides resulted in greater 
energy expenditure when compared with long chain triglycerides (Baba, Bracco, & 
Hashim, 1982; Dulloo, Fathi, Mensi, & Girardier, 1996; St-Onge et al., 2003). St-Onge et 
al. (2003) fed seventeen obese women a diet high in medium chain triglycerides for four 
weeks, followed by a wash out period and then fed a diet high in long chain triglycerides 
for four weeks, which were matched for calorific content apart from the different fats. 
They reported that when the women consumed a diet high in medium chain triglycerides 
energy expenditure and fat oxidation were higher, which was supported by a larger 
reduction in body weight when compared with long chain triglycerides. Considering the 
large fat content in the western diets any reduction in fat digestion would be beneficial, 
but specifically a reduction in longer chain triglycerides. Medium and short chain 
triglyceride digestion begins in the stomach and they are absorbed quicker than longer 
chain triglycerides (Bloom, Chaikoff, & Reinhardt, 1951; Jandacek et al., 1987; Mu & 
Hoy, 2004). The alginate release data from the bread illustrated earlier in this thesis 
indicates that between 80-90% of the alginate is released in the small intestines. Therefore 
if the alginate is being released where the long chain triglycerides digestion is taking 
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place, this may account for the larger levels of inhibition reported here for glyceryl 
trioleate, butter and olive oil.  
The data previously presented in this thesis alongside previous work in this laboratory has 
reported that alginates are able to attenuate the activity of digestive enzymes pepsin and 
pancreatic lipase (Strugala et al., 2005; Sunderland et al., 2000; Wilcox et al., 2013). 
Although these previous studies do provide evidence that alginates are able to reduce the 
activity of digestive enzymes, all of the previous work has been conducted in carefully 
controlled experiments and only considered individual enzymes such as pancreatic lipase 
and pepsin. The data from the current chapter demonstrated a reduction in fat digestion 
using alginate enriched bread in a synthetic model gut, which is more realistic to in-vivo 
than the afore mentioned studies. Furthermore, these data along with the earlier work in 
this thesis demonstrate the stability of alginate and further support the claim that alginate 
possess the ability to be used as an obesity treatment. The addition of alginate to a vehicle 
such as bread removes the poor palatability issue, which seems to be the main obstacle in 
using alginate as an obesity treatment (Ellis et al., 1981). Despite the encouraging results 
presented here further in-vivo and in-vitro work must be conducted in order to ascertain 
whether alginate enriched products possess the ability to be used as a treatment for 
obesity. 
 
.  
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Chapter 5 Clinical Trial   
5.1 Introduction 
The WHO and the NHS indicate that the healthiest form of weight management is to 
maintain a healthy diet and exercise at least 3-4 times per week. Although this is 
recognised as the healthiest form of weight management worldwide (Nestle & Jacobson, 
2000) adherence rates to diet plans and exercise routines can be as low as 15% (Ayyad & 
Andersen, 2000). With adherence rates as low as this it is unsurprising that any weight 
lost is regained quickly during any interruption of the diet and exercise programme. In 
addition to the poor maintenance of a healthy diet and exercise routine, it is the large 
quantities of calories that individuals are consuming and the relative low cost and ease of 
access of palatable fast foods that are also contributing substantially to the obesity 
epidemic (Nestle & Jacobson, 2000). New dietary interventions to address satiety, body 
fat and obesity related metabolic conditions are essential to combat the obesity epidemic.  
Amongst these alternative treatments is a manipulation of the stomach, which is referred 
to as bariatric surgery (Santry et al., 2005). Bariatric surgery encompasses a whole host of 
operations on the stomach, such as reducing the size of the stomach with band and 
removal of a portion of the stomach. Essentially these different surgeries are designed to 
prevent individuals from consuming as many calories as prior to the operation. Despite an 
average weight loss of 61.3%, these are generally a last resort due to the expensive nature 
and the possible complications that can be associated with them (Buchwald et al., 2004). 
An additional treatment is pharmaceutical interventions that target the CNS and suppress 
appetite. Drugs such as amphetamines and phenylpropanolamine have been used as 
appetite suppressants with weight loss reported in a clinical setting, although the adverse 
effects to drugs such as these include depression, addiction, primary pulmonary 
hypertension, diarrhoea and stomach pain (Fujimiya et al., 1997; Rich et al., 2000). 
Orlistat is an additional pharmaceutical intervention; however it does not work on the 
CNS. Orlistat works in the upper GI tract by covalently binding to the active site of 
pancreatic lipase, and therefore renders the lipase in-active (Hadvary et al., 1988). 
Although there is evidence to support its use in weight loss studies, adverse effects 
include stomach pain, flatulence, oily stools and severe diarrhoea. In retrospect all of the 
treatments mentioned here have long and short term benefits. However any treatment 
aimed at reducing obesity must have the potential to be maintained long term and adhered 
to without adverse side effects. 
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An alternative treatment may be to increase the daily intake of dietary fibre. Dietary fibre 
is essentially a shorthand expression for the un-digestible components of the cell walls of 
plants (Roehrig, 1988). The WHO recommends that 30g a day of dietary fibre should be 
consumed. The earliest health claims for dietary fibre came in 1953, when Hipsley 
travelled to Africa and reported that those consuming high levels of dietary fibre had 
lower rates of pregnancy toxaemia (Hipsley, 1953). Since then there has been a 
substantial increase in the interest in dietary fibre and the potential health benefits 
associated with it. Such benefits include adding bulk to faeces, reduced constipation, 
increased satiety, decreasing gastric emptying, reducing postprandial glucose and insulin 
responses, decreasing fat digestion and increasing cholesterol turnover (Holt et al., 1979; 
Sandberg et al., 1994; Terada et al., 1999).  
Early animal studies have used rats to observe the effects of cellulose, pectin, guar gum 
and lignin as a potential enzyme inhibitor. Burkitt et al. (1972), Trowell (1973) and Shah 
et al. (1986) all reported that dietary fibre resulted in attenuation in enzyme activity 
including trypsin, chymotrypsin, amylase and lipase. In addition to studies on rats work 
by Bueno, Praddaude, Fioramonti, and Ruckebusch (1981) looked at the effects of adding 
guar gum to the diet of dogs and reported a significantly slower transit time of 51%, and a 
reduced postprandial glucose response however this was not significant. A later study by 
Meyer and Doty (1988) observed the effect of guar gum on the digestion in dogs using 
fistulas. They reported that the guar gum increased the weight of the chyme, significantly 
increased the transit time of digesta and reduced the digestion of fat. Kimura et al. (2010) 
and Seal and Mathers (2001) also reported on the ability of sodium alginate to alter the 
digestion process. Kimura et al. (2010) demonstrated that feeding rat’s alginate resulted in 
an increased cholesterol excretion and an attenuated glucose response when compared 
with the control meal. In a similar fashion Seal and Mathers (2001) reported an increase 
in bile acid excretion and faecal weight. In addition they also reported a reduction in 
plasma cholesterol when compared to the control meals. Although the previously 
mentioned studies highlight the potential effects of dietary fibres, the work of Calvert et 
al. (1985) and El Kossori et al. (2000) provided results to the contrary. Calvert et al. 
(1985) observed the effects of cellulose, pectin, guar gum and alfalfa on rats fed these 
dietary fibres for four weeks, and reported no effect on pancreatic amylase and proteolytic 
enzymes. Furthermore El Kossori et al. (2000) observed the effects of similar dietary 
fibres on in-vitro digestive enzymes and reported no effect on pepsin activity.  
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Although there is conflicting evidence in-vitro and in animal models there is undoubtedly 
a significant body of research to suggest that dietary fibre may possess the potential to be 
used as an obesity treatment. This is evident in the large number of in-vivo studies using 
ileostomy patients. The use of patients with ileostomies is extremely useful because 
digestion as far as the small intestines can be assessed with relative ease. By the end of 
the small intestines up to 95% of all food consumed should have been digested and 
absorbed, therefore any alteration in digestion through the addition of dietary fibre can be 
assessed in effluent fluid (Sandberg et al., 1981). A further point of interest is that there 
will be little or no bacterial degradation which would generally take place in the large 
intestines. Early work by Bosaeus and Andersson (1987) observed the effects of soya 
bean on bile acid and cholesterol excretion. The authors reported no significant increase 
in bile acids and cholesterol excretion, but failed to measure fat digestion or to make 
postprandial blood measurements. Furthermore although soya bean is classed as a dietary 
fibre the authors failed to report the amount of dietary fibre that was consumed, which 
may suggest the amounts used here were not sufficient to elucidate a response. 
Contrastingly a study by Higham and Read (1992) gave ileostomy patients 5g of guar 
gum three times a day for 5 days compared to 5 days with a matched diet with no guar 
gum. The authors reported a reduction in viscosity of effluent fluid in the guar gum, 
despite previous reports that dietary fibre increases viscosity in the digestive system 
(Blackburn et al., 1984). Despite the lack of viscosity the authors reported a reduction in 
both fat and protein digestion and an increase in both dry and wet weight of effluent. 
Supporting Higham and Read (1992) two more recent studies by Olson et al. (1997) and 
Ellegard and Andersson (2007) have reported positive effects of oat bran in ileostomy 
subjects. Olson et al. (1997) reported that a diet containing 16.3g of dietary fibre 
compared to 6.4g of dietary fibre resulted in an increase in cholesterol and more than a 
50% increase in fat excretion. Despite not being significant the authors also reported a 
reduction in serum insulin, chylomicorns cholesterol and triacylglycerols, although the 
small sample size may have contributed to the lack of significance. In a later study by 
Ellegard and Andersson (2007), they compared the effect of hydrolysed oat bran with 
native oat bran in combination with β-glucans. The authors reported a significant increase 
in dry and wet weight effluent weight which was supported by a much larger viscosity in 
effluent fluid when the native oat bran when compared to hydrolysed oat bran. 
Furthermore the authors demonstrated that native oat bran significantly increased the sum 
of bile and cholesterol by 40% when compared to hydrolysed oat bran. The data from 
ileostomy patients in combination with the work on animals and in-vitro research does 
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appear to support the use of dietary fibres. However, there remain some inconsistencies 
with dietary fibres which may be due to the large range of dietary fibres used and their 
degree of esterification. Furthermore the use of dietary fibre as a potential treatment for 
obesity has come under some scrutiny which is generally due to the discrepancies within 
human studies, such as poor control of important factors such as body weight and total 
calories consumed (Franz et al., 1994). An additional point of interest is the small sample 
sizes used within the studies mentioned previously with sample sizes ranging from 5-12, 
making it difficult to assess the findings.  
As previously mentioned, one of the main inconsistencies is the dietary fibre examined. 
Work from this laboratory has examined a number of dietary fibres, but specifically a 
large range of alginates. Sunderland et al. (2000) demonstrated that 58 various alginates 
ranging in G and M content and Mr all inhibited pepsin activity in-vitro. This was further 
supported by Strugala et al. (2005) who demonstrated a correlation between the G content 
of alginates and the level of inhibition used, with a range of pepsin inhibition of 39-89%. 
Wilcox et al. (2013) and Richardson et al. (2011) substantiated these findings further by 
demonstrating that certain alginates were able to reduce pancreatic lipase activity by up to 
75%. These studies and the data presented in chapters 3 and 4 indicate that alginates are 
able to inhibit digestive enzymes in controlled conditions, but also in a system which 
simulates digestion in the upper GI tract. Although there is compelling evidence to 
suggest alginate does have the potential to be used as an obesity treatment, further in-vivo 
research is required, and an effective delivery method for alginate must be designed. 
Table 7 summarises human in-vivo studies that have used alginate as a source of dietary 
fibre. The physiological effects of adding alginate to an individual’s diet has been 
subdivided into: 
5.1.1 Upper GI Tract Motility  
As previously mentioned alginate possess an ability to form both ionic and acidic gels, 
and specifically acidic gels in-vivo (Draget et al., 2005; Hoad et al., 2004). This gel 
formation within the stomach has been cited as the main reason for reducing gastric 
emptying (Torsdottir et al., 1991). Torsdottir et al. (1991) conducted a study observing 
the effects of 5g of alginate with 60% M and 40% G content added to a fruit juice drink 
on gastric emptying. They used radioactive labelled chromium chloride to detect gastric 
movement and reported a significant reduction in gastric emptying time compared to the 
control drink. Despite these differences the authors also failed to mention accurately 
whether there was any form of washout period between the test meals, meaning there may 
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have been some carry over between treatments. Sandberg et al. (1994) also added 7.5g of 
sodium alginate (60% M and 40% G content) to a milk shake and observed the 
physiological effects in ileostomy subjects. Total wet and dry effluent weights were 
significantly increased when subjects consumed the alginate enriched beverage. Although 
both Torsdottir et al. (1991) and Sandberg et al. (1994) reported effects of the alginate 
beverages, both studies had small sample sizes of 7 and 6 respectively. Mattes (2007) 
provided results to the contrary and reported no significant difference in bowel 
movements. Although Mattes (2007) did use a much larger sample size, the delivery 
vehicle used was a cereal bar which may have affected the ability of the alginate to form a 
viscous solution within the stomach. Furthermore the authors added a combination of 
guar gum and alginate, with only 1.1g of alginate and no details of the M:G content. The 
relatively low amount of alginate and the delivery vehicle used may have been an 
additional contributing factor to why there was no significant difference in gastric 
emptying between the alginate and control cereal bar. 
5.1.2 Satiety/Hunger/Calories Consumed 
As previously mentioned alginates are able to form viscous solution in conditions where 
the pH drops below the pKa of alginate (Draget et al., 1997; Smidsrod, 1974). The 
formation of an acidic gel within the stomach has been linked with an increase in volume 
of the stomach (Duncan, Bacon, & Weinsier, 1983). Phillips and Powley (1996) implied 
that the formation of a gel in the stomach would result in an increased firing rate of 
stretch receptors within the stomach, due to an enlarged volume. This increased firing rate 
of stretch receptors has been associated with simulating the sensation of fullness. 
Furthermore the increased volume within the stomach has been associated with a slowing 
of food passing from the stomach into the small intestine. If the digesta remain in the 
stomach for a longer period this in turn may prolong gastric distension and therefore 
elongate the sensation of satiety, and ultimately reduce calories consumed (Duncan et al., 
1983; Mattes, 2007). The work of Mattes (2007) as previously mentioned used a cereal 
bar with a relatively small amount of alginate (1.1g) and did not report any effect of the 
alginate cereal bar on gastric movements. It is unsurprising then that the same author 
reported that there was no effect on appetite and satiety following the ingestion of the 
treatment cereal bar when compared with the control bar. More recently there have been a 
number of studies that have reported a drink supplemented with alginate significantly 
increased the sensation of satiety and reduced Kcal intake. Pelkman, Navia, Miller, and 
Pohle (2007). Paxman et al. (2008) and Peters et al. (2011) all used similar amounts of 
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alginate ranging between 1-2.6g of alginate, with a large G content. All three of these 
studies reported a significant increase in satiety, reduced feeling of hunger and Paxman et 
al. (2008) showed a reduced intake of 134 kcal. 
Further work using a beverage supplemented with alginate has been conducted by a group 
in Denmark. They have conducted three trials relatively recently, but have used a 
considerably larger amount of alginate than the studies mentioned previously. The first 
was a pilot study that added 15g of alginate, without mentioning the composition of the 
alginate. Jensen et al. (2011) administered a calorie restricted diet for subjects including 
either a control or alginate beverage for each group, and assessed anthropometric 
measures including waist circumference and body weight. Although there was a reduction 
in body weight and waist circumference, this was not significant between the two groups. 
Although there was no significant difference in weight loss this may have been because 
the study was only conducted over two weeks, which may not have been long enough to 
observe any substantial weight loss. Two later studies by Jensen et al. (2012 (a)) and 
Jensen et al. (2012 (b)) also used 15g of alginate added to a 500ml beverage. The first of 
these two studies observed the acute response of the alginate beverage on satiety and 
hunger feelings following consumption, when compared with the control beverage. The 
authors indicated that the gelling of the alginate within the stomach was sufficient to 
account for the significantly increased feeling of satiety and a reduced feeling of hunger. 
A potentially more interesting finding was reported in the third study by this group. 
Jensen et al. (2012 (b)) observed the effects of a beverage containing 15g of alginate and 
an energy restricted diet 3 times a day for 12 weeks. The authors reported a weight loss of 
6.78kg when consuming the alginate beverage when compared with 5.08kg loss in body 
weight when participants consumed the control beverage. Although these are positive 
findings, there are a number of discrepancies when comparing the control and alginate 
group with regards to some of the anthropometric measurements. The baseline body 
weight and percentage of body fat were significantly higher in the alginate group than the 
control group. Although these may not have had a significant bearing on the overall 
findings of the study, this seems difficult as the authors attempt to attribute the reduction 
in percentage of body fat to the alginate beverage. Therefore if the alginate group have a 
significantly larger percentage of body fat to begin with, then they potentially have a 
larger proportion of fat mass to lose when compared with control group.  
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5.1.3 Blood Response and Nutrient Digestion 
Although an increase in satiety is important, the ability of alginate to attenuate gastric 
emptying has also been linked with a reduced absorption and digestion of macronutrients, 
which may have a substantial impact on obesity (Brownlee, 2009). The early work of 
Torsdottir et al. (1991) was some of the first to observe the effects of alginate on the 
blood glucose and insulin response in humans. They reported a significant reduction in 
glucose and serum insulin response following ingestion of an alginate beverage. Any 
reduction in insulin response following a meal would have substantial implications for 
individuals suffering with diabetes. Interestingly Sandberg et al. (1994) did not assess the 
response in blood samples but rather the remains of digested products in the effluent fluid 
of ileostomy patients. There was a significant increase in the FFA recovered in the 
effluent samples when individuals consumed the alginate beverage. These data indicated 
that there was a reduction in fat absorption; however no assessment was made of plasma 
triglyceride levels to confirm this. Jensen et al., (2012) provided results to the contrary of 
both Torsdottir et al. (1991) and Sandberg et al. (1994) and reported no effect of an 
alginate loaded beverage on plasma triglycerides, insulin and glucose response. 
Interestingly the authors here only measured the plasma response once a week; however a 
response may have been present if the plasma samples were taken for a number 
consecutive hours following the meal and alginate beverage. Furthermore the authors did 
not assess the AUC for plasma triglyceride, which may have demonstrated a reduction in 
fat digestion. This assumption was confirmed by another study from the same group 
(Jensen et al., 2012 (b)). They used a 15g of alginate in a 500ml beverage, but they took 
blood samples every 30 minutes and reported a significant reduction in area under the 
curve (AUC) for blood glucose response. The AUC is the actual body exposure to blood 
glucose after the administration of food or drink consumed. The reduction in AUC of 
blood glucose response suggests that alginate beverage reduced the digestion rate of 
carbohydrates. Wolf et al. (2002) and Williams et al. (2004) provide further evidence to 
substantiate the use of alginate as a potential treatment to attenuate the blood plasma 
response following ingestion of a meal. A point of interest when comparing these two 
studies was that low amounts of alginate used just 1.5 and 1.6g, respectively. Despite the 
small amounts of alginate used both authors reported a blunting of the blood glucose 
response. An additional point of interest was the large sample sizes of 30 and 48 used 
respectively, which allows the findings to be generalised and also increases the sensitivity 
of the study and highlight any significant differences between the control and alginate 
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products. These data suggest that alginate enriched beverages are able to reduce the 
digestion of carbohydrates and triglycerides.  
The data presented in Chapters 3 and 4 along with the research presented in Table 7 do 
provide evidence that alginate may have potential in the treatment of obesity. The earlier 
studies in both humans and animals do provide positive results although the majority of 
these studies have small sample sizes. More recent findings have addressed this issue with 
larger sample sizes, specifically studies such as Jensen et al. (2012 (a)), and Paxman et al. 
(2008), with 96 and 69 respectively. An additional point to consider is the amount of 
alginate that is required to observe an effect, and the studies here do not allow for any 
conclusions to be made. There have been positive effects reported when using small 
amounts of alginate such as 1.5g (Wolf et al., 2002) compared to a significantly larger 
amount of 15g (Jensen et al., 2012 (a)). The composition of alginate used is important for 
a number of reasons including the costs of supplementing a product, the effect the 
alginate has on the properties of the product and the potential of any adverse or poor 
palatability associated with the addition of alginate to a food or beverage. All of the 
studies summarised within Table 7 do report where they purchased the alginate from; 
however a number of these studies failed to include the composition of the alginate used. 
Studies such as Mattes (2007), Paxman et al. (2008)and Jensen et al. (2011) reported no 
significant effect of the alginate and control vehicle, although they did not mention the 
M/G ratio of the alginate used. This therefore raises the question as to whether there was 
a large M content incorporated and thus a weak gel would have been formed (Draget et 
al., 1994). The information reported here does suggests that both cereal bars and 
beverages elucidate physiological responses, however the response reported appears to be 
dependent on the delivery method. For example if the there is a group of obese 
individuals that have type-2 diabetes then a beverage may be the best delivery method as 
this appears to have the greatest effect on blood glucose (Torsdottir et al., 1991; Wolf et 
al., 2002). Despite the various methodological differences one of the main issues reported 
throughout the research is the poor palatability of the alginate supplemented product. As 
previously mentioned alginate increases the viscosity of a solution at varying pH’s 
(Draget et al., 2003). This is a problem when adding alginate to a beverage as the 
beverage can exhibit a slimy mouth feel, tooth packing and poor palatability for subjects 
(Ellis et al., 1981). The majority of the studies in Table 7 have some form of adverse 
effects associated with them such as returning products due to poor taste (Sandberg et al., 
1994), control product preferred (Mattes, 2007), stomach intolerance (Pelkman et al., 
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2007; Wolf et al., 2002)(Wolf et al., 2002; Pelkman et al., 2008), poor appearance, taste 
and after taste (Jensen et al., 2012 (a)). The evidence here does appear to support the 
potential use of alginate as a treatment for obesity, however a main issue is the method in 
which alginate is delivered.  
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Table 7.  Summary of alginate supplemented vehicle in humans. 
Author Delivery Vehicle Alginate Amount 
and type 
No. Subjects Satiety/Hunger Plasma effects Gastric Effects Fat Digestion Side 
Effects 
Torsdottir et al 
(1990) 
Drink 5g – 
40%G 
7 No data ↓ blood glucose 
↓ serum insulin 
↑ gastric emptying Not  reported Not 
reported 
Sandberg et al 
(1994) 
Drink 7.5g 
40%G 
6 No  data No mention ↑ wet effluent weight 
↑ dry effluent weight 
↑ Fatty acid in effluent Alginate 
products 
returned 
Wolf et al., (2002) Drink 1.5g alginate 
No compositional 
data 
17 No  data ↓ AUC for 
serum glucose 
and insulin 
Not reported Not reported Stomach 
intolerance 
Williams et al., 
(2004) 
Cereal Bar 1.6 alginate 
No compositional 
data.  
5.5g guar gum 
48 No  data ↓ blood glucose Not reported Not reported Not 
reported 
Mattes (2007) Cereal Bar 1.1g alginate 
No compositional 
data.  
3.9g guar gum 
25 No difference in 
appetite and satiety 
No  data No difference Not reported Control bar 
more 
pleasant 
Pelkman et al., 
(2007) 
Drink 1 and 2.8g alginate 
No compositional 
data. 
29 ↑ satiety 
↓ Kcal intake  
No  data Not reported Not reported ↑ flatulence 
↑ stomach 
ache  
Paxman et al., 
(2008) 
Drink 1.5g alginate 
65-75 G 
69 ↓ Kcal intake  No  data Not reported Not reported Not 
reported 
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Paxman et al., 
(2008) 
Drink 1.5g alginate 
No compositional 
data. 
14 No  data Only difference 
in overweight (5 
subjects) 
Not reported No difference No 
reported 
Peters et al., (2011) Drink 2 and 2.6g alginate 
70% G 
23 ↓ Hunger No mention Not reported Not reported None 
Jensen and Astrup 
(2011) 
Drink  15g alginate  
No compositional 
data. 
20 No difference  No difference  Not reported Not reported Poor 
palatability 
Jensen et al., (2012) Drink 9.9 and 15g alginate 
No compositional 
data. 
20 ↑ satiety 
↓ hunger 
No difference Not  reported Not reported Poor 
palatability 
Jensen et al., (2012) Drink 15g alginate 
65-75% G 
96 ↑ weight loss ↑ BP 
No difference in 
insulin 
Not reported No difference Poor 
palatability 
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5.2 Aims 
The initial aim of the present chapter is to assess the acceptability of an alginate bread 
with additional fat compared with the control bread in a pilot study. Subjects will 
consume the alginate bread (which contains more fat, as seen in Table 2, or control bread 
at least three weeks apart in a fasted state in an attempt to ascertain the acceptability of 
the alginate enriched bread compared with the control bread. This will address whether 
the alginate enriched bread has any of the side effects that have been associated with 
alginate enriched products. In addition subjects will complete well-being questionnaires 
to ascertain if there are any differences in subjects feeling of hunger, fullness and general 
well-being between the alginate and control bread. 
The second aim of the current chapter is to assess whether consuming alginate enriched 
bread will reduce fat digestion. If alginates are able to attenuate the activity of pancreatic 
lipase then the expected result would be a reduction in the fat digestion. This chapter will 
assess if there is a reduction in fat digestion between the control and alginate bread in 
plasma samples and effluent fluid. Post consumption of the alginate or control bread the 
anticipated result would be an increase in plasma triglycerides. Therefore if alginate bread 
has any effect on fat digestion then the triglycerides in the plasma will be lower than the 
control bread. Furthermore as previously mentioned if triglycerides are not broken down 
to monoglycerides and FFA then they are too big to pass across the epithelial walls of the 
small intestines. Therefore by measuring the weight and fat content of the effluent fluid 
this will address whether the alginate bread has reduced fat digestion in comparison to the 
control bread. 
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5.3 Methods 
5.3.1 Materials 
Alginate and control bread were identical to those used in chapter 3 produced by Greggs 
Plc. Anchor butter and standardised meals were purchased from Marks and Spencers 
(Newcastle Upon Tyne, UK). Glycerol reagent A and B were purchased from Amsbio 
(Abingdon, UK). Methanol, chloroform, sodium chloride were all purchased from Sigma-
Aldrich (Poole, UK). A Thermo Jouan BR4i Mu Scientific Centrifuge (Basingstoke, UK) 
was used to separate red blood cells from plasma. Ultra-Turrax T18 IKA Homogeniser 
with dispersing tools S 18 N – 10G and 19G from Fischer Scientific (Loughborough, UK) 
was used to homogenise effluent samples from various time points. An Edwards Modulyo 
EF4-174 Freeze Dryer (London, UK) was used for isolating solid contents of effluent. 
5.3.2 Subjects 
Subjects were recruited from areas around Newcastle Upon Tyne, UK, from ileostomy 
meetings. Inclusion criteria were as follows: aged 18 years or above, generally healthy, 
able to provide multiple blood samples, able to fulfil study commitments and research 
burden within their usual lifestyle, have undergone an ileostomy operation at least two 
years prior to the commencement of the study and the ileostomy must be fully functional 
and stable. Exclusion criteria included: an unstable ileostomy, smoker, receiving medical 
treatment during the study which required them to take medication, allergic or intolerant 
to the foods used within the study, history of substance or alcohol abuse, currently or 
planning a pregnancy in the next 12 months or were planning a change in dietary habits, 
physical activity or change in body weight during the study. Subjects were free to 
withdraw from the study at any time. 36 subjects were recruited and screened. Patients 
within study had undergone the operation for an ileostomy for reasons including bowel 
cancer, ulcerative colitis and Crohn’s disease.  
5.3.3 Protocol 
A double-blind, randomised, cross-over design was used. All randomisation was carried 
out in anonymous fashion by an independent researcher, who coded the breads and 
participants accordingly. 51 subjects were screened following either a telephone interview 
or in person to ensure subjects fulfilled all inclusion criteria and to advise them of what 
the research they will be taking part in would involve. Following a telephone or in person 
chat 36 subjects were invited into the clinical research facility (CRF), within the Royal 
Victoria Infirmary for an induction visit. During the induction visit subjects were 
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provided with full details of what the study entailed and what they would be taking part 
in, and asked to sign the consent form. Participants were given two standardised meals, 
nutritional composition provided in Table 8 and two 500ml bottle of water to take home 
with them. Each of these meals would be consumed prior to their visits to the CRF (one 
per visit). An experienced nurse from the CRF was on hand to answer any questions and 
provide further information on the visit days. Of the 36 subjects recruited 29 completed 
the consent form and were happy to partake in the study. The final study sample was 
comprised of 29 adults (mean + S.E.M) 62.1 (+ 0.14) years of age with a BMI of 27.4 (+ 
0.02). There were 15 males and 14 females. Seven subjects withdrew due to time 
constraints (Figure 30). 
 
Figure 30. Consort chart for enrolment in Ileostomy study. 
  
T0 
T2 
T1 
T3 
Screening by telephone or 
in person (n=51) 
Ineligible based on 
inclusion and exclusion 
criteria (n=15) 
Eligible subjects attended 
induction visit (n=36) 
Withdrew due to time 
constraints (n=7) 
Randomly allocated 
to consumed AB 
(n=14) 
Randomly allocated 
to consumed CB 
(n=15) 
Consumed AB 
(n=15) 
Completed study (n=14) Completed study (n=15) 
Consumed CB 
(n=14) 
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Table 8.  Nutritional composition of standardised meals given to subjects on induction visit. 
NUTRITION 
Typical Values Per 100g Per Pack 
Energy kJ 475 1900 
Energy kcal 115 460 
Protein 8.9g 35.6g 
Carbohydrates 11.7g 46.8g 
Fat 3.1g 12.4g 
of which saturates  1.0g 4.0g 
Fibre 1.5g 6.0g 
Sodium 0.25g 1.0g 
Equivalent as salt 0.63g 2.5g 
 
Subjects were randomly allocated to one of two treatment groups following their 
induction visit as depicted in Figure 32. Group one received 100g of alginate enriched 
bread, as toast with 20g of anchor butter (Test meal A), whereas group two received 100g 
of control bread, as toast with 20g of anchor butter (Test meal B). On the evening prior to 
subjects first visit they were advised to eat their standardised meal before 8pm, and 
refrain from all food and drink, except water before visiting the CRF. Subjects arrived at 
the CRF fasted for each main study visit early in the morning (10 am or before). Upon 
arrival, subjects were asked to fill out a Wellbeing study questionnaire on their general 
wellbeing and their feelings of fullness/hunger. Subjects were given instructions on how 
to fill in the questionnaire and provided with an example question as depicted in Figure 31, 
and then instructed to mark on a line how they were feeling at that time point. The 
analysis was completed by measuring in cm where on the line the subjects had marked for 
each question. The nearer the marked line to excellent the lower the score for the 
question. Figure 31 illustrates how the score for each question was measured. The 
questionnaire also included two sections at the end, where subjects were able to add any 
unusual symptoms or discomfort experienced that were not included in the previous 
questions, and add any additional comments. The questionnaire was divided into two 
sections general wellbeing (question 1) and whether the subjects were currently 
experiencing any of the symptoms within the questionnaire (question 2). The questions 
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that subjects were asked can be seen in Table 9 and Table 10. Subjects were informed that 
the questionnaire should take no more than 5 minutes to complete. The questionnaire has 
been used previously in whole grain research and is valid and repeatable (Aitken, Zealley, 
& Rosenthal, 1969; Brownlee, Moore, et al., 2010). 
 
 
Figure 31.  Example question provided to subjects as part of the wellbeing questionnaire. The line 
depicts a potential answer to the question. 
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Table 9.  Question 1 of wellbeing questionnaire assessed on an analogue scale.  
Alert  Sleepy 
Fine  Nauseous 
Full  Starving 
Not Bloated  Bloated 
Not flatulent  Flatulent 
Calm  Irritable 
Relaxed  Anxious 
 
Table 10.  Question2 of wellbeing questionnaire assessed on an analogue scale. 
Light-headedness or dizziness? 
Not at all                                                                                   Very 
Blurred Vision? 
Not at all                                                                                   Very 
A difficulty to concentrate? 
Not at all                                                                                   Very 
A difficulty to think? 
Not at all                                                                                   Very 
Excessive Thirst? 
Not at all                                                                                   Very 
Headaches/Migraines? 
Not at all                                                                                   Very 
Cravings for sweets? 
Not at all                                                                                   Very 
Abdominal Discomfort? 
Not at all                                                                                   Very 
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In addition the complete contents of effluent bags were collected. A nurse from the CRF 
identified an appropriate vein via palpitation and visual inspection from both arms to 
assess the most appropriate anticubital vein of the forearm. The nurse then confirmed 
subject’s particulars and cleaned the site from which the blood samples were taken from. 
A tourniquet was then applied to the arm approximately 7-10cm above the puncture point. 
The subject’s arm was then placed in a downward position and a 21 ml gauge needle (S-
Monovette, Sarstedt, Germany) was placed into the anticubital vein. The vacutainer tube 
was then placed into the needle holder and a six millimetres blood sample was extracted, 
during which time the tourniquet was released. The remaining blood samples were taken 
using a cannula to ensure patient comfort. All procedures were consistent with NHS 
standards. The initial questionnaire, effluent sample and blood sample were baseline. 
Subjects then consumed their allocated toast and were allowed to consume water ad 
libitum. Upon finishing the toast subjects filled in another wellbeing questionnaire, 
provided a 6ml blood sample and emptied their effluent bag of its contents. Subsequent 
questionnaires, blood samples and effluent samples were taken every 30 minutes for a 
total of five hours. All effluent and blood samples were stored on ice until analysis. Upon 
completing the study subjects were provided with a lunch of their choice. Subjects then 
returned at least three weeks after the initial visit and received the alternative bread from 
the first visit. Both visits were identical apart from the different bread provided (Figure 
32). Following completion of both visits, subjects received travel expenses and a study 
honorarium (in the form of vouchers). 
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Figure 32.  Double blind randomised ileostomy study protocol.   
  
Visit 1 – Test meal A given. Participants provide effluent 
and blood sample and filled out wellbeing questionnaire 
prior to meal and every 30 minutes thereafter for 5 hours.  
Visit 2 – Test meal A given. Participants provide effluent 
and blood sample and filled out wellbeing questionnaire 
prior to meal and every 30 minutes thereafter for 5 hours. 
Visit 2 – Visit 1 – Test meal B given. Participants provide 
effluent and blood sample and filled out wellbeing 
questionnaire prior to meal and every 30 minutes 
thereafter for 5 hours. 
>3 weeks 
Week 0 
Invitation to participate.  
Pre-screening of 
volunteers.  
Information Sheet sent to 
eligible participants.  
Induction Visit - Participant Consent 
taken. Provide participants with standard 
meals and water for following two visits. 
Participants randomly allocated into 
Group 1/Group 2 
Group 1 
Group 2 
1 – 4 
weeks 
Visit 1 – Test meal B given. Participants provide effluent 
and blood sample and filled out wellbeing questionnaire 
prior to meal and every 30 minutes thereafter for 5 hours. 
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5.3.4 Effluent Sample Analysis 
Effluent samples were weighed for each time point and then frozen at -80
0
C until 
analysis. During analysis samples were diluted 1:1 (w:w) in DH₂O. As not all participants 
had an effluent sample at each time point, the 12 time points were subdivided into four 
separate points as follows: 
1 - 0 and 30 minutes 
2 - 60, 90 and 120 minutes  
3 – 150, 180 and 210 minutes 
4 – 240, 270 and 300 minutes 
Samples were then homogenised for five minutes, and 4ml samples for both test meals 
AB and CB at each of the above four time point were then placed into separate pre-
weighed 15 ml universals. The effluent samples were then re-frozen at -80˚C before being 
placed in a freeze dryer for 48 hours. Following freeze drying samples were left at room 
temperature for 30 minutes before being weighed again. 4ml of a chloroform and 
methanol solution (2:1) was added to each sample and mixed for 5 minutes by hand. 1ml 
of 0.73% sodium chloride was then added and mixed for a further 5 minutes on a vortex 
mixer. Samples were then centrifuged at 4100 RPM for 10 minutes at 4˚C. The above 
process produced three layers, as evident in Figure 33. The top layer was discarded and the 
middle layer was pierced to extract the lower layer using a glass pasteur pipette. The 
lower layer of each sample was transferred to a pre- weighed 15ml universal. 4ml 
chloroform/methanol (2:1) was then added to the middle layer and the process from this 
point was repeated a further two times, which is consistent with previous research. 
Repeating this procedure three times is to ensure complete extraction of all lipids is 
achieved. This method has been demonstrated to be efficient at recovering up to 98% of 
lipids (Folch, Lees, & Sloane Stanley, 1957). Following three repeats of the procedure the 
universals containing the pooled lower layers were then placed into an incubator at 50˚C 
for 48 hours to evaporate the contents. The remaining contents of the tube were then 
weighed to ascertain total fat content. To ascertain total fat content from complete 
effluent samples Equation 7 was used. 
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A = non lipid contaminants. 
B = undigested digesta. 
C = lipids. 
 
Figure 33.  Fat extraction remnants from an effluent fluid sample following mixing with  
chloroform/methanol mixture, and centrifugation. 
 
                
 
           
TF 4ml = Weight of sample from 4ml sample following extraction process. 
TW of EF = Total weight of effluent sample for each of the 4 time points (e.g. 60 + 90 + 120 minutes, time 
point 2). 
The assumption that 1g of effluent =1ml was made. This was confirmed by weighing 1ml of three fat 
substrates, glycerol tributyrate, glyceryl trioctanoate and glyceryl trioleate.  
 
Equation 7.  Calculation for total fat from effluent samples. 
  
A 
 
B 
 
C 
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5.3.5 Plasma Samples 
Samples were centrifuged at 4100rpm for 10 minutes at 4˚C to separate the serum from 
blood cells. Two aliquots (1.2ml each) of the resulting serum samples were taken and 
stored at -20°C for later analysis. To ascertain total plasma triglycerides a total serum 
triglyceride assay kit (STG-1-NC, Amsbio, Abingdon, UK) was used. Working reagent A 
was prepared using glycerol reagent with deionised H₂O in a 4:1 ratio, respectively. 
Working reagent B was prepared using triglyceride reagent and glycerol reagent on a 1:4 
ratio, respectively. Both working reagents A and B were reconstituted at room 
temperature. 5µl of serum from each time point for each subject was added to a 96 well 
plate in duplicate, before 100µl of working reagent A was added to the appropriate wells 
and mixed, before being left at room temperature for 15 minutes. The plate was then read 
at 540nm on the plate reader, which provided free glycerol measurement. 5µl of serum 
samples was then added to a separate 96-well plate for each time point for each subject in 
duplicate. 100 glycerol reagent B was added to the appropriate wells and mixed before 
being left at room temperature for 15 minutes. Working reagent A quantifies any glycerol 
present in plasma and working reagent B breaks down triglyceride into glycerol and 
ensures complete digestion of all plasma triglycerides. The plate was then read at 540nm 
on the plate reader which provided total triglyceride measurement. The absorbance from 
glycerol reagent A was subtracted from glycerol reagent B, giving total plasma 
triglycerides, as seen in Equation 8. A standard curve was produced using working reagent 
A for glycerol (Figure 18, Chapter 4). 
 
                               
 
OD Serum B = Absorbance from serum sample using working reagent B 
OD Serum A = Absorbance from serum sample using working reagent A 
 
Equation 8.  Total triglyceride calculation using serum triglyceride assay kit.   
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5.4 Statistics 
Statistical calculations were undertaken using SPSS Statistics 19 (IBM, Predictive 
Analysis Software, USA). Data is presented as mean and standard error of mean (± 
S.E.M) or standard deviation (± SD).  A paired t-test was undertaken at a significant level 
(α) of 0.05 to compare effluent weights at four time points and total effluent weight, fat at 
four time points and total fat in effluent samples and compare subject’s response from the 
wellbeing questionnaires between control and alginate bread. A bivariate Pearsons 
correlation was carried out to observe any relationship between effluent weight and fat in 
effluent samples in alginate and control bread. A One Way Repeated ANOVA followed 
by a Post-Hoc Bonferroni was undertaken at a significant level (α) of 0.05 to compare 
plasma triglyceride levels.   
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5.5  Results  
5.5.1 Wellbeing questionnaires 
The postprandial changes for question 1 and 2 from subjects reported a significant 
difference in fullness (Figure 34) and excessive thirst (Figure 35) between the alginate 
and control bread (P<0.05) at 0 and 30 minutes respectively. There were no other 
significant differences between control and alginate bread for any other questions at any 
other times points (P>0.05) (Table 11, Table 12). However there was a trend that 
subjects were thirstier after consuming alginate bread compared to the control bread. 
There were no significant differences for area under the curve (AUC) between control 
and alginate bread at any time points for any questions (P>0.05). 
 
 
Figure 34.  Mean (± S.D) response from subjects for question 1 from the wellbeing questionnaire 
(Full (0) or Starving (10)). (* indicates a significant difference at P<0.05) (-30 represents Baseline) (n=29).   
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Figure 35.  Mean (± S.D) response from subjects for question 2 from the wellbeing questionnaire 
(Not thirsty (0) or Thirsty (10)). (* indicates a significant difference at P<0.05) (-30 represents Baseline) 
(n=29).
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Table 11.  Significant values comparing subject’s response between control and alginate bread for question 1 of wellbeing questionnaire.  
Time (minutes) Baseline 0 30 60 90 120 150 180 210 240 270 300 
Alert (0) –Sleepy (10) 0.32 0.17 0.27 0.28 0.97 0.86 0.99 0.38 0.47 0.32 0.96 0.47 
Fine (0) – Nauseous (10) 0.35 0.37 0.98 0.94 0.66 0.31 0.93 0.59 0.63 0.77 0.94 0.23 
Full (0) – Starving (10) 0.72 0.05 0.65 0.33 0.21 0.77 0.85 0.32 0.63 0.30 0.85 0.87 
Not bloated (0) – Bloated (10) 0.45 0.67 0.31 0.73 0.73 0.77 0.50 0.18 0.67 0.97 0.81 0.91 
Not flatulent (0) – Flatulent (10) 0.07 0.17 0.10 0.26 0.17 0.51 0.66 0.72 0.43 0.49 0.48 0.22 
Calm (0) – Irritable (10) 0.59 0.96 0.98 0.77 0.42 0.41 0.27 0.30 0.35 0.82 0.41 0.10 
Relaxed (0) – Anxious (10) 0.56 0.63 0.96 0.53 0.30 0.35 0.32 0.49 0.45 0.84 0.49 0.61 
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Table 12. Significant values comparing subject’s response between control and alginate bread for question 2 of wellbeing questionnaire.    
Time (minutes) Baseline 0 30 60 90 120 150 180 210 240 270 300 
Light Headedness or Dizziness 
 
0.90 0.24 0.72 0.68 0.65 0.26 0.68 0.81 0.93 0.37 0.25 0.48 
Blurred Vision 0.52 0.27 0.16 0.76 0.62 0.27 0.97 0.88 0.38 1.00 0.45 0.13 
A difficulty to concentrate 0.91 0.33 0.58 0.52 0.87 0.16 0.39 0.24 0.33 0.95 0.43 0.24 
A difficulty to think 0.70 0.10 0.12 0.55 0.40 0.38 0.87 0.26 0.99 0.81 0.33 0.41 
Excessive thirst 0.82 0.75 0.04 0.30 0.20 0.30 0.36 0.16 0.67 0.33 0.62 0.97 
Headaches/Migraines 0.34 0.24 0.51 0.31 0.91 0.45 0.91 0.97 0.91 0.96 0.36 0.75 
Cravings for sweets 0.70 1.00 0.33 0.70 0.35 0.16 0.59 0.87 0.87 0.75 0.61 0.10 
Abdominal discomfort 0.55 0.52 0.32 0.26 0.49 0.45 0.13 0.66 0.56 0.36 0.28 0.13 
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5.5.2 Wet Effluent Weights 
The baseline samples were removed from the analysis of both the control and alginate 
bread as these samples would only contain digesta from the standardised meal, mucus and 
shed cells. Figure 36 illustrates the combined effluent weights for subjects at the four time 
points, and the combined effluent weights for alginate and control bread across all four 
time points. A paired samples t-test reported a significant difference in effluent weight 
between alginate and control bread at 240-270-300 minutes (P<0.05). There was an 
increase in effluent weight of 292g between the alginate and control bread at 240-270-300 
minutes (time point 4). There was no significant difference in effluent weight at any other 
time point between alginate and control bread (P>0.05), although at time points 1 and 3 
the weights were larger when subjects consumed alginate bread. The combined effluent 
weight for alginate bread was 2489 (+ 182) grams, which was 20% larger than the 2010 
(+ 54) grams in the control bread samples. Despite these changes between the breads the 
paired t-test revealed no significant difference in the combined effluent weights between 
alginate and control bread (P>0.05). There was no significant difference in AUC for 
effluent weights between alginate and control bread (P>0.05). 
 
Figure 36.  Total effluent weights for four time points and combined total effluent weights for 
alginate and control bread. * indicates at significant difference at P<0.05. (0-300 mins is the total effluent 
for all four time points and for all volunteers) (n=29). The number of effluent samples for each time point 
was 29, 25, 26 and 24 for AB and 26, 24, 22 and 23 for CB. 
  
0
500
1000
1500
2000
2500
3000
0
200
400
600
800
1000
0-30 mins 60-90-120
mins
150-180-210
mins
240-270-300
mins
0-300 mins
W
ei
g
h
t 
(g
) 
W
ei
g
h
t 
(g
) 
Time Point  
AB CB Total AB Total CB
* 
130 
 
5.5.3 Effluent Fat 
The baseline samples were removed from both the control and alginate bread as these 
samples would only contain digesta from the standardised meal, mucus and shed cells.. 
Figure 37 illustrates the combined fat in effluent samples for subjects at the four time 
points, and the combined fat from effluent for all time points for alginate and control 
bread. There was more fat at time points 1, 3, 4 and the combined total fat weights when 
alginate bread was consumed when compared to the control bread. The amount of fat 
found in effluent sample when consuming alginate bread was 81 and 112g larger at 240-
270-300 and total fat for combined time points respectively than the fat found in effluent 
samples when consuming control bread. A paired t-test revealed a significant increase in 
fat from effluent fluid at 240-270-300 minutes and total fat weights for combined time 
points (P<0.05) (Figure 37). The paired samples t-test revealed no significant difference 
between fat from effluent samples at any other time point between alginate and control 
bread (P>0.05). There was also a significantly larger AUC for the alginate bread when 
compared to the control bread (P<0.05).  
 
Figure 37.  Total weights of fat in effluent for four time points and total fat weight from effluent 
combined for alginate and control bread. * indicates at significant difference at P<0.05. (0-300 mins is the 
total fat weight from effluent for all four time points and for all volunteers) (n=29). The number of effluent 
samples for was time point were 29, 25, 26 and 24 for AB and 26, 24, 22 and 23 for CB.  
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5.5.5 Wet Effluent weight and fat content from effluent 
The date in Figure 38 illustrates the relationship between wet effluent weight and fat 
extracted from effluent samples. A bivariate Pearsons correlation test revealed a 
significant relationship between wet effluent weight and fat in effluent samples when 
subjects consumed alginate bread (P<0.05), which was confirmed with an r
 
of 0.99. The 
bivariate Pearsons correlation revealed no significant relationship between wet effluent 
weight and fat in effluent samples when subjects consumed control bread (P>0.05), which 
was also evident by the r of 0.53 (Figure 38).  
 
 
Figure 38. Mean (+ S.E.M) relationship between wet effluent weight and fat from effluent for four 
time points for alginate bread (r = 0.98) and control bread (R2 = 0.28) (n-29).  
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5.5.6 Plasma Samples 
Figure 39 illustrates total plasma triglycerides following ingestion of alginate and control 
bread. Baseline data was removed as this contained fasting plasma samples. Although 
there was less triglyceride in the alginate bread samples the one way repeated ANOVA 
showed no interaction between control and alginate bread, or time interaction (P<0.05). 
The ANOVA reports that there was no significant difference between the alginate and 
control bread at any time point, or the combined plasma triglycerides for all time points. 
The post-hoc bonferroni indicated that there was no significant differences between 
alginate and control bread at any time point (P>0.05). A paired t-test revealed no 
significant difference in AUC between alginate and control bread.  
 
Figure 39.  Mean (S.E.M) plasma triglycerides following consumption of alginate and control bread 
at 30 minute intervals (n=29).  
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5.6  Discussion 
The data presented here indicates that bread enriched with alginate and additional fat is 
able to increase effluent weight and increase fat content in effluent samples in ileostomy 
patients. There was also a relationship between the increased wet effluent weight and the 
amount of fat found in effluent samples. In addition the alginate bread reduced the plasma 
triglycerides levels in ileostomy patients, although this was not significant. There were no 
substantial differences in palatability between the two breads, apart from one time point 
where subjects reported an increase in thirst and reduced fullness following consumption 
of alginate bread. 
The incorporation of alginate into beverages has previously been shown to increase 
satiety and reduce the feeling of hunger (Jensen et al., 2012 (b); Paxman et al., 2008; 
Pelkman et al., 2007). The data from the Wellbeing Questionnaire used in the current 
study included a question on whether the subjects were full or starving (Table 9) and 
whether subjects were craving sweets (Table 10). There was no significant difference in 
the cravings for sweets between alginate and control bread. There was however a 
significant difference between the alginate and control bread, with regards to the feeling 
of fullness. In the current study subjects experienced a larger feeling of hunger 30 
minutes after consuming the alginate compared to the control bread. These findings 
contradict previous work that has reported a significant increase in satiety and a reduction 
in hunger (Jensen et al., 2012 (b); Paxman et al., 2008; Pelkman et al., 2007). 
Furthermore the findings of Pelkman et al. (2007) and Paxman et al. (2008) also reported 
that this increase in satiety and reduction in hunger was matched with an average reduced 
kcal consumption of 138 per day (Paxman et al., 2008). The previously mentioned studies 
all used a beverage as a delivery vehicle. However the current study and the work of 
Mattes (2007) and Williams et al. (2004) used food as a delivery vehicle, with both the 
afore mentioned authors in accordance with the current study reporting no significant 
difference in appetite or food intake. One potential explanation for this may have been the 
presence of the alginate in the bread, and its ability to alter digestion of the bread. If the 
control bread was digested quickly it would resemble a watery chyme as the bread is 
broken down in the stomach creating a large volume within the stomach. Data from the 
current laboratory has been shown that alginates are able to reduce the activity of pepsin 
(Strugala et al., 2005; Sunderland et al., 2000). If the activity of pepsin is reduced in the 
presence of the alginate bread then the gluten that holds the bread together may not be 
digested as quickly as normal. If this is the case then the alginate bread will resemble 
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more of a solid chyme and thus may not provide the same volume as the control bread in 
the stomach. This may ultimately affect stretch receptors, which have been linked with 
the feeling of fullness. Although this has not been confirmed in the current thesis further 
work is required to ascertain whether alginate bread is able to attenuate the activity of 
pepsin in a model gut.  
The use of the visual analogue scale (VAS) used here has been validated as a repeatable 
and valid method to quantify any changes in an individual’s feelings regarding a specific 
question (Aitken et al., 1969). There are however questions marks over the sensitivity of 
the VAS and whether it can highlight any significant differences between people’s 
feelings (McCormack, Horne, & Sheather, 1988). Hornblow and Kidson (1976) reported 
that although the VAS may be user friendly and repeatable, there may also be problems 
with a clumping effect of responses. For example subjects may either put their answers in 
the middle or at one end of the scale. This appeared to be the case for the questions of 
whether subjects were full or thirsty. For example after an overnight fast the anticipation 
would be that subjects would be starving, however the mean answer for whether the 
subjects were starving was only 4.8. However, when looking at the raw data there were a 
number of subjects that gave a response of between 8 and 9. Although there was a clear 
clumping of the responses, as evident in the mean, the subjects who gave a response 
nearer to 10 would strongly influence the SD. The same response was evident in the thirst 
question with the majority of subjects giving a mean answer of 2.3. However, a number 
of subjects gave a much larger answer, which is surprising considering all subjects 
consumed the same food and drink. This clumping may have been the cause for the large 
variability in subjects response reported in the current study. This meant that reporting SD 
in Figure 34 and Figure 35 was difficult, and the reason for reporting SEM, despite the 
small size of this. An additional reason for the clumping effect may have been a poor 
explanation of the marking scheme, or subject’s failure to remember the instructions 
given. An alternative option may be to shorten the scale from 0-10 down to 0-5. This 
would make the scale smaller and would potentially be more sensitive as the subjects only 
have a small scale to mark a response on and potentially increase the sensitivity of the 
scale. Despite what the scale is that is used the emphasis must be on a detailed and 
repeated explanation of the marking criteria for the VAS in future work to ensure 
understanding from the subjects. 
DiMeglio and Mattes (2000) conducted a study over 4 weeks and compared the effects of 
liquid and solid meals on fullness and energy intake. The authors reported that the solid 
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foods have a greater impact upon increasing fullness than beverages. As food may take 
longer to be homogenised into a chyme in the stomach it may stay there for longer, which 
may attenuate the ability of the stomach to empty and thus contribute to prolonging 
gastric distension. Prolonged gastric distension has also been linked with increasing 
fullness (Phillips & Powley, 1996), which has also been linked to a reduction in calories 
consumed (Paxman et al., 2008; Pelkman et al., 2007). The lack of response on the 
feeling of hunger reported here and by Mattes (2007) and Williams et al. (2004) do not 
support the suggestion that foods may increase satiety greater than beverages. Although 
this may be valid for beverages that do not contain alginate, it appears that the alginate 
could be modifying the suggestions of DiMeglio and Mattes (2000) that a solid food may 
increase the feeling of fullness more than a liquid meal. The authors reported that when 
consuming the liquid meals subjects had a significantly larger BMI and body weight after 
4 weeks, compared with the solid meal. The authors attributed this increase in body 
weight and BMI to increase calorie consumption when consuming the liquid meal. The 
formation of a gel in the stomach as reported by Hoad et al. (2004) may give the alginate 
enriched beverage more of a food like consistency and this could reduce gastric emptying. 
The fact that there was not an increase in fullness in the present study may have been due 
to the inability of the alginate to form a viscous acid gel within the stomach. If the 
alginate is properly homogenised and cooked into the delivery vehicle this may delay the 
release of the alginate as reported earlier in this thesis. The main constituents of the bread 
used here and other alginate enriched foods would not be digested until the small 
intestines, and thus the alginate in the alginate bread would also be released there. If the 
alginate is not released until the small intestines, as suggested by earlier work in this 
thesis, there may be no increase in the volume within the stomach as a result of increased 
viscosity or gel formation, and thus no reduction in hunger was reported. These data 
suggest that alginate enriched foods may not be suitable if the purpose of the study is to 
promote satiety. However it must be noted that there were no significant differences in 
palatability between the alginate and control bread product as reported in alginate 
enriched beverages. Furthermore in the current study subjects only consumed two slices 
of toast with butter, however in previous studies such as Pelkman et al. (2007) and 
Paxman et al. (2008) subjects were given an alginate beverage in addition to breakfast, 
which makes a direct comparison on fullness with the present study difficult.  
An additional reason for the increase in hunger at 30 minutes may have been due to the 
dimensions of the breads when consumed. Post defrosting and toasting the alginate bread 
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appeared to reduce in size, when compared to the control bread. Visual cues have been 
reported to play a significant role in the feeling of hunger. Leidy, Apolzan, Mattes, and 
Campbell (2010) fed 43 subjects meals over eight day that were similar in calorie content 
but differed in size and form, such as drink vs solids. The authors indicated that there was 
reduced satiety and increased hunger when subjects consumed beverages and the smaller 
portion sizes, despite the calorie content being similar. These findings confirm the 
suggestions that if the bread size is reduced post freezing and toasting then this may have 
affected the early response in hunger as reported here. Leidy et al. (2010) also went on to 
suggest that people already have a pre-conceived idea of what should or should not make 
them full just by looking at the food they are about to consume. Therefore if the alginate 
bread does reduce in size after defrosting and toasting then this may have an impact upon 
the subjects feeling of fullness. This is important when designing a vehicle for delivering 
alginate as the delivery vehicle should not be making an individual feel hungrier than 
when they consume a control vehicle. Although the findings from the current study may 
be merely an inconsistency within the data as beyond this time point there were no other 
significant differences in the feeling of hunger, this must still be taken into account when 
designing any future alginate delivery vehicles and trials to ensure the control and 
treatment vehicles are identical apart from the alginate.  
An additional mechanism by which alginates may be used to treat obesity is their ability 
to alter the digestion and absorption of metabolizable nutrients (Englyst, Quigley, & 
Hudson, 1994). Although the exact mechanism by which this occurs is unknown there is 
evidence to suggest that alginates are able to attenuate the postprandial blood glucose 
response (Williams et al., 2004; Wolf et al., 2002) and fat digestion (Sandberg et al., 
1994). The implications for this are substantial not only in reducing obesity but also 
diseases associated with obesity, such as diabetes. Salmeron et al. (1997) conducted a 
longitudinal study over six years and looked at the diet of over 46,000 subjects, and how 
this may link with type-2 diabetes. They reported that individuals who consume large 
amounts of high glycaemic, easily digestible carbohydrates were almost six times more 
likely to develop type-2 diabetes. In addition Jenkins, Storlien, Chisholm, and Kraegen 
(1988) reported that diets high in saturated fats may alter membrane structure. Any 
alteration in cell membrane structure has been suggested to attenuate the cells insulin 
receptor activity, and therefore contribute to an increased risk of type-2 diabetes. A 
potentially more obvious effect of diets high in fat may be due to their high calorific 
content. One gram of fat contains 9 Kcal (37kJ) compared with 4 Kcal (16kJ) in 1 gram 
137 
 
of protein and carbohydrates (Horowitz & Klein, 2000). An excess of fat consumption 
will ultimately outweigh energy expenditure and the excess calories will then be stored as 
adipose tissue. Increased adipose tissue is closely associated with an increased BMI, 
elevated levels of cholesterol, and raises the risk of developing type 2 diabetes (Gostynski 
et al., 2004). Although both the increased consumption of fat and carbohydrates may 
contribute to the increased incidence of obesity worldwide, the current study concentrated 
on the effect of alginate enriched bread on fat digestion within ileostomy patients.  
The data from the current study indicated that when subjects consumed the alginate 
enriched bread there was a significant increase in the amount of fat in the effluent fluid 
when compared with when subjects consumed the control bread. More fat was recovered 
in the effluent fluid at all four time points when subjects consumed alginate bread when 
compared with the control bread. However this was only significant at 240-270-300 
minutes. There was an increase of 57% (81g) at 240-270-300 minutes between the 
alginate and control bread effluent fluid. In addition the AUC and combined fat for all 
four time points was significantly larger when alginate enriched bread was consumed 
compared to the control bread. The total weight of the four time points combined was 
264g for the control bread, compared with 376g for the alginate bread, which was a 
difference of 30%. These results were consistent with the work of Sandberg et al. (1994), 
who conducted a two week study with six subjects and fed them a constant low fibre diet 
for four days with 7.5g of alginate with each meal, followed by a wash out period and 
then four days of a low fibre diet alone. The authors reported that over the four days when 
subjects consumed alginate there was an increase of 140% in the fat content recovered in 
the effluent fluid. Although this increase was substantially more than the current study, it 
must be noted that the Sandberg et al. (1994) study was conducted over four days and 
administered a larger amount than here. Furthermore two of the subjects used by 
Sandberg et al. (1994) had substantially larger FFA concentration in effluent fluid than 
the remaining 4, and because of the small sample used this may have biased the results. In 
addition to alginate other dietary fibres have elicited a similar response in fat excretion. 
Both Bosaeus, Carlsson, Sandberg, and Andersson (1986) and Higham and Read (1992) 
administered subjects 15g of pectin and guar gum respectively and observed the effects 
on fat content found in effluent fluid. Both studies reported a significant increase in fat 
content in effluent fluid which supports the data in the current study although both studies 
used a substantially more than the 4g of dietary fibre used in the current study. 
Interestingly Higham and Read (1992) reported a significant reduction in viscosity of the 
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effluent fluid when subjects consumed the guar gum. This was also accompanied by an 
increased weight of wet effluent fluid and a reduced transit time through the upper GI 
tract. Despite the small sample sizes and larger quantities of dietary fibre these data 
support the findings of the current study. These data combined would seem to suggest 
that the presence of alginate and other dietary fibres within the upper GI tract can reduce 
the absorption of fat.  
Previous data from this laboratory and previously presented data in this thesis suggest that 
alginates possess the ability to attenuate the activity of pancreatic lipase (Wilcox et al., 
2013), and therefore reduce fat absorption. Although the previous data suggests that the 
alginate is reducing fat digestion, this may not be the case in clinical studies. Although 
Sandberg et al. (1994) reported a significant increase in fat content in effluent fluid, the 
majority of this was FFA as confirmed by high performance liquid chromatography. 
These findings may not support the work from this laboratory that suggest alginates are 
attenuating digestive enzymes, but potentially encapsulating the digested FFA, and thus 
reducing the absorption potential of the small intestines. In the same study Sandberg et al. 
(1994) reported a significant increase in effluent weight, which may support the 
encapsulation of FFA, as the additional weight in part may be due to the increased FFA. 
The data from the current study lends some support to this idea as there was an increase 
in fat in the effluent fluid. However the methods used here did not distinguish between tri, 
di, monglycerides or FFA. It is therefore difficult to conclude that this was the mechanism 
for the increased fat found in the effluent fluid in the current study. The potential of 
encapsulation of digestible nutrients is a feasible idea but further work is required to 
substantiate this suggestion.  
Although encapsulation of digested nutrients may be a feasible explanation for the 
increased fat found in the current study there may be other mechanisms involved. An 
additional mechanism which may have accounted for the increased fat in the effluent 
fluid reported here could have been as a result of a reduced transit time. A review by 
Brownlee (2009) indicated that as the dietary fibre passes through the upper GI tract 
undigested it may add to luminal bulk. If the luminal bulk is increased the 
mechanoreceptors within the upper GI tract will respond by increasing muscular 
contractions and move the digesta through the small intestines at an accelerated rate. This 
increase in luminal bulk has been suggested to be due to the water binding capacity of the 
dietary fibre (Chaplin, 2003). The data from the current study reported a significant 35% 
increase in the wet effluent weight at 240-270-300 minutes, and although not significant 
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there was also an increase in the total combined wet effluent weight when alginate bread 
was consumed compared to the control bread. The total effluent weight for the combined 
time points was 20% larger in the alginate bread when compared to the control bread. The 
mean wet effluent weight for each subject consuming alginate bread was 85g (2489g/29 
subjects), which is consistent with previous studies observing the effects of a range of 
dietary fibres 106g (Sandberg et al., 1994), 76g (Sandberg et al., 1981). The data from the 
current study support the suggestions of Brownlee (2009) and Chaplin (2003) that dietary 
fibre may bind with water and other constituents within the upper GI tract and thus 
increase faecal weight.  
An additional point to consider is that fat in effluent of ileostomy patients should be 
minimal in a normal diet as it should have been digested and absorbed, therefore some of 
the difference in wet effluent weight could be accounted for by the presence of alginate. 
Furthermore dietary fibres have been shown to bind with large amounts of water 
(Chaplin, 2003) and therefore this may also have contributed to the wet weight of the 
effluent fluid, although it is difficult to ascertain whether the amount of alginate used can 
account for the total difference in weight. A comparison of wet and dry weight would be 
beneficial in future work, which would take the additional weight from water content out 
of the equation. This would therefore mean that any additional weight could be attributed 
to an additional fat content and dry alginate in the effluent fluid. Contrastingly (Mattes, 
2007) reported no difference in bowel movements when administering an alginate 
enriched cereal bar. Similar to the current study Mattes (2007) used food as a delivery 
vehicle and a similar sample size. Although Mattes (2007) reported that there was no 
significant difference between the alginate and control bar in alteration of bowel 
movements the assessment of gastric motility used was subjective. They used 
questionnaires, rather than any direct assessment such as wet effluent weight used in the 
present study. Additionally the authors only administered a cereal bar of 55g which is 
nearly half the amount of bread administered here. The small cereal bar means that this 
would be well dispersed and therefore may not have had any significant impact upon 
gastric movements. The authors also used a combination of alginate (1.1g) and guar gum 
(3.9g). The amount of alginate used was less than in the current study, suggesting 1.1g of 
alginate may not have been sufficient to elicit a response. The use of guar gum may also 
have contributed as the ability of guar gum to both inhibit digestive enzymes and form a 
viscous solution and alter the digestion process is questionable (Higham & Read, 1992). 
Although the current study reports an increase in wet effluent weight, this study and 
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previous studies that have reported an increase in faecal weight such as Sandberg et al. 
(1994) would only be able to confirm a decreased transit time by measuring wet effluent 
weight for longer time periods after ingestion of the meal/beverage. If in fact the alginate 
caused a decreased transit time as suggested previously then the effluent weight of control 
bread would eventually be larger than the alginate bread if later time points were 
collected, as it would take longer to pass through the upper GI tract, but this was not 
confirmed in the current study. 
A decreased transit time in the upper GI tract and an encapsulation of digestible nutrients 
may very well be enough to account for the increased fat in the effluent fluid alone, but it 
may be more realistic that it is a combination of the two mechanisms. If the fats 
consumed by the subjects here and in Sandberg et al. (1994) study were in fact digested, 
then the expected result would be for them to be absorbed as monoglyceride and FFA 
(Carey et al., 1983),although this does not appear to be the case. The increased fat in 
effluent fluid in the current study was closely related to an increase in wet effluent 
weight. A similar relationship was reported by Sandberg et al. (1994), who also reported 
an increased fat content in effluent fluid with an increase in wet effluent weight. The 
relationship between effluent fat and wet effluent weight provides evidence to support the 
idea of encapsulation of fat and a decreased transit time in the upper GI tract. If the transit 
time alone was reduced then the small intestines would still be expected to be able to 
absorb the fat that subjects consumed. Therefore a potential encapsulation may also have 
contributed to the increased fat in effluent weight reported here. Lin, Zhao, Chu, Lin, and 
Wang (1997) contradicted the suggestion that dietary fibre decreases transit time. The 
authors suggested that when the sensory receptors within the small intestine are exposed 
to a meal with a large nutritional content, the movement through the small intestines is 
reduced, which has been defined as the ileal break. The ileal break is essentially an action 
of the small intestines which reduces movement through the small intestine when 
undigested nutrients, specifically triglycerides are sensed in the ileum. Marciani et al. 
(2001) supported the findings of Lin et al. (1997) and indicated that movement through 
the upper GI tract is due to the nutritional content of the meal and not the viscosity of the 
digesta. They fed twelve healthy volunteers four 500 ml beverages ranging in viscosity 
and nutrient content over a 4 day period. Using MRI to monitor movement through the 
upper GI tract the authors reported that both nutrient and viscosity make-up of the 
beverages reduced movement through the upper GI tract. However when viscosity and 
nutrient content were compared the beverages that contained a larger nutritional content 
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resulted in a more substantial reduction in movement through the upper GI tract when 
compared with viscosity alone. Therefore if the meal consumed in the present study had 
more fat present by the time the digesta reached the ileum then the expected result would 
be a decreased movement through the small intestines, and a smaller effluent weight 
when subjects consumed alginate bread. The increased wet effluent weight and fat 
content in effluent fluid supports the suggestion that alginate bread may be encapsulating 
the fat in the toast and butter. If, in fact, the alginate bread is encapsulating the fat, then 
the sensory receptors of the small intestines may not be able to sense the fat, and therefore 
movement through the small intestines would not be reduced as suggested by Marciani et 
al. (2001) and Lin et al. (1997). Although it remains to be seen if the amount of alginate 
used in the current study is enough to encapsulate the fat found in the effluent fluid, 
further in-vivo research is required to confirm if in fact this is the case.  
A further point to consider is that movement through the upper GI tract determines the 
digestion rates of nutrients and the control of movement of digesta through peristalsis, 
which ensures complete digestion and absorption of the digesta (Brownlee, Forster, et al., 
2010). If in fact the transit through the small intestines is reduced, as suggested in the 
present study, potentially due to encapsulation of fat and an increase in digesta bulk then 
this alone may account for the increased fat in the effluent fluid. The work of Jensen et al. 
(2012 (a)) suggests that the viscosity of an alginate enriched product may also increase 
the bulk of the chyme entering the small intestine from the stomach. This increased 
bulking of the chyme entering the small intestine has been suggested to result in a 
thickening to the unstirred water layer at the luminal surface of the small intestine, and 
thus reduce the removal of nutrients (Lin et al., 1997). If in fact the alginate bread 
increases the bulk of the chyme in the small intestine, then this may increase the unstirred 
water layer at the luminal surface, and ultimately a reduction in postprandial plasma 
triglyceride response. Although initial observation of the plasma triglycerides may 
suggest that alginate bread is attenuating absorption of triglycerides this was not 
significant. There was no significant difference in plasma triglycerides at any time points 
or AUC between alginate and control bread. These data confirm earlier work by Paxman 
et al. (2008) who reported no significant difference in plasma triglycerides when 
administering an alginate enriched beverage compared to a control beverage.  
In a more recent study by Jensen et al. (2012 (a)) they assessed the ability of an alginate 
enriched beverage to alter the postprandial response to a meal in 96 obese individuals. 
The authors reported a slight reduction in plasma triglycerides, however this was not 
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significantly different between the alginate and control beverages. An interesting point of 
the study though was that they only compared the plasma triglycerides level to baselines 
after a 12 week intervention. Therefore if the study had assessed plasma triglycerides 
directly post consumption of the beverage and then for a number of hours post 
consumption of the meal they may have reported an affect. Furthermore it is difficult to 
ascertain whether fat digestion was truly affected in either the Paxman et al. (2008) or 
Jensen et al. (2012 (a)) studies because there were no faecal or effluent samples taken. An 
additional point of interest to add is that the fat content of the two breads in the current 
study were not identical. The fat content of the alginate bread was 14.1g/100g compared 
to 1.7g/100g, which is substantially larger. The purpose of the study was to compare two 
breads that were matched for calorific content, apart from the addition of alginate, which 
was the information given to Greggs Plc. The breads were designed by Greggs Plc master 
baker to ensure the bread was of a high standard. During this process the master baker 
incorporated unwanted additional fat to the alginate bread. Although it is unclear why the 
alginate bread was produced with extra fat, one possibility is that the alginate absorbed 
the water in the bread making process and therefore dried out the bread. Therefore if a fat 
in liquid form was added this may give the bread a more doughy and moist texture and 
therefore increase palatability. Although there was considerably more fat in the alginate 
bread the plasma triglyceride levels were lower when subjects consumed alginate bread 
compared to the control bread, suggesting that alginate attenuated fat absorption. In 
addition it cannot be excluded that the additional fat in the alginate bread may have 
impacted upon the increased wet weight in the effluent fluid and the increased fat content 
in effluent fluid. Even though this may be the case, the fact of the matter remains that if 
alginate was not present in the bread the additional fat in the bread should have been 
digested and absorbed. Particularly as the subjects were in a fasting state when given the 
test meal. This therefore suggests that the alginate bread did have an impact upon fat 
digestion. Consequently if the two breads were matched for fat content then the 
anticipation may have been a significant reduction in plasma triglycerides, which would 
correlate with an increase in fat content in effluent samples. Any future studies must 
ensure that the calorific content and the fat content of the alginate and control vehicles are 
identical, other than alginate content.  
Although the data presented here does not conclusively prove that alginate enriched bread 
are able to attenuate the plasma triglyceride response, there is evidence from the literature 
that indicates alginate enriched products may be able to attenuate the blood glucose and 
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insulin response following a meal. Alginate enriched products including beverages 
(Paxman et al., 2008; Torsdottir et al., 1991; Wolf et al., 2002) and cereal bars (Williams 
et al., 2004) have reported significant reductions in both glucose and insulin response. In 
contrast more recent work by Jensen et al. (2012 (a)); (Jensen et al., 2012 (b)) reported no 
significant difference in blood glucose or insulin response. A potential reason for the lack 
of effect reported by these authors could have been due to the large amount of alginate 
and the composition of the alginate used. A large concentration made up of 65-70% 
guluronic acid would result in a much more rigid gel (Draget et al., 1997), and thus a 
clumping effect may have occurred. This clumping effect may have reduced the 
interaction with digesta in the upper GI tract, and thus no reduction in blood glucose or 
insulin response was reported. The question however remains as to why in the previously 
mentioned studies alginate enriched products resulted in a blunting of the glucose and 
insulin response, however no significant reductions in plasma triglycerides were reported 
in this thesis. This may have been due to the digestion process of carbohydrates compared 
to triglycerides. Carbohydrates and short/medium chain triglycerides are generally 
digested and absorbed earlier than long chain triglycerides (Bernard & Carlier, 1991; 
Blomstrand, 1955).  
The plasma triglyceride response reported here is consistent with the plasma response of 
previous research following ingestion of a meal which included fat (Daly et al., 1998; 
Sasahara, Burns, Miyashita, & Stensel, 2012). In the current study there was a small spike 
prior to 90 minutes which is consistent with the afore mentioned studies. However, 
beyond this point the increase in plasma triglycerides was not to the same extent as 
Sasahara et al. (2012). The authors administered subjects with a meal containing butter, 
but did not mention the total amount which makes it difficult to compare with the current 
study. Despite this the authors reported an increase of 50% in plasma triglycerides 
between 0 and 120 minutes. Contrastingly in the current study and the work of Daly et al. 
(1998) the increase was only 8 and 12% respectively between 0-120 minutes. The small 
rise of 8% reported here in the alginate bread samples may suggest a reduction in 
absorption, however the control bread only increased by 10% over the same time period. 
Although the exact amounts of short, medium and long chain triglycerides in butter are 
unknown, Fallon and Enig (2000) indicated that most butter contains 12-15% short or 
medium chain triglycerides. The remaining 85-88% must be made up of long chain 
saturated triglycerides, which allows the butter to become a solid. The amount of short 
and medium chain triglycerides would be much lower, but is also important to ensure that 
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when the butter is spread on bread or toast that it is able to be spread and does not remain 
a solid. The composition of the butter may have had an impact upon the small peak in 
plasma triglyceride reported here beyond 90 minutes may have been due to the absorption 
of short and medium triglycerides which do not require the same level of digestion, and 
thus less fat was absorbed. Furthermore these saturated long chain triglycerides would 
enter the small intestine as a coarse emulsion created by acid and contractions within the 
stomach. Bile salts are then released from the liver, which are detergents with polar side 
chains which allow them to interact with both water and lipids, and therefore create water 
soluble droplets. If dietary fibre alters this process in any way then the digestion of fat 
may be affected.  
There is currently no research which has observed the michaelis menton kinetics (Km) of 
pancreatic lipase with a range of triglycerides, including short, medium and long chain 
triglycerides. If the medium and short chain triglycerides have a smaller Km than long 
chain triglycerides then this would mean that they may be digested faster and therefore 
absorbed quicker. Another potential explanation for the increased absorbance of the short 
and medium chain triglycerides may be because of the solubility of them. As previously 
mentioned Smits et al. (1968) indicated that bile salts and micelle formation was not 
crucial for digestion of short and medium chain triglycerides. Essentially if short and 
medium chain triglycerides do not require the same lengthy digestion process involved 
with long chain triglycerides, then pancreatic lipase can begin digestion earlier. 
Furthermore Camire and Dougherty (2003) reported that dietary fibres are able to bind 
with bile and therefore reduce their interaction with triglycerides. Any reduction in bile 
function would ultimately reduce the digestion of triglycerides, and may have contributed 
towards the increased fat in the effluent fluid here, but no major difference in plasma 
triglycerides. Although the increased fat found in the effluent fluid does suggest that the 
alginate enriched bread may have reduced fat digestion, however the blood response does 
not confirm this. Although both the Km, solubility of the medium and short chain 
triglycerides and binding of bile salts may explain the earlier appearance in the blood of 
medium and short chain triglycerides, an additional reason may be the manner in which 
they enter the blood stream. Due to the size of the long chain triglycerides they are too big 
to cross the epithelia cells of the capillaries and therefore must be reformed as 
chylomicrons and enter the lymphatic system. They then travel through the lymphatic 
system and enter the blood stream at the subclavian vein via the thoracic duct. Short and 
medium chain triglycerides are able to be absorbed directly into the portal vein and will 
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therefore appear in the blood earlier than long chain triglycerides. Any future work 
observing the effects of alginate on fat digestion must consider the fat source used in the 
study to ensure a larger peak in plasma triglycerides.  
An additional explanation for the lack of difference between the plasma triglyceride 
levels for the control and alginate bread may have been due to the “second meal 
response” (Lambert & Parks, 2012). The second meal response suggests that triglycerides 
that are consumed during an initial meal are not completely absorbed into the bloods to be 
used by the body, but rather stored in enterocyte cells. Following the consumption of a 
second meal these triglycerides are then reformed into chylomicrons before passing 
through the liver and into the blood. Robertson, Henderson, Vist, and Rumsey (2002) 
reported that the increase in plasma triglycerides generally begins after 10-30 minutes of 
meal consumption, with the peak rise in plasma triglycerides occurring 3-5 hours later. 
Therefore the early rise in triglycerides that appear in chylomicrons occurs before the 
meal containing fat can be digested and absorbed. This was also supported by Chavez-
Jauregui, Mattes, and Parks (2010) who used stable isotopes to confirm that up to 12% of 
the triglycerides contained within the chylomicrons appeared 15-20 minutes following 
meal ingestion, and therefore could not have been from the meal subjects had just 
consumed. Heath et al. (2006) observed the effects of meal at breakfast and one at lunch 
where the fats were labelled. The authors reported a normal peak after each meal which 
began to return back to normal, however following lunch the peak in plasma triglycerides 
was larger than the peak at breakfast despite matching for calorific content. These data 
support the suggestion that consumption of subsequent meals results in larger 
concentration of triglycerides within chylomicrons than that which would occur following 
the first meal consumed. The “second meal response” may have been the cause for the 
blunting of the plasma triglycerides response reported here in both control and alginate 
bread samples. Data from Lambert and Parks (2012) would suggest that the plasma 
triglyceride response reported here may have been from the standardised meal consumed 
the evening before and not from the toast and butter. Therefore if an additional meal had 
been consumed by both groups three hours after the toast which was matched for calorific 
content as the toast and butter, then the anticipated result would be a lower plasma 
triglyceride response in the alginate bread samples. This would correspond with the 
increased fat content of the effluent samples, and support the data here that fat digestion 
was reduced when subjects consumed alginate bread. An additional point of interest was 
promoted by Robertson et al. (2002), who demonstrated that carbohydrates and fat can 
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adversely influence each other’s metabolism after a meal. Therefore the subjects in the 
Sasahara et al. (2012) study consumed a meal high in fat then this may explain the large 
increase in plasma triglycerides compared with the current study. Subjects in the current 
study consumed a standardised meal containing 47g of carbohydrates and only 12g of fat, 
which may have resulted in the muted plasma triglyceride response as suggested by 
Robertson et al. (2002). Although here a number of suggestions have been proposed for 
the small rise in the plasma triglycerides it is difficult to draw strong conclusions from the 
current study because of the different fat contents of the two breads. 
The data in the present study reports an increase in wet effluent weight and fat content 
when consuming the alginate bread. However there was no significant attenuation in the 
plasma triglyceride levels or hunger. Although here there was no reduction in hunger the 
test meals given were small with just two slices of toast given, which may not have been 
enough to reduce the feeling of hunger, as portion size has been related to hunger (Leidy 
et al., 2010). A potentially important result of the current study was that there were no 
significant adverse side effects of the alginate enriched bread. A minor effect was that 
subjects were more thirsty 60 minutes after consuming the alginate bread than when 
compared to the control bread. Thirst is the craving for fluids which can be brought about 
by the loss of water. The alginate that is present in the bread is sodium alginate which 
may have resulted in the sensation of thirst. Although the sodium is bound to the alginate 
some of the sodium may be absorbed and increase osmotic pressure of the plasma. This 
can initiate the cravings on thirst and make people drink. An additional point of interest is 
that soluble dietary fibres possess the ability to retain large amounts of water (Chaplin, 
2003) which may also contribute to the increased thirst. Beyond this time point there were 
no significant differences in thirst. Despite this small increase in thirst there were no other 
adverse effects, which have previously been reported when consuming alginate enriched 
products. Adverse effects have previously included products being returned (Sandberg et 
al., 1994), burping, nausea (Wolf et al., 2002), flatulence, stomach ache (Pelkman et al., 
2007) and subjects preferring the control products over alginate products due to poor 
palatability (Jensen et al., 2012 (a); Jensen et al., 2012 (b); Mattes, 2007). The previously 
mentioned studies all use varying amounts of alginate ranging from 1.1g up to 15g, which 
suggests that the amount of alginate may not have been the main factor contributing to the 
adverse side effects mentioned. All of these studies, except Mattes (2007) used a drink as 
a delivery vehicle, suggesting that the delivery vehicle may be the main contributing 
factor. Mattes (2007) used a cereal bar and the main problem reported by the author was a 
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poor taste between the alginate and control bar, but no gastrointestinal adverse side 
effects. These data indicate that if the alginate is not mixed thoroughly within a delivery 
vehicle then this may have an impact upon adverse side effects in the upper GI tract. 
Although the adverse effects of these alternative alginate enriched products may not be 
severe, they will all contribute to poor adherence, and subjects are less likely to consume 
products that have adverse side effects and poor palatability (Ellis et al., 1981).  
This is the first pilot study to date that has assessed the effects of an alginate enriched 
product on fat digestion in-vivo. The data in the current study suggests that alginate 
enriched products are able to attenuate the digestion of fat, yet a direct comparison 
between the current study and previous work is difficult due to the variance in 
methodologies. For example the sample size and subjects observed, various amounts and 
composition of alginate used, delivery vehicles used and varying meals consumed post 
consumption of alginate enriched product. The addition of alginate to bread in the current 
study increased effluent weight and fat content. The findings from the current study 
support a food vehicle as a delivery method for alginate in reducing adverse effects 
associated with alginate enriched products. There is only one longitudinal study to date 
that has reported weight loss with an alginate supplemented product. Therefore it is too 
early to make conclusions on whether alginate enriched bread may be able to aid in 
weight loss, however further longitudinal studies in healthy populations will answer this 
question. Future research must observe the effects of an alginate enriched product of 
equal fat content between test meals on healthy subjects in order for any health claim to 
be associated with alginate.  
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Chapter 6 Overall Conclusion 
6.1 Alginate Quantification 
Alginates are extracted from the cell walls of a number of brown seaweed species 
(Brownlee et al., 2005) using a purification step involving an acid treatment that 
precipitates alginate as alginic acid (Draget et al., 1997). Although used within a number 
of industries, alginate has received considerable interest specifically over the last 10-15 
years for its beneficial physiological effects in-vivo; such as a reduced postprandial 
insulin response, reduced fat digestion, increased satiety and reduce absorption of 
nutrients consumed (Jenkins et al., 1978; Paxman et al., 2008; Sandberg et al., 1994; 
Torsdottir et al., 1991). Furthermore in-vitro work from this laboratory has demonstrated 
the ability of a wide range of alginates varying in Mr and composition to attenuate the 
activity of proteolytic enzymes by up to 85% (Strugala et al., 2005; Sunderland et al., 
2000; Wilcox et al., 2013) 
In combination with the beneficial physiological effects reported from adding alginate to 
a food or beverage and the work from this laboratory, these data suggest that alginate has 
the potential to be used as an obesity treatment. If alginate is to be used as an obesity 
treatment it must be incorporated with minimum effort into an individual’s normal diet. 
Although the addition of alginate to a food or beverages has the potential to treat obesity, 
there is one common problem which has plagued alginate enriched products, namely 
palatability. The ability of alginate to form both ionic and acidic gels makes alginates 
unique (Draget et al., 1997; Smidsrod, 1974). However it is the gel formation that has 
contributed to the problem of poor palatability and the addition of alginate to a food or 
beverage has caused a slimy mouth feel of the product and poor taste of these products. 
Consequently, despite the potential beneficial effects of alginate enriched products 
previously discussed the poor palatability makes them difficult to incorporate into a day 
to day diet. The alginate enriched bread used here removed the problem of poor 
palatability, as subjects actually preferred the alginate enriched bread compared to the 
control bread during the ileostomy study. 
In addition to producing a product which is palatable enough that subjects may consume 
it on a daily basis, there is no in-vivo or in-vitro study to date that has reported the release 
rate of alginate from the enriched products. The work of Hoad et al. (2004) demonstrated 
that alginate gels in the stomach, yet no assessment was made on the ability of the 
alginate to form a gel within the small intestines. The small intestines is where the 
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majority of macronutrients are digested and absorbed, therefore if alginate is to attenuate 
the digestion and absorption in the upper GI tract the release rate of alginate throughout 
the whole of the upper GI tract from a delivery vehicle must be determined. 
Current techniques to quantify alginate are lengthy processes, requiring extensive sample 
preparation, and are unable to work throughout a range of conditions that would be 
present during in-vivo digestion. The work of Richardson et al. (2004) developed a 
method using DMMB and suggested that this method was suitable for quantifying 
alginate. The data provided here does not support the use of DMMB or a number of other 
dyes for quantifying alginate in a solution or in samples taken from a synthetic model gut, 
which could potentially be due to low positive charge density of the dyes.  
The modified PAS assay is able to quantify alginate in DH2O, with excellent sensitivity 
and linearity (0.5mg/ml and R
2
 0.99, respectively). Furthermore the PAS assay was able 
to quantify alginate in samples taken from the model gut once interference was removed. 
The PAS assay also allowed the release rate of alginate from a bread vehicle to be 
determined during digestion in the model gut. The data indicate that between 80-90% of 
the alginate is being released in the small intestinal phase of digestion. The quantification 
of alginate released from delivery vehicle is essential if alginate is to be used as an 
obesity treatment. These data correlate with the digestion of carbohydrates and fats within 
the diet, which are the main constitutes of the bread. Although the release of the alginate 
in the small intestine is not crucial, these data confirm that alginate is released in the 
small intestines where between 85-90% of triglycerides are digested and absorbed. The 
PAS assay is a suitable method for quantifying alginate in a solution and for determining 
the release rate from a delivery vehicle.  
  
150 
 
6.2 Biological Activity of Alginate  
Alginates have been reported to be able to pass through the upper GI tract undigested, and 
thus resemble characteristics of dietary fibre, which can be loosely defined as 
“unavailable plant material, which is not digested or absorbed in the upper GI tract” (Asp, 
1987). The ability of alginate to evade digestion has been reported in-vivo by Sandberg et 
al. (1994) who recovered 96% of uronic acids within the effluent fluid from ileostomy 
patients, and thus further support the classification of alginate as a dietary fibre. In-vitro 
work presented here demonstrates that alginate is recovered in the model gut simulating 
digestion in the upper GI tract, and further demonstrates the robustness of alginate.  
Although alginate appears to be able to pass through the upper GI tract undigested, there 
is evidence that suggests when alginates are exposed to temperatures in excess of 100˚C 
they are broken down (McDowell, 1977). If the alginate structure is affected during 
cooking of the bread, which can reach temperatures in excess of 180˚C, then this may 
affect the ability of the alginates to form gels or attenuate the activity of digestive 
enzymes.  
The evidence presented here in chapter 3 indicates that although alginate is being 
released, there is no substantial increase in viscosity, as would be expected when alginate 
is exposed to a range of pH’s in the upper GI tract (Draget et al., 2005; Hoad et al., 2004). 
Furthermore the heating of alginate confirms that temperatures in excess of 100˚C may 
alter the structure of alginate as suggested by McDowell (1977), and therefore reduce the 
ability of alginate to form viscous gels. The ability of alginate to form viscous gels in 
both the stomach (Hoad et al., 2004) and small intestines (Seal & Mathers, 2001) has 
been suggested as a potential mechanism responsible for a reduction in nutrient digestion 
and absorption. Therefore if the alginate bread is unable to increase the viscosity within 
the upper GI tract, the expectation may be that alginate bread is unable to alter the 
digestion and absorption process of macronutrients, specifically fat.  
Although there was a small increase in viscosity at the end of the end of the model gut 
when all of the alginate has been released this does not correspond with the viscosity that 
would be expected. Despite the small increase in viscosity the data presented here 
demonstrate that viscosity may not be the determining factor contributing to a reduction 
in enzyme activity. The alginate released from the bread as reported here has been 
exposed to cooking into the bread, digestion in the model gut and an isolation process, yet 
it still retained the same level of inhibition as alginate that had not undergone any of the 
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aforementioned processes. Furthermore when dry alginate was exposed to temperatures 
up to 180˚C the alginate retained an ability to inhibit pancreatic lipase activity. Although 
at 180˚C the level of inhibition was low compared with alginate heated at 37˚C. The level 
of inhibition remained relatively consistent up to 150˚C when compared with alginate 
heated at 37˚C, however it then falls off up to 180˚C. These data suggest that viscosity 
may not be crucial in relation to the ability of alginate to inhibit pancreatic lipase. 
These data provide evidence that alginate enriched bread may be a suitable delivery 
vehicle to treat obesity. Not only is alginate able to withstand a number of processes and 
still reduce the activity of pancreatic lipase, but the lack of viscosity as reported here 
suggests that poor palatability due to slimy mouth feel of other alginate enriched products 
(Ellis et al., 1981) may not be a problem. The data from the ileostomy study confirms this 
with subjects preferring the alginate bread to the control bread. In addition these findings 
suggest that viscosity may not have a substantial bearing on the digestion and absorption 
of macronutrients in the small intestines, and suggest that another mechanism is 
responsible for the attenuated activity of pancreatic lipase activity.  
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6.3 Triglyceride Substrate and Food Inhibition by Alginate Bread  
The in-vitro data presented by Richardson et al. (2011) and Wilcox et al. (2014) indicate 
that dry alginate is able to attenuate the activity of pancreatic lipase in an olive oil 
turbidity assay. In addition using the same olive oil turbidity assay the isolated alginate 
from the digested bread retains its inhibition ability despite being cooked into the bread, 
digested in the model gut and isolated. Although these findings do support the use of 
alginate as an obesity treatment, the olive oil turbidity assay does not take into account 
the plethora of variables within the model gut and in-vivo digestion.  
These data indicate that the model gut is a suitable model for simulating digestion in the 
upper GI tract and provides optimal conditions for digestion to occur. This was 
demonstrated by the pH reported here and also by the increase in glycerol released 
throughout the model gut when fat substrates were digested. This was further 
substantiated when two food sources high in fat content (butter and olive oil) were 
digested in a similar manner as the triglyceride substrates. Both the triglyceride substrates 
and foods demonstrated an increase in glycerol throughout the model gut, peaking in the 
small intestinal phase. The majority of glycerol was released in the small intestine, which 
is consistent with normal in-vivo digestion of triglycerides (Carey et al., 1983). This 
release of glycerol is harmonious with the release of alginate from the bread as described 
earlier.  
As previously mentioned alginate bread removes the issue of poor palatability as 
described with previous alginate enriched products and is able to reduce pancreatic lipase 
activity in a strictly controlled olive oil turbidity assay. The data here demonstrates that 
alginate enriched bread is able to reduce the amount of glycerol released during 
triglyceride substrate and food digestion. These levels ranged from 32-62% in triglyceride 
substrates and 79% and 90% for butter and olive oil, respectively. Furthermore there 
appears to be a greater inhibition of triglycerides that have a longer FA chain length. 
Although any inhibition of fat digestion using alginate enriched bread would be beneficial 
in treating obesity, a reduction in digestion of longer chain triglycerides would be a 
significant finding due to the high calorific content of these triglycerides and also the 
impact these triglycerides may have on obesity and diseases associated with obesity. 
Further research is required to ascertain whether alginate is able to inhibit fat digestion in-
vivo and to assess whether alginate enriched products are able to inhibit the digestion of 
long chain triglycerides more than medium and short chain triglycerides in the model gut 
and in-vivo.  
153 
 
6.4 Clinical Implications 
There is strong evidence that suggests alginate possesses the potential to be used as an 
obesity treatment. The data presented here support the use of bread as a delivery vehicle 
and something that individuals can incorporate into their diet on a regular basis. This easy 
incorporation into the current diet removes the adherence problems commonly associated 
with current obesity treatments (Ayyad & Andersen, 2000). Furthermore the previous in-
vitro work from this laboratory and the data presented here indicate that alginate is robust 
enough to withstand a number of processes and still inhibit fat digestion on a 96-well 
plate and also in more realistic version of digestion, such as the model gut.  
Ileostomy patients were used here due to the similarities between their digestive system 
and the synthetic model gut and ease of access to effluent samples. Ileostomy patients 
generally have normal digestion up until the end of the small intestine which corresponds 
well with the model gut. The data presented here demonstrate a substantial increase in 
effluent weight and fat in the effluent samples when subjects consumed the alginate 
bread. Furthermore there was a reduction in the plasma triglyceride concentrations, 
although this was not significant. These data indicate that regular consumption of an 
alginate enriched product with each meal may result in a reduction in the amount of fat 
digested. Two potentially important factors that were not taken into account in the current 
study were consistent levels of fat in the bread and the second meal theory. There was 
12.4g more fat in the alginate bread compared to the control bread, which is substantially 
larger. Furthermore there is evidence to suggest that fat that appears in the blood 
immediately after a meal is not from the meal they have just consumed. The second meal 
theory indicates that fat is stored in the enterocyte cells and then released when more fat 
is digested and absorbed, and therefore the fat from the meal consumed will be stored in 
enterocytes cells ready for the following meal (Lambert & Parks, 2012). Both of these 
factors must be taken into account when considering future research. Even though the 
alginate bread had a larger fat content the plasma triglyceride levels were still lower when 
consuming alginate bread compared with the control bread. A further point of interest 
may be that the fat that appeared in the plasma of the ileostomy patients may have been 
from the standardised meal consumed the evening prior to testing. When taking into 
account these two potential factors there was still significantly more fat in the effluent 
fluid when subjects consumed the alginate bread, indicating that the alginate bread 
reduced the absorption of fat consumed.  
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Although these findings do demonstrate the ability of alginate to reduce fat digestion in 
ileostomy patients these findings must be confirmed in a healthy population group. If 
similar positive findings can be repeated in a healthy group of subjects then this will 
support any health claims that may be attributed to alginate and the potential for its use as 
an obesity treatment. A longitudinal study is also required assessing weight loss and 
observing the effects of a number of alginate meals to account for the second meal 
response.  
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6.5 Final Conclusion 
The release rate of alginate from a bread vehicle during in-vitro digestion is determined 
here using a modified PAS assay. This assay reports that the majority of alginate is 
released in the small intestine phase of digestion. Furthermore alginate appears to evade 
digestion in the upper GI tract where it is able to attenuate the activity of pancreatic 
lipase. This was demonstrated by a reduction of glycerol released in the model gut when 
normal substrate and foods high in fat content were digested. Furthermore there was a 
small reduction in plasma triglyceride levels and a significant increase in effluent weight 
and fat content of effluent samples.  
Although the alginate enriched bread appears to have an acute response in ileostomy 
patient’s further work is required in healthy populations. The delivery vehicle selected 
here was bread, which did not have any significant adverse side effects and was palatable 
for subjects. Furthermore it appears that certain alginate enriched products may elicit 
certain physiological effects and depending on what the main aim of the study is will also 
determine the selected delivery vehicle. For example alginate beverages appear to 
increase satiety and reduce the blood insulin response, however alginate enriched bread 
did not seem to affect hunger levels, but reduced fat digestion. Future studies may want to 
compare a number of delivery vehicles for alginate that people are already consuming.   
An additional concept would be to select the appropriate alginate as this appears to be one 
of the main issues when observing the effects of alginate enriched products. Strugala et al. 
(2005) demonstrated that alginates with a large M:G content has a larger inhibition of 
pepsin, and although Wilcox et al. (2013) does provide some evidence that alginates high 
in G content may be more effective at inhibiting pancreatic lipase. Therefore further 
research is required to determine which alginates are more effective at inhibiting 
pancreatic lipase. Furthermore, as well as the Mr and composition the amount of alginate 
used will also be crucial. Here only a small amount was used, however further work is 
required to assess if there is a dose response and also what the cut-off point is for the 
amount of alginate that can be added before adverse side effects are experienced, whilst 
maintaining the beneficial physiological responses reported here.  
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